

New York University

**Report on Federal Awards in Accordance With
the OMB Uniform Guidance**

August 31, 2022

Entity Identification Number: 13-5562308

New York University
Index
August 31, 2022 and 2021

	Page(s)
Part I – Financial Statements	
Report of Independent Auditors	1–3
Consolidated Financial Statements	
Balance Sheets	4
Statements of Activities	5
Statements of Cash Flows	6
Notes to Financial Statements	7–47
Appendix A	
Supplemental Schedules	48–57
Note to Consolidating Supplemental Schedules	58
Part II – Supplemental Schedule of Expenditures of Federal Awards	
Schedule of Expenditures of Federal Awards	59–81
Notes to Schedule of Expenditures of Federal Awards	82–84
Schedule of Financial Responsibility Data	85
Part III – Reports on Internal Control and Compliance	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	86–87
Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance	88–90
Part IV – Findings	
Schedule of Findings and Questioned Costs	91–92
Summary Schedule of Status of Prior Audit Findings	93

Part I
Consolidated Financial Statements



Report of Independent Auditors

To the Board of Trustees of
New York University

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of New York University and its subsidiaries (the "Company"), which comprise the consolidated balance sheets as of August 31, 2022 and 2021, and the related consolidated statements of activities and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of August 31, 2022 and 2021, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.



Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The accompanying consolidating information as of and for the years ended August 31, 2022 and 2021 is presented for purposes of additional analysis and is not a required part of the consolidated financial statements, nor is it intended to present the financial position, changes in net assets and cash flows of the individual companies. The consolidating information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures,



including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the consolidating information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended August 31, 2022 and schedule of financial responsibility data as of and for the year ended August 31, 2022 are presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the Department of Education, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards and schedule of financial responsibility data are fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 14, 2022, except with respect to Note 20 to the consolidated financial statements and the opinion on the supplemental schedule of financial responsibility data, as to which the date is March 31, 2023, on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended August 31, 2022. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

New York, New York

December 14, 2022, except for Note 20 to the consolidated financial statements and with respect to the opinion on the schedule of financial responsibility data, as to which the date is March 31, 2023

New York University

Consolidated Balance Sheets

August 31, 2022 and 2021

(in thousands of dollars)

	2022	2021
Assets		
Cash and cash equivalents	\$ 3,014,564	\$ 3,340,195
Short-term investments (Note 5)	175,945	193,532
Accounts and loans receivable, net (Note 6)	847,849	758,529
Patient accounts receivable, net (Note 4)	1,215,720	1,059,493
Contributions receivable, net (Note 7)	622,216	638,104
Other assets (Note 8)	1,074,070	1,075,431
Deposits with trustees (Note 9)	622,951	866,472
Long-term investments (Note 5)	6,479,554	7,093,866
Operating right to use assets (Note 11)	2,154,222	2,154,999
Assets held for professional liabilities (Note 13)	950,996	914,127
Land, buildings, and equipment, net (Note 10)	<u>13,524,087</u>	<u>12,900,693</u>
Total assets	<u>\$ 30,682,174</u>	<u>\$ 30,995,441</u>
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	\$ 2,551,333	\$ 2,777,772
Deferred revenue	1,413,925	1,327,589
Operating lease liability (Note 11)	2,316,986	2,295,086
Professional liabilities (Note 13)	917,229	847,910
Debt and other obligations (Note 12)	9,566,406	9,640,911
Funds held for others (Notes 6 and 8)	493,479	533,123
Accrued benefit obligation (Note 14)	398,718	537,447
Accrued postretirement obligation (Note 14)	510,738	632,710
Asset retirement obligation	<u>287,047</u>	<u>353,852</u>
Total liabilities	<u>18,455,861</u>	<u>18,946,400</u>
Net assets		
Without donor restrictions	7,489,240	6,936,140
With donor restrictions (Note 17)	<u>4,737,073</u>	<u>5,112,901</u>
Total net assets	<u>12,226,313</u>	<u>12,049,041</u>
Total liabilities and net assets	<u>\$ 30,682,174</u>	<u>\$ 30,995,441</u>

The accompanying notes are an integral part of these consolidated financial statements.

New York University

Consolidated Statements of Activities

Years Ended August 31, 2022 and 2021

(in thousands of dollars)

	2022	2021
Changes in net assets without donor restrictions		
Operating revenues		
Tuition and fees (net of financial aid awards of \$852,272 and \$825,662)	\$ 2,452,721	\$ 2,107,670
Grants and contracts (Note 2)	1,391,271	1,193,596
Patient care (Note 4)	8,862,837	8,162,916
Hospital affiliations (Note 15)	448,827	415,355
Insurance premiums earned	108,014	106,708
Contributions	74,415	67,243
Endowment distribution (Note 5)	198,345	185,904
Return on short-term investments (Note 5)	45,157	33,452
Auxiliary enterprises (net of financial aid awards of \$70,701 and \$47,077)	382,105	238,627
Program fees and other	687,937	888,184
Net assets released from restrictions	173,496	134,916
Total operating revenues	14,825,125	13,534,571
Expenses (Note 16)		
Salaries and fringe	8,394,663	7,824,432
Medical and pharmaceutical costs	1,477,431	1,356,236
Professional services	737,180	601,242
Facilities costs	904,243	830,384
Fees, insurance and taxes	460,450	411,055
Depreciation and amortization	945,911	902,340
Interest	368,647	368,152
Other	818,674	712,357
Total expenses	14,107,199	13,006,198
Excess of operating revenues over expenses	717,926	528,373
Nonoperating activities		
Investment return (Note 5)	(475,133)	573,097
Appropriation of endowment distribution (Note 5)	(64,208)	(59,335)
Pension and postretirement nonservice costs (Note 14)	26,171	6,277
Changes in pension and postretirement obligations (Note 14)	271,079	399,853
Net assets released from restrictions for capital	20,215	19,140
Non-clinical COVID costs (Note 2)	(37,792)	(110,482)
Other	94,842	(51,498)
Increase in net assets without donor restrictions	553,100	1,305,425
Changes in net assets with donor restrictions		
Contributions	299,803	606,113
Investment return (Note 5)	(339,241)	795,379
Appropriation of endowment distribution (Note 5)	(134,137)	(126,569)
Other	(8,542)	24,486
Net assets released from restrictions	(193,711)	(154,056)
(Decrease) increase in net assets with donor restrictions	(375,828)	1,145,353
Increase in net assets	\$ 177,272	\$ 2,450,778

The accompanying notes are an integral part of these consolidated financial statements.

New York University

Consolidated Statements of Cash Flows

Years Ended August 31, 2022 and 2021

(in thousands of dollars)

	2022	2021
Cash flows from operating activities		
Change in net assets	\$ 177,272	\$ 2,450,778
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Depreciation and amortization	945,911	902,340
(Gain) loss on sale or disposal of land, buildings and equipment	(201)	361
Net loss (gain) on investments, deposits with trustees, and split-interest agreements	893,019	(1,328,602)
Bad debt expense	18,407	21,530
Pension and postretirement obligation change	(271,079)	(399,853)
Contributions received for permanent investment and capital	(113,609)	(119,739)
Proceeds from insurance recovery for capital or FEMA award	(1,236)	(4,793)
Amortization of operating right to use assets	265,324	267,675
Acquisition of Long Island Community Hospital	(105,967)	-
Changes in operating assets and liabilities		
Increase in accounts and loans receivable, net	(90,233)	(94,009)
Increase in patient accounts receivable	(129,017)	(212,239)
Decrease (increase) decrease in nonendowment and noncapital contributions receivable	9,425	(245,500)
Increase in other assets	(31,740)	(30,991)
Decrease in asset retirement obligation	(16,265)	(980)
(Decrease) increase in accounts payable and accrued expenses	(389,796)	348,851
Decrease in operating lease liability	(252,314)	(240,494)
Increase in professional liabilities	45,374	77,169
Increase in deferred revenue	86,336	316,364
Decrease in accrued benefit obligation	(1,452)	(37,512)
Increase in accrued postretirement obligation	11,830	29,105
Net cash provided by operating activities	<u>1,049,989</u>	<u>1,699,461</u>
Cash flows from investing activities		
Purchases of investments	(3,271,831)	(4,238,859)
Sales and maturities of investments	2,951,822	3,667,095
Drawdowns of unexpended bond proceeds	87,603	376,744
Additions to land, buildings, and equipment	(1,377,026)	(1,043,429)
Cash from acquisition of Long Island Community Hospital	86,068	-
Proceeds from insurance recovery	45	100
Net cash used in investing activities	<u>(1,523,319)</u>	<u>(1,238,349)</u>
Cash flows from financing activities		
Contributions received for permanent investment and capital	113,609	119,739
Proceeds from FEMA award for future mitigation	1,191	4,693
Proceeds from short-term borrowings	-	200,000
Proceeds from long-term borrowings	38,870	335,302
Principal payments on long-term borrowings	(231,619)	(276,585)
Line of credit repayments	-	(450,000)
Payments of deferred financing costs	-	(1,153)
Decrease in funds held for others	(5,590)	(5,983)
Net cash used in financing activities	<u>(83,539)</u>	<u>(73,987)</u>
Net (decrease) increase in cash	(556,869)	387,125
Cash, cash equivalents and restricted cash		
Beginning of year	<u>3,930,195</u>	<u>3,543,070</u>
End of year	<u>\$ 3,373,326</u>	<u>\$ 3,930,195</u>
Supplemental disclosure of cash flow information		
Interest paid	\$ 385,168	\$ 387,066
Change in noncash acquisitions of land, buildings, and equipment	60,097	(117,929)
Right-of-use assets obtained		
In exchange for new operating lease obligations	\$ 249,270	\$ 148,514
In exchange for new finance lease obligations	50,243	809,818

The accompanying notes are an integral part of these consolidated financial statements.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

1. Description of New York University

Founded in 1831, New York University (NYU) is a private institution of higher education, research, and patient care located primarily in New York City. NYU is recognized both nationally and internationally as a leader in scholarship and is a member of the distinguished Association of American Universities.

The consolidated reporting entities for NYU consist of the University and NYU Langone Health, which represents the activities of NYU Langone Health System (Health System) and its two medical schools: the NYU Robert I. Grossman School of Medicine (NYUGSoM) and NYU Long Island School of Medicine (collectively the NYU Schools of Medicine).

The University

The University includes twenty-one colleges and divisions each with its own traditions, programs and faculty. The schools, in order of founding date, are the College of Arts and Science, School of Law, NYUGSoM (reported as a part of NYU Langone Health), College of Dentistry, Graduate School of Arts and Science, Steinhardt School of Culture, Education and Human Development, Leonard N. Stern School of Business, Courant Institute of Mathematical Sciences, School of Professional Studies, Institute of Fine Arts, Robert F. Wagner Graduate School of Public Service, Post-Graduate Medical School, Silver School of Social Work, Tisch School of the Arts, Gallatin School of Individualized Study, Rory Meyers College of Nursing, Institute for the Study of the Ancient World, NYU Abu Dhabi, Tandon School of Engineering (formerly Polytechnic University founded in 1854), NYU Long Island School of Medicine (reported as part of NYU Langone Health), and The School of Global Public Health. The University also operates academic program sites and research programs in other parts of the United States and abroad.

In addition to the colleges and divisions, NYU operates NYU Shanghai, which grants NYU degrees as a joint venture with East China Normal University. The New York-based activities of NYU Shanghai are reported in the University's consolidated balance sheets and consolidated statements of activities.

NYU Langone Health

The Health System is the sole corporate member of NYU Langone Hospitals, which is a quaternary care teaching hospital that operates five inpatient acute care facilities and over 40 ambulatory facilities in Manhattan, Brooklyn, and Long Island. The 813-bed inpatient facilities in Manhattan are comprised of the Kimmel Pavilion (which also houses the Hassenfeld Children's Hospital) and Tisch Hospital. The NYU Langone Orthopedic Hospital, also located in Manhattan, is a 225-bed facility specializing in orthopedic, neurologic, and rheumatologic services. NYU Langone Hospital-Brooklyn is a 444-bed facility in the Sunset Park section of Brooklyn. NYU Langone Hospital-Long Island is a 591-bed acute care facility located in Mineola, New York. Ambulatory facilities include the Laura and Isaac Perlmutter Cancer Center, a comprehensive cancer and ambulatory care center, as well as a freestanding Emergency Department in the Cobble Hill section of Brooklyn, amongst others.

On March 1, 2022, the Health System completed an affiliation agreement (the Affiliation) with and became the sole corporate member of Brookhaven Health Care Services Corporation, d/b/a Long Island Community Hospital Foundation and Brookhaven Memorial Hospital Medical Center Inc., d/b/a Long Island Community Hospital. Brookhaven Memorial Hospital Medical Center Inc. subsequently changed its name to Long Island Community Hospital at NYU Langone Health (LICH). LICH is a 306-bed acute care hospital located in Patchogue, New York.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

NYUGSoM employs approximately 3,450 faculty physicians (the Faculty Group Practice) who render patient care in more than 350 practice locations primarily in the New York City region.

NYU Langone Hospitals is the sole corporate member of CCC550 Insurance, SCC. (CCC550), which provides the hospitals' professional and general liability insurance, as well as insurance to physicians employed by the NYUGSoM. CCC550 is subject to taxation in accordance with Section 29 of the Exempt Insurance Act in Barbados.

Affiliation with Long Island Community Hospital

The Health System's Affiliation with and the subsequent change in control of LICH was accounted for as a business combination in accordance with Accounting Standards Codification (ASC), Topic 805, *Business Combinations*, and ASC 958-805-05, *Acquisition by a Not-for-Profit Entity*. NYU recorded \$101,557 of non-operating income in the 2022 consolidated statement of activities which represents LICH's net assets without donor restriction at March 1, 2022 and the excess of the fair value of assets acquired over the fair value of liabilities assumed. No consideration was exchanged for the acquisition.

As a result of the Affiliation, LICH changed its fiscal year from a calendar year to a fiscal year beginning September 1st and ending August 31st to align with the fiscal year of the Health System. As a result of this change, obtaining revenues and changes in net assets as though the acquisition occurred at the beginning of fiscal year 2022 was impracticable.

The following is a summary of the LICH activity included in the 2022 consolidated statement of activities:

Net assets without donor restriction as of March 1,2022	\$ 100,540
Excess fair value of assets acquired over liabilities	1,017
Acquisition of Long Island Community Hospital	<u>101,557</u>
Operating revenues	118,815
Operating expenses	<u>138,522</u>
	(19,707)
Nonoperating activities	<u>(6,733)</u>
Change in net assets without donor restrictions	75,117
Change in net assets with donor restrictions	3,861
Total change in net assets as a result of acquisition	<u>\$ 78,978</u>

The following is a summary of the LICH amounts included in the consolidated balance sheet as of August 31, 2022:

	August 31, 2022
Assets	\$ 293,466
Liabilities	214,488
Net assets without donor restrictions	75,117
Net assets with donor restrictions	3,861

As of August 31, 2022, LICH was not in compliance with its debt service coverage ratio covenant.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements of NYU have, in all material respects, been prepared on an accrual basis in accordance with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements include the accounts of NYU, as well as its separately incorporated affiliates. NYU and, generally, all of its affiliates are exempt from federal income taxes under the provisions of Section 501(c)(3) of the Internal Revenue Code.

NYU prepares its consolidated financial statements in accordance with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 958, *Not for Profit Entities*. This standard focuses on the entity as a whole and requires classification of net assets as determined by the existence or absence of restrictions placed on the assets' uses by donors or by provision of law. A description of the net asset classifications follows:

Without Donor Restrictions: net assets of NYU that are used to carry out its missions of education, research and patient care which are not subject to donor restrictions.

With Donor Restrictions: Net assets subject to donor-imposed restrictions that will be met either by the actions of NYU or the passage of time. Items that are included in donor restricted net assets are gifts for which donor-imposed restrictions have not been met in the year of receipt; endowments, annuity, and life income gifts; pledges; investment return on donor restricted endowment funds; and endowments where the principal may be expended upon the passage of a stated period of time. Expirations of restrictions on net assets with donor restrictions are reported as net assets released from restrictions. In addition, NYU has elected the simultaneous release option for contributions that are also subject to purpose restrictions.

Activities

Revenues and expenses related to conducting programmatic activities and provision of services by NYU are classified as operating in the consolidated statements of activities. Investment return relating to board-designated endowment funds and the related endowment appropriation, as well as nonservice changes in pension and postretirement obligations, incremental non-clinical COVID-19 related expenses, and other activity that is not part of NYU's core activities, are classified as nonoperating in the consolidated statements of activities.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

Tuition and Fees

Tuition and fees are derived from degree-granting programs as well as executive and continuing education programs. Tuition and fee revenue is recognized within the fiscal year in which the related educational services are provided as the performance obligation is satisfied. Tuition and fee receipts received in advance of a semester are recorded as deferred revenue. Financial aid, in the form of scholarships and grants, including amounts funded by the endowment, research funds, and gifts reduces the published price of tuition for students receiving such aid. As such, financial aid is referred to as a tuition discount and represents the difference between the stated charge for tuition and fees and the amount that is billed to the student and/or third parties making payments on behalf of the student. Tuition and fees are reported net of financial aid on the consolidated statements of activities.

Auxiliary Enterprises

Auxiliary enterprises are self-supporting activities that furnish goods or services to students, faculty, staff, or incidentally to the general public, and charge a fee directly related to, although not necessarily equal to, the cost of the goods or services. Auxiliary enterprises include student housing and dining, real estate rental income, and other similar activities. Student housing and dining services are delivered over the academic terms and revenues are recognized ratably as the performance obligation is satisfied. Student housing and dining services are presented net of financial aid on the consolidated statements of activities.

Grants and Contracts

NYU receives funding for sponsored programs from various government agencies, foundations, and corporations. The funding may represent a reciprocal transaction in exchange for an equivalent benefit in return, or it may be a nonreciprocal non-exchange transaction in which the funding provided is for the benefit of NYU, the funding organization's mission, or the public at large.

Revenues from non-exchange transactions may be subject to conditions, in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments). NYU's grants and contracts are primarily conditional non-exchange transactions and revenues are recognized when expenses are incurred. Unspent conditional contributions from grants and contracts total \$1,096,310 and \$1,172,400 at August 31, 2022 and 2021, respectively. Revenues from unconditional non-exchange transactions are recognized in the period awarded.

In 2022 and 2021, grants and contracts revenue recognized from U.S. governmental sources totaled \$761,319 and \$585,304 respectively. Such sponsored grants and contracts generally provide for the recovery of indirect costs supporting these activities. Indirect costs, included in grant and contract revenues, are recovered at rates established in advance by NYU through negotiations with the U.S. federal government and other private sponsors and totaled \$219,185 and \$198,237, respectively.

In 2014, NYU Langone Health was awarded a \$982,400 multi-year fixed capped public assistance grant from the Federal Emergency Management Agency (FEMA) for both repair and replacement of damages and hazard mitigation projects as a result of Superstorm Sandy. The hazard mitigation project portion of the award was recognized as a contribution with donor restriction (Note 17), with a corresponding FEMA receivable (Note 6). The net assets are released from restriction as the costs are incurred and totaled \$11,369 and \$8,126 for the years ended August 31, 2022 and 2021, respectively.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

Contributions

Contributions, including unconditional promises to give, are recognized as revenue in the period received at their fair value. Contributions receivable are reported at their discounted present value, using an estimated interest rate for the year in which the promise was received and considering market and credit risk as applicable (4.15% in 2022 and 1.87% in 2021). Amortization of the discount is recorded as additional contribution revenue. Allowances are recorded for estimated uncollectible contributions based upon management's judgment and analysis of the creditworthiness of the donors, past collection experience and other relevant factors.

Fair Value Measurements

Authoritative guidance of fair value measurements, ASC 820, *Fair Value Measurements*, establishes a hierarchy of valuation methodologies based on the extent to which asset valuations are observable in the marketplace.

The following describes the hierarchy of methodologies used to measure fair value of investments:

Fair value for Level 1 is based on unadjusted quoted prices in actively traded markets that NYU has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets.

Fair value for Level 2 is based on quoted prices for instruments similar to those held by NYU in actively traded markets, quoted prices for identical instruments held by NYU in markets that are not actively traded and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data. Inputs are obtained from various sources including market participants, dealers and brokers.

Fair value for Level 3 is based on valuation techniques used to assess prices that are unobservable as the assets trade infrequently or not at all.

Investments for which fair value is measured at net asset value (NAV) per share as a practical expedient consist primarily of NYU's ownership in alternative investments (principally limited partnership interests in public equity, hedge funds, credit, real assets, private equity, real estate, and other similar funds). The NAV of the securities held by limited partnerships that do not have readily determinable fair values are determined by the general partner and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investment securities, the fair value is determined by the general partner taking into consideration, among other things, the cost of the securities, prices of recent significant placements of securities of the same issuer and subsequent developments concerning the companies to which the securities relate. NYU has performed due diligence on these investments and believes the reported NAV as a practical expedient is an appropriate measure of fair value as of August 31, 2022 and 2021.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while NYU believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

Cash and Cash Equivalents

Cash and cash equivalents include cash and all highly-liquid debt instruments with original maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates fair value due to the short-term maturity of the instruments. NYU maintains its deposits with high credit quality financial institutions, with balances that exceed federal depository insurance limits. Management does not believe the credit risk related to these deposits is significant. All short-term, highly liquid investments, which would otherwise qualify as cash equivalents that are included in NYU's investment pool within long-term investments, are treated as investments and are therefore excluded from cash and cash equivalents in the consolidated statements of cash flows.

The following table provides a reconciliation of cash and cash equivalents reported within the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows at August 31, 2022 and 2021:

	2022	2021
Cash and cash equivalents	\$ 3,014,564	\$ 3,340,195
Cash in long-term investment pool (Note 5)	123,227	177,070
Cash in other long-term investments (Note 5)	7,097	4,078
Cash in other assets (Note 8)	845	332
Cash in deposits with trustees (Note 9)	189,996	382,923
Cash in assets held for professional liabilities (Note 13)	37,597	25,597
	<u>3,373,326</u>	<u>3,930,195</u>
Cash, cash equivalents and restricted cash	<u>\$ 3,373,326</u>	<u>\$ 3,930,195</u>

Land, Buildings, and Equipment

Land, buildings, and equipment are carried at their acquisition or construction cost. If donated, these assets are recorded at their fair value on the date of the gift. Buildings and equipment are depreciated over their estimated useful lives (buildings and building improvements 10-60 years, equipment 3-10 years) using the straight-line method. Repairs and maintenance expenditures are expensed when incurred.

Leases

NYU leases certain academic spaces, medical offices, administrative offices, and equipment under finance and operating leases. Operating lease right-of-use (ROU) assets and operating lease obligations are recognized based on the present value of lease payments over the lease term, where the initial term of the lease exceeds 12 months. NYU uses its incremental borrowing rate to calculate the present value of lease payments because the leases do not have a readily determinable implicit discount rate. As a practical expedient, NYU elected to include both lease and non-lease components in the calculation of the operating lease ROU asset and operating lease obligation. Variable lease payments are excluded for purposes of calculating the operating ROU asset and operating lease obligation unless the variable lease payments depend on an index or rate or are in substance fixed payments. Lease payments related to periods subject to renewal options are also excluded for purposes of calculating the operating ROU asset and operating lease obligation unless NYU is reasonably certain to exercise the option to extend the lease.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

Lease expense for operating leases is recognized on a straight-line basis over the term of the lease. Deferred rent liability is reported as a reduction to the ROU assets within the consolidated balance sheets.

Collections

The University does not assign a value to collection items. Collection items are generally held for educational purposes and are not disposed of for financial gain or otherwise encumbered in any manner.

Deferred Revenue

Deferred revenue consists of tuition and fees and student housing and dining fees received in advance of the Fall semester as well as funding received for grants and contracts in advance of incurring the qualifying expenses.

Asset Retirement Obligation

NYU recognizes asset retirement obligations on future events, such as the abatement of asbestos and removal of lead-based paint and petroleum bulk storage tanks from buildings. The fair value of the liability for a conditional asset retirement obligation is recognized in the period in which it occurred, provided that it can be reasonably estimated. Corresponding asset retirement costs (net of accumulated depreciation) have been included in land, buildings, and equipment.

Funds Held for Others

Funds held for others consist of NYU's federal grants refundable and deferred compensation plan liabilities (457(b)). Corresponding assets are included within accounts receivable (Note 6) and other assets (Note 8), respectively.

Accounting Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingencies at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Authoritative Pronouncements Adopted

In August 2018, the FASB issued ASU 2018-14, *Compensation-Retirement Benefits-Defined Benefit Plans*, which addresses changes to the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments in the update remove disclosures that no longer are considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. The standard is effective for fiscal years beginning after December 15, 2019. NYU adopted this standard in fiscal year 2021 using a retrospective approach and updated the disclosures in Note 14.

In August 2018, the FASB issued ASU 2018-13, *Fair Value Measurement: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement*, which eliminates, adds and modifies certain disclosure requirements related to fair value measurement. The standard is effective for fiscal years beginning after December 15, 2019, with early adoption permissible. NYU adopted this standard in fiscal year 2021 using a retrospective approach with no material impact on NYU's consolidated financial statements.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

In August 2018, the FASB issued ASU 2018-15, *Intangibles – Goodwill and Other – Internal Use Software*. The new standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal use software. This ASU is effective for fiscal years beginning after December 15, 2020. NYU adopted this standard in fiscal year 2022 using a prospective approach with no material impact on NYU's consolidated financial statements.

New Authoritative Pronouncements not yet Adopted

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments*. The new standard removes the previous requirement that a credit loss be probable of occurring for it to be recognized, and requires entities to use historical experience, current conditions, and reasonable and supportable forecasts to estimate their future expected credit losses. The standard is required to be applied using the modified retrospective approach with a cumulative-effect adjustment to net assets, if any, upon adoption. This ASU is effective for fiscal years beginning after December 15, 2022. NYU is currently evaluating the impact of the new standard on the consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, *Reference Rate Reform, Facilitation of the Effects of Reference Rate Reform on Financial Reporting*. The standard provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This standard is effective immediately and can be applied through December 31, 2022. NYU does not expect the adoption to have a material impact on the NYU's consolidated financial statements.

Impact of COVID-19

The University incurred expenses relating to COVID-19 testing, incremental space for social distancing, and other pandemic related expenses supporting student instruction, research, and pandemic related campus services. These expenses have been recorded as non-clinical COVID costs in non-operating activity for the years ended August 31, 2022 and 2021, respectively.

Coronavirus Aid, Relief and Economic Security Act

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was enacted. The CARES Act impacted NYU as follows for the years ended August 31, 2022 and 2021:

- NYU Langone Health received \$441,276 in advanced payments from the Centers for Medicare and Medicaid Services (CMS) (\$432,800 in April 2020 and \$8,476 in September 2020), for which repayment began in April 2021 and concluded in May 2022. There were no amounts outstanding as of August 31, 2022. As of August 31, 2021, NYU Langone Health had a remaining Medicare advance of \$317,099, which is reported in accounts payable and accrued expenses on the consolidated balance sheets.
- LICH received \$47,267 in advanced payments from CMS, for which repayment began in April 2021. As of August 31, 2022, LICH has a remaining Medicare advance of \$11,076, which is reported in accounts payable and accrued expenses on the consolidated balance sheets.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

- The Higher Education Emergency Relief Fund (HEERF) appropriated funding to the Office of Postsecondary Education. The U.S. Department of Education (DOE) awarded HEERF funds based on an institution of higher education's Pell Grant recipients and full-time enrollment. Based on these criteria, the University recognized \$2,461 and \$121,414 in program fees and other revenues in the consolidated statements of activities for the years ended August 31, 2022 and 2021, respectively. Financial aid awards include \$30,091 and \$69,899 of COVID-related emergency grants to students supported by University funds, HEERF funds, and donations for the years ended August 31, 2022 and 2021, respectively.
- NYU deferred the deposit and payment of the employer's share of Social Security taxes. NYU has \$93,886 and \$181,950 in accounts payable and accrued expenses for these deferred tax payments as of August 31, 2022 and 2021, respectively, which are due to be paid in equal installments on December 31, 2022 and December 31, 2023.

Federal Emergency Management Agency

NYU Langone Health recognizes revenue on awarded project worksheets as expenses are incurred and determined to be eligible for FEMA reimbursement. NYU Langone Health recognized \$13,478 and \$199,661 as program fees and other in the consolidated statements of activities for reimbursement of eligible operating expenses and \$772 and \$4,305 in nonoperating activities in the consolidated statements of activities related to FEMA reimbursement of capital expenditures for the years ended August 31, 2022 and 2021, respectively. NYU Langone Health has a balance due from FEMA of \$61,297 and \$54,358 in accounts and loans receivable on the consolidated balance sheets as of August 31, 2022 and 2021, respectively.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

3. Financial Assets and Liquidity Resources

As of August 31, 2022 and 2021, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt, and capital expenditures not financed with debt, were as follows:

	2022	2021
Financial assets		
Cash and short-term investments	\$ 3,190,509	\$ 3,533,727
Investments available for general purposes	1,094,856	1,273,620
Accounts receivable, net	213,674	236,143
Grants and contracts receivable, net	206,917	153,773
Insurance premiums and recoveries receivable	110,633	105,457
Patient accounts receivable, net	1,215,720	1,059,493
Non-endowment pledge payments due within one year	79,807	182,239
Other assets	25,697	44,725
Subsequent year endowment distribution	228,822	198,428
Total financial assets available within one year	<u>6,366,635</u>	<u>6,787,605</u>
Liquidity resources		
Undrawn bank lines of credit (Note 12)	1,446,770	1,355,600
Funds functioning as endowment available for operations (Note 17)	1,712,150	1,849,753
Total liquidity resources	<u>3,158,920</u>	<u>3,205,353</u>
Total financial assets and liquidity resources available within one year	<u>\$ 9,525,555</u>	<u>\$ 9,992,958</u>

The University's cash flows have seasonal variations during the year attributable to tuition billing cycles and, at times, a concentration of contributions received at calendar year end. The University's Reserve and Liquidity Management Policy provides guidelines for calculating and reporting the global cash position on a daily basis as well as rigorous cash flow forecasting. This approach is adopted to maximize the portion of working capital funds that may remain invested. The Working Capital Fund Investment Policy (the Investment Policy) has a primary objective of aligning the maturity and liquidity profile of the working capital portfolio with the University's anticipated spending needs, while preserving the principal invested and maximizing return among a subset of approved investment grade products and providers. The Investment Policy establishes concentration limits for both investments and banking institutions. Liquidity resources are available with NYU board of trustees' approval.

As part of NYU Langone Health's liquidity management, financial assets are structured to be available as its general expenditures, liabilities and other obligations come due. In addition, NYU Langone Health may invest cash in excess of daily requirements in short-term or liquid investments.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

4. Patient Care Revenue and Receivable

Patient care revenue and receivables consist primarily of patient care services provided by NYU Langone Health. The University's College of Dentistry provides dental clinic services to patients as part of a student's training.

NYU Langone Health has agreements with third party payors that provide for payments at amounts different from its established rates (i.e. gross charges). Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges and per diem payments.

NYU Langone Health grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor arrangements. NYU Langone Health bills patients and third-party payers several days after the services are performed and/or the patient is discharged. Patient care revenue is recognized as performance obligations are satisfied over time based on actual charges incurred in relation to total expected charges. Generally, performance obligations over time relate to patients receiving inpatient acute care services or patients receiving services in NYU Langone Health's outpatient and ambulatory care centers. NYU Langone Health measures the performance obligation from admission into the hospital or the commencement of an outpatient or physician service to the point when it is no longer required to provide services to that patient, which is generally the time of discharge or the completion of the outpatient or physician visit.

As substantially all of its performance obligations relate to contracts with a duration of less than one year, NYU Langone Health has elected to apply the optional exemption provided in ASC 606-10-50-14(a) *Revenue from Contracts with Customers* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

NYU Langone Health determines the transaction price based on gross charges for services provided, reduced by adjustments provided to third-party payers based on contractual agreements, discounts provided to uninsured patients in accordance with NYU Langone Health's policy, and implicit concessions provided to uninsured patients. For the years ended August 31, 2022, and 2021, NYU Langone Health recorded \$133,566 and \$154,642 of implicit price concessions as a direct reduction to patient care revenue.

NYU's patient accounts receivable, after contractual adjustments and implicit price concessions, is \$1,215,720 and \$1,059,493 at August 31, 2022 and 2021, respectively. NYU Langone Health estimates its implicit price concessions using a quarterly standardized approach to review historical collections based on major payor classification as a practical expedient to account for patient contracts as collective groups rather than individually. Based on historical collection trends, the financial statement effects of using this practical expedient are not materially different from an individual contract approach. In addition, NYU Langone Health assesses the current state of its billing functions in order to identify any known collection or reimbursement issues and assess the impact, if any, on estimates. NYU Langone Health believes that the collectability of its receivables

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

is directly linked to the quality of its billing processes, most notably those related to obtaining the correct information in order to bill effectively for the services it provides. Subsequent changes to the estimate of transaction price are recorded as adjustments to net patient care revenue in the period of the change. Certain patient care revenues received are subject to retroactive adjustments under reimbursement agreements with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined.

NYU Langone Health has established estimates, based on information presently available, of amounts due to or from Medicare and non-Medicare payors for adjustments to current and prior year payment rates, based on industry-wide and hospital-specific data. The amounts due to third party payors included in accounts payable and accrued expenses on the consolidated balance sheets is \$140,281 and \$149,883 at August 31, 2022 and 2021, respectively. Additionally, certain payors' payment rates for various years have been appealed by NYU Langone Health. If the appeals are successful, additional income applicable to those years will be realized.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. NYU Langone Hospitals' cost reports have been audited by the Medicare fiscal intermediary through August 31, 2016; however, final settlements are pending for 2003 and 2004. NYU Langone Hospital-Brooklyn's cost reports have been audited by the Medicare fiscal intermediary through December 31, 2015; however, final settlements are pending for the years 2008 to 2013. NYU Langone Hospital-Long Island's Medicare cost reports have been audited by the Medicare fiscal intermediary through July 31, 2019, and there are no final settlements pending. LICH's Medicare cost reports have been audited by the Medicare fiscal intermediary through December 31, 2019.

The mix of patient care revenue for the years ended August 31, 2022 and 2021 are as follows:

	2022		2021	
	Health System	NYUGSoM	Health System	NYUGSoM
Medicare	18 %	17 %	18 %	18 %
Medicaid	2	1	2	1
Medicare and Medicaid managed care	22	14	20	14
Blue Cross	26	20	26	18
Managed care and other	32	48	34	49
	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

The mix of patient accounts receivable, net from patients and third party payors at August 31, 2022 and 2021 are as follows:

	2022		2021	
	Health System	NYUGSoM	Health System	NYUGSoM
Medicare	9 %	12 %	9 %	13 %
Medicaid	2	1	1	1
Medicare and Medicaid managed care	21	15	19	15
Blue Cross	26	21	28	19
Managed care and other	42	51	43	52
	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>

NYU Langone Health's charity care policy, in accordance with the New York State Department of Health's guidelines, ensures the provision of quality health care to the community served while carefully considering the ability of the patient to pay. The policy has sliding fee schedules for inpatient, ambulatory and emergency services provided to the uninsured and under-insured patients that qualify. Patients are eligible for the charity care fee schedule if they meet certain income tests. Since payment of the difference between NYU Langone Health's standard charges and the charity care fee schedules is not sought, these forgone charges for charity care are not reported as revenue. Total forgone charges for charity care totaled \$120,516 and \$101,318 for the years ended August 31, 2022 and 2021, respectively. This equated to an approximate cost of \$22,084 and \$19,297 for the years ended August 31, 2022 and 2021, respectively which is based on a ratio of cost to charges.

New York State regulations provide for the distribution of funds from an indigent care pool, which is intended to partially offset the cost of uncompensated care and service provided to uninsured. The funds are distributed to NYU Langone Health based on an uninsured methodology. Subsidy payments recognized as revenue amounted to approximately \$46,128 and \$49,408 for the years ended August 31, 2022 and 2021, respectively, and are included in patient care revenue in the consolidated statements of activities. NYU Langone Health has paid \$70,146 and \$63,004 into the indigent care pool for the years ended August 31, 2022 and 2021, respectively.

5. Investments

Asset Classes

NYU invests across a broad range of asset classes, including public equity, fixed income, hedge funds, credit, real assets, private equity, real estate, and cash and other. NYU may invest directly in the securities of these asset classes, or indirectly through interests in funds and limited partnerships. Securities held directly by NYU are valued at their observable market prices. The value of holdings in funds and limited partnerships are in accordance with the valuations provided by their investment managers. Funds and limited partnerships may make investments in securities that are publicly traded, which are generally valued based on observable market prices. Managers of investment funds and limited partnerships value those investments based upon the best information available for a given circumstance and may incorporate assumptions that are the investment manager's best estimates after consideration of a variety of internal and external factors.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

Investments held by NYU's investment pool are categorized as follows:

Public Equity

Public equity consists of publicly-traded equity, mutual funds, and other commingled funds (which may include passive index exposure).

Fixed Income

Fixed income includes investments in securities such as U.S. government securities, non-U.S. sovereign bonds, and corporate and asset-backed securities.

Real Assets

Real assets include public and private investments in real asset funds.

Cash and Other

Cash and other predominantly includes cash and cash equivalents.

Hedge Funds

Hedge funds include investments with managers who invest across different strategies such as long and short equity, multi-strategy, event driven and relative value funds. These managers typically employ some leverage.

Credit

Credit includes public and private investments in strategies including distressed debt and special situations.

Private Equity

Private equity investments include limited partnership investments in funds pursuing strategies in corporate buyouts, growth equity, and venture capital.

Real Estate

Real estate includes public and private investments in real estate funds.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

The following tables summarize the fair value of investments at August 31, 2022 and 2021:

	2022			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Long-term investments-investment pool				
Public equity	\$ 1,284,792	\$ -	\$ -	\$ 1,284,792
Fixed income	-	366,606	-	366,606
Real assets	16,768	-	-	16,768
Cash and other	123,227	-	-	123,227
	<u>1,424,787</u>	<u>366,606</u>	<u>-</u>	<u>1,791,393</u>
Alternative investments measured at NAV as a practical expedient				<u>3,505,993</u>
Subtotal investment pool				<u>5,297,386</u>
Other long-term investments				
Public equity	1,103,060	2,701	-	1,105,761
Fixed income	65,230	-	-	65,230
Cash and other	7,097	-	4,080	11,177
Subtotal other long-term investments	<u>1,175,387</u>	<u>2,701</u>	<u>4,080</u>	<u>1,182,168</u>
Total long-term investments	<u>\$ 2,600,174</u>	<u>\$ 369,307</u>	<u>\$ 4,080</u>	<u>\$ 6,479,554</u>
Short-term investments				
Cash and other	\$ 175,945	\$ -	\$ -	\$ 175,945
Total short-term investments	<u>\$ 175,945</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 175,945</u>
2021				
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Long-term investments-investment pool				
Public equity	\$ 1,442,361	\$ -	\$ -	\$ 1,442,361
Fixed income	-	377,629	-	377,629
Real assets	23,483	-	-	23,483
Cash and other	177,070	-	-	177,070
	<u>1,642,914</u>	<u>377,629</u>	<u>-</u>	<u>2,020,543</u>
Alternative investments measured at NAV as a practical expedient				<u>3,757,891</u>
Subtotal investment pool				<u>5,778,434</u>
Other long-term investments				
Public equity	805,368	2,780	-	808,148
Fixed income	499,746	-	-	499,746
Cash and other	4,078	-	3,460	7,538
Subtotal other long-term investments	<u>1,309,192</u>	<u>2,780</u>	<u>3,460</u>	<u>1,315,432</u>
Total long-term investments	<u>\$ 2,952,106</u>	<u>\$ 380,409</u>	<u>\$ 3,460</u>	<u>\$ 7,093,866</u>
Short-term investments				
Cash and other	\$ 193,532	\$ -	\$ -	\$ 193,532
Total short-term investments	<u>\$ 193,532</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 193,532</u>

Level 3 activity was not significant for either of the years ended August 31, 2022 or 2021.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

The following tables represent NYU's investments measured at NAV as a practical expedient by asset class and the respective liquidity terms as of August 31, 2022 and 2021:

2022				
Asset category	Redemption Frequency (if currently eligible)		Redemption Notice Period	Fair Value
Redeemable alternative investments				
Public equity	Daily, Weekly, Monthly, Quarterly, Annually		1 to 90 days	\$ 1,334,845
Hedge funds	Monthly, Quarterly, Semi-Annual, Annual, Bi-Annual		15 to 100 days	818,719
				<u>2,153,564</u>
Nonredeemable alternative investments				
	Remaining Life	Time to draw Commitment	Unfunded Commitments	Fair Value
Private equity	Up to 10 years	7-14 days	\$ 888,993	\$ 814,670
Credit	Up to 7 years	7-14 days	99,950	203,241
Real assets	Up to 3 years	7-14 days	2,682	57,832
Real estate	Up to 13 years	7-14 days	303,828	276,686
			<u>\$ 1,295,453</u>	<u>1,352,429</u>
				<u>\$ 3,505,993</u>

2021				
Asset category	Redemption Frequency (if currently eligible)		Redemption Notice Period	Fair Value
Redeemable alternative investments				
Public equity	Daily, Weekly, Monthly, Quarterly, Annually		1 to 180 days	\$ 1,733,289
Hedge funds	Monthly, Quarterly, Semi-Annual, Annual, Bi-Annual		15 to 100 days	980,005
				<u>2,713,294</u>
Nonredeemable alternative investments				
	Remaining Life	Time to draw Commitment	Unfunded Commitments	Fair Value
Private equity	Up to 10 years	7-14 days	\$ 517,673	\$ 579,211
Credit	Up to 8 years	7-14 days	159,553	170,280
Real assets	Up to 4 years	7-14 days	3,538	55,242
Real estate	Up to 12 years	7-14 days	157,165	239,864
			<u>\$ 837,929</u>	<u>1,044,597</u>
				<u>\$ 3,757,891</u>

NYU maintains an investment pool for its long-term investments which include its endowment and similar funds. The pool is managed to achieve the maximum long-term return given prudent risk parameters. NYU relies on a total return strategy, the objective of which is to achieve a long-term rate of return consisting of a combination of current income and capital appreciation, recognizing that changes in market conditions and interest rates will result in varying strategies in an attempt to optimize results. Investment return (realized and unrealized net gains or losses, interest and dividends) and the appropriation for the approved endowment distribution for board-designated endowment funds are reported as nonoperating activities in the consolidated statements of activities. Investment return and the appropriation for the approved endowment distribution for donor-restricted endowment funds are reported as changes in net assets with donor restrictions in the consolidated statements of activities.

NYU's Board of Trustees has authorized a spending policy designed to allow asset growth while providing a predictable flow of return to support activities. Distributions from the endowment to support activities (approximately 4.5% in 2022 and 2021) are based on a fixed percentage of the 12-quarter average market value. To preserve the endowment's purchasing power, caps may

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

further limit spending as follows: 1) the distribution of endowment return to support activities may not exceed the prior year's distribution by more than 10%, unless the increase was the result of new gifts to the endowment, and 2) if the results of using only the average market value of either the final four quarters alone or the final eight quarters alone would be a decline in the distribution from the prior year's distribution, then the distribution may not exceed the previous year's level.

6. Accounts and Loans Receivable, Net

Accounts and loans receivable, net of allowances for uncollectable amounts, consist of the following at August 31, 2022 and 2021:

	2022	2021
Students and other	\$ 257,059	\$ 208,719
Grants and contracts	217,977	163,745
Student loans	77,764	84,278
FEMA award receivable	104,477	97,188
Housing loans and other loans to employees	59,258	67,202
Insurance premiums and recoveries (Note 13)	199,763	202,568
	<u>916,298</u>	<u>823,700</u>
Allowance for uncollectible amounts	(68,449)	(65,171)
Accounts and loans receivable, net	<u>\$ 847,849</u>	<u>\$ 758,529</u>

Student loans consist primarily of Federal advances to the University under Perkins and other Federal loan programs which totaled \$41,015 and \$48,226 at August 31, 2022 and 2021, respectively. NYU records a liability on its consolidated balance sheets for these advances within funds held for others.

A reasonable estimate of the fair value of loans receivable from students under government loan programs could not be made because the notes cannot be sold and can only be assigned to the U.S. government or its designees. The fair value of loans receivable from students under NYU's loan programs approximates carrying value.

Housing loans and other loans to employees are secured by an interest in the underlying property or continued employment.

Management regularly assesses the adequacy of the allowance for credit losses by performing ongoing evaluation of the accounts and loans receivable portfolios.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

7. Contributions Receivable

Contributions receivable consist of the following at August 31, 2022 and 2021:

	2022	2021
Amounts expected to be collected in		
Less than one year	\$ 279,816	\$ 274,933
One to five years	313,822	349,259
More than five years	149,588	128,984
	<u>743,226</u>	<u>753,176</u>
Discount	(29,295)	(27,073)
Allowance for uncollectible amounts	(91,715)	(87,999)
	<u>\$ 622,216</u>	<u>\$ 638,104</u>
Contributions receivable, net		

Contributions receivable activity for the years ended August 31, 2022 and 2021 is as follows:

	2022	2021
Contributions receivable, gross, beginning of year	\$ 753,176	\$ 505,100
New pledges received	178,243	477,173
Adjustments and write-offs	(6,803)	(10,490)
Pledge payments received	(181,390)	(218,607)
	<u>743,226</u>	<u>753,176</u>
Contributions receivable, gross, end of year		
Discount and allowance for uncollectible amounts	(121,010)	(115,072)
	<u>\$ 622,216</u>	<u>\$ 638,104</u>
Contributions receivable, net, end of year		

Conditional promises to give are not reported in the consolidated balance sheets and consist of the following as of August 31, 2022 and 2021:

	2022	2021
Bequests	\$ 791,304	\$ 748,154
Intentions to give	123,674	103,893
Conditional promises to give	323,871	331,861
	<u>\$ 1,238,849</u>	<u>\$ 1,183,908</u>

Expenses related to fundraising activities are \$57,563 and \$52,175 for the years ended August 31, 2022 and 2021, respectively.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

8. Other Assets

Other assets consist of the following at August 31, 2022 and 2021:

	2022	2021
Deferred compensation plan assets held for others	\$ 452,035	\$ 486,090
Prepaid expenses and deferred charges	208,351	195,761
Inventory	189,964	168,571
Intangible assets and goodwill	51,199	51,293
Third-party payor receivables	32,256	53,856
Split-interest agreements	36,553	43,008
Other	103,712	76,852
	<u>\$ 1,074,070</u>	<u>\$ 1,075,431</u>
Other assets		

Deferred compensation plan assets held for others represent employee contributions and investment return for NYU's 457(b) plans. A corresponding obligation is recorded within funds held for others on the consolidated balance sheets.

NYU invests in various retirement plan assets as part of the deferred compensation plans. In addition to the asset classes described in Note 5, investments held by the deferred compensation plans also include:

Variable Annuity

Variable annuity contracts invest in a variety of public equity securities to generate varying rates of return based on the underlying public equities.

Fixed Income Annuity

Fixed income annuities are used to purchase a guaranteed amount of future retirement benefits.

The following tables summarize the fair value of other assets at August 31, 2022 and 2021:

	2022			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Other financial instruments				
Split-interest agreements	\$ -	\$ -	\$ 36,553	\$ 36,553
Deferred compensation plan held for others				
Variable annuities	\$ 131,453	\$ 51,921	\$ -	\$ 183,374
Fixed income annuity	23,200	7,503	48,609	79,312
Public equity	187,551	1,798	-	189,349
Total deferred compensation plan assets held for others	<u>\$ 342,204</u>	<u>\$ 61,222</u>	<u>\$ 48,609</u>	<u>\$ 452,035</u>

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

	2021			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Other financial instruments				
Split-interest agreements	\$ -	\$ -	\$ 43,008	\$ 43,008
Deferred compensation plan held for others				
Variable annuities	\$ 142,935	\$ 63,539	\$ -	\$ 206,474
Fixed income annuity	24,037	7,825	41,675	73,537
Public equity	204,991	1,088	-	206,079
Total deferred compensation plan assets held for others	\$ 371,963	\$ 72,452	\$ 41,675	\$ 486,090

Level 3 activity was not significant for either of the years ended August 31, 2022 or 2021.

9. Deposits with Trustees

Deposits with Trustees include unexpended bond proceeds to fund various construction projects held by the trustee, the Dormitory Authority of the State of New York (DASNY), and debt service funds, consist of the following at August 31, 2022 and 2021:

	2022	2021
Construction funds held by DASNY	\$ 597,930	\$ 849,197
Debt service funds	90	48
Debt service reserve funds	23,929	15,885
Other	1,002	1,342
	<u>\$ 622,951</u>	<u>\$ 866,472</u>

The following tables summarize the fair value of deposits with trustees at August 31, 2022 and 2021 according to the asset categories defined in Note 5.

	2022			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 432,955	\$ -	\$ -	\$ 432,955
Cash and other	189,996	-	-	189,996
Total deposits with trustees	<u>\$ 622,951</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 622,951</u>

	2021			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 483,549	\$ -	\$ -	\$ 483,549
Cash and other	382,923	-	-	382,923
Total deposits with trustees	<u>\$ 866,472</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 866,472</u>

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

10. Land, Buildings, and Equipment

Land, buildings, and equipment consist of the following at August 31, 2022 and 2021:

	2022	2021
Land	\$ 403,038	\$ 384,458
Buildings and building improvements	14,831,709	14,137,946
Equipment	3,289,833	2,983,769
Finance leases	1,606,877	1,632,225
Construction in progress	<u>2,009,444</u>	<u>1,429,112</u>
	22,140,901	20,567,510
Less: Accumulated depreciation	<u>(8,616,814)</u>	<u>(7,666,817)</u>
Land, buildings, and equipment, net	<u>\$ 13,524,087</u>	<u>\$ 12,900,693</u>

Depreciation expense is \$968,151 and \$924,444 for the years ended August 31, 2022 and 2021, respectively.

In September 2020, NYUGSoM extended an existing lease in Manhattan for 30 years, resulting in a reclassification of the lease from an operating lease to a finance lease totaling \$743,300.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

11. Leases

The components of lease expense included in the statements of activities consist of the following for the years ended August 31, 2022 and 2021:

	2022	2021
Lease cost		
Finance lease cost		
Amortization of right-of-use assets	\$ 89,946	\$ 89,283
Interest on finance lease obligations	63,840	61,976
Total finance lease cost	<u>153,786</u>	<u>151,259</u>
Operating lease cost	313,461	306,142
Short-term and variable lease costs	46,669	54,248
Total operating lease cost included in facilities costs	<u>360,130</u>	<u>360,390</u>
Total lease cost	<u>\$ 513,916</u>	<u>\$ 511,649</u>
Other information		
Cash paid for amounts included in the measurement of lease obligations		
Operating cash flows for operating leases	\$ 292,073	\$ 290,549
Operating cash flows for finance leases	63,840	59,728
Financing cash flows for finance leases	66,235	69,735
Right-of-use assets obtained		
In exchange for new operating lease obligations	\$ 249,270	\$ 148,514
In exchange for new finance lease obligations (Note 10)	50,243	809,818
Weighted-average remaining lease term		
Operating leases	18.2 years	18.7 years
Operating leases excluding ground lease through 2087	11.8 years	11.2 years
Finance leases	26.6 years	26.6 years
Weighted-average discount rate		
Operating leases	2.79 %	2.71 %
Finance leases	3.83 %	3.83 %

Aggregate future minimum lease payments under operating leases as of August 31, 2022 are as follows:

2023	\$ 290,885
2024	277,180
2025	268,918
2026	234,712
2027	210,414
Thereafter	<u>1,954,132</u>
Total minimum lease payments	3,236,241
Less: Imputed interest	<u>(919,255)</u>
Total operating lease obligation	<u>2,316,986</u>
Less: Deferred rent liability	<u>(162,764)</u>
Total operating right-to-use asset	<u>\$ 2,154,222</u>

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

12. Debt and Other Obligations

NYU has various bond issues outstanding, primarily issued through DASNY. The University and NYU Schools of Medicine are considered the legally obligated group for certain borrowings presented below as the "Obligated Group."

Debt and other obligations consist of the following at August 31, 2022 and 2021:

Issuer	2022				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
Dormitory Authority of the State of New York (DASNY)	\$ 3,696,789	\$ 808,785	\$ 4,505,574	\$ 794,135	\$ 5,299,709
New York University	245,581	57,096	302,677	-	302,677
NYU Langone Hospitals	-	-	-	2,039,751	2,039,751
Nassau County Local Economic Assistance Corporation	-	-	-	28,222	28,222
Brookhaven Local Development Corporation	-	-	-	83,866	83,866
Other obligations	167,638	1,268,851	1,436,489	375,692	1,812,181
Debt and other obligations	<u>\$ 4,110,008</u>	<u>\$ 2,134,732</u>	<u>\$ 6,244,740</u>	<u>\$ 3,321,666</u>	<u>\$ 9,566,406</u>

Issuer	2021				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
Dormitory Authority of the State of New York (DASNY)	\$ 3,811,174	\$ 831,736	\$ 4,642,910	\$ 820,457	\$ 5,463,367
New York University	256,431	61,350	317,781	-	317,781
NYU Langone Hospitals	-	-	-	2,039,298	2,039,298
Nassau County Local Economic Assistance Corporation	-	-	-	33,078	33,078
Other obligations	169,410	1,281,990	1,451,400	335,987	1,787,387
Debt and other obligations	<u>\$ 4,237,015</u>	<u>\$ 2,175,076</u>	<u>\$ 6,412,091</u>	<u>\$ 3,228,820</u>	<u>\$ 9,640,911</u>

In July 2021, DASNY issued \$212,695 of revenue bonds (Series 2021A) on behalf of the Obligated Group, with interest rates ranging from 0.66% to 2.23%, maturing serially through July 2041 and payable thereafter in annual sinking fund installments to maturity in 2051. The 2021A bonds maturing in July 2046 are payable in annual sinking fund installments from July 2042 to maturity. The 2021A bonds maturing in July 2051 are payable in annual sinking fund installments from July 2047 to maturity. In July 2021, DASNY issued \$37,305 of taxable bonds (Series 2021B) on behalf of the Obligated Group with interest rates ranging from 0.25% to 2.02%. The Series 2021B bonds mature serially from July 2022 through July 2031. The proceeds from the DASNY Series 2021A and Series 2021B were used to fund improvements on the Manhattan and Brooklyn campuses and repay certain lines of credit that were incurred to refund a portion of Series 2016A.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

The principal amounts outstanding for debt and other obligations consist of the following at August 31, 2022 and 2021:

	2022				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
DASNY					
Series 1998A bonds, with interest rates ranging from 5.75% to 6.00%, maturing serially through July 2020, payable thereafter in annual sinking fund installments to maturity in 2027 (including premium of \$1,134)	\$ 78,819	\$ -	\$ 78,819	\$ -	\$ 78,819
2001 Series 1 bonds, with an interest rate of 5.50%, maturing serially from July 2011, through July 2025, payable thereafter in annual sinking fund installments to maturities in July 2031 and July 2040 (including premiums of \$1,532 and \$1,900)	52,591	43,676	96,267	-	96,267
Series 2012C taxable bonds, with interest rates ranging from 1.93% to 3.62%, maturing serially through July 2027	11,440	-	11,440	-	11,440
Series 2013B taxable bonds, with interest rates ranging from 2.33% to 5.25%, maturing serially through July 2028, payable thereafter in annual sinking fund installments to maturities in July 2033 and July 2043	21,480	-	21,480	-	21,480
Series 2014 bonds, with interest rate ranging from 2.00% to 5.00%, maturing serially through July 2032 and July 2036 (including premium of \$6,181)	-	-	-	66,316	66,316
Series 2014 S2 bonds, with interest rate ranging from 3.75% to 4.95%, maturing serially through July 2034 and July 2035 (including premium of \$11,651)	-	-	-	81,011	81,011
Series 2014A taxable bonds, with an interest rate of 2.59% maturing in July 2034, payable in annual sinking fund installments through July 2034	43,325	-	43,325	-	43,325
Series 2015 bonds, with interest rates ranging from 2.00% to 5.50%, maturing serially through July 2035, payable in annual sinking fund installments from July 2036 to July 2048 (including premium of \$53,181)	607,220	-	607,220	-	607,220
Series 2016A bonds, with interest rates ranging from 2.00% to 5.00%, maturing serially through July 2036 payable thereafter in annual sinking fund installments until July 2043 (including premiums of \$53,663 and \$18,896)	458,323	137,471	595,794	-	595,794
Series 2016B taxable bonds, with interest rates ranging from 1.20% to 5.00%, maturing serially through July 2022 payable thereafter in annual sinking fund installments until July 2046	141,090	29,970	171,060	-	171,060
Series 2016A bonds, with interest rates ranging from 3.53% to 4.77%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2043 (including premium of \$17,557)	-	-	-	134,302	134,302
Series 2017A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2047 (including premium of \$28,967 and \$18,347)	289,387	161,677	451,064	-	451,064
Series 2017B taxable bonds, with interest rates ranging from 1.60% to 4.15%, maturing serially to maturity in July 2032	163,804	50,406	214,210	-	214,210
Series 2018A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$28,402 and \$8,453)	287,892	76,523	364,415	-	364,415
Series 2018B taxable bonds, with interest rates ranging from 2.27% to 4.85%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$6,029 and \$2,526)	146,170	100,371	246,541	-	246,541
Series 2019A bonds, with interest rates ranging from 4.00% to 5.00%, maturing serially through July 2049 payable thereafter in annual sinking fund installments (including premiums of \$71,254 and \$11,362)	581,380	87,167	668,547	-	668,547
Series 2019B-1 taxable bonds, with interest rates ranging from 2.76% to 4.29%, maturing serially through July 2044 payable thereafter in annual sinking fund installments	136,505	27,375	163,880	-	163,880
Series 2019B-2 taxable bonds, with an interest rate of 4.01% payable thereafter in annual sinking fund installments maturing on July 2049	77,925	5,245	83,170	-	83,170

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

	University	NYU Schools of Medicine	2022 Total Obligated Group	Health System	Consolidated NYU
Series 2020A bonds, with interest rates ranging from 3.00% to 4.00% maturing serially through July 2053 (including net premiums of \$52,195)	-	-	-	518,500	518,500
Series 2020B taxable bonds, with interest rates ranging from 1.29% to 2.77%, maturing serially through July 2030 and payable thereafter in annual sinking fund installments to maturity in 2043	368,150	36,255	404,405	-	404,405
Series 2021A bonds, with interest rates ranging from 0.66% to 2.23%, maturing serially through July 2041 and payable thereafter in annual sinking fund installments to maturity in 2051 (including premiums of \$39,679 and \$9,951)	212,739	49,586	262,325	-	262,325
Series 2021B taxable bonds, with interest rates ranging from 0.25% to 2.02%, maturing serially through July 2031	29,965	4,495	34,460	-	34,460
Deferred financing costs	(11,416)	(1,432)	(12,848)	(5,994)	(18,842)
Subtotal of DASNY bonds	<u>3,696,789</u>	<u>808,785</u>	<u>4,505,574</u>	<u>794,135</u>	<u>5,299,709</u>
NYU					
Series 2009 taxable bonds, with an interest rate of 5.24%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	11,019	57,486	68,505	-	68,505
Series 2010 taxable bonds, with an interest rate of 4.96%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	16,830	-	16,830	-	16,830
Series 2015 taxable bonds, with interest rates ranging from 1.32% to 4.14%, maturing serially through July 2028, payable in annual sinking fund installments from July 2029 to July 2048	218,485	-	218,485	-	218,485
Deferred financing costs	(753)	(390)	(1,143)	-	(1,143)
Subtotal of NYU bonds	<u>245,581</u>	<u>57,096</u>	<u>302,677</u>	<u>-</u>	<u>302,677</u>
NYU Langone Hospitals					
Series 2012 taxable bonds, with an interest rate of 4.40%, maturing in July 2042 (including discount of \$690)	-	-	-	249,310	249,310
Series 2013 taxable bonds, with an interest rate of 5.75%, maturing in July 2043 (including discount of \$1,003)	-	-	-	348,997	348,997
Series 2014 taxable bonds, with an interest rate of 4.78%, maturing in July 2044 (including discount of \$921)	-	-	-	299,079	299,079
Series 2017A taxable bonds, with an interest rate ranging from 4.17% to 4.37%, maturing in August 2047	-	-	-	600,000	600,000
Series 2020B taxable bonds, with a fixed interest rate of 3.38% to maturity in July 2055 (including a discount of \$2,518)	-	-	-	548,507	548,507
Deferred financing costs	-	-	-	(6,142)	(6,142)
Subtotal of NYU Langone Hospitals bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>2,039,751</u>	<u>2,039,751</u>
Nassau County Local Economic Assistance Corporation					
Series 2014 taxable bonds, with an interest rate of 2.99%, maturing in July 2036	-	-	-	28,222	28,222
Subtotal of Nassau County Local Economic Assistance Corporation bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>28,222</u>	<u>28,222</u>
Brookhaven Local Development Corporation					
Series 2020A taxable bond series, with varying interest rates of 4.2% to 5.0%, maturing in October 2050 (including premium of \$7,381)	-	-	-	66,516	66,516
Series 2020B taxable bond series, with varying interest rates of 5.5% to 6.0%, maturing in October 2030 (including premium of \$1,470)	-	-	-	17,350	17,350
Subtotal of Brookhaven Local Development Corporation	<u>-</u>	<u>-</u>	<u>-</u>	<u>83,866</u>	<u>83,866</u>
Other obligations					
Mortgage loans	-	39,095	39,095	6,954	46,049
Commercial loans	-	-	-	14,277	14,277
Lines of credit	-	43,030	43,030	-	43,030
Finance leases (Note 10)	167,638	1,186,726	1,354,364	354,461	1,708,825
Subtotal of other obligations	<u>167,638</u>	<u>1,268,851</u>	<u>1,436,489</u>	<u>375,692</u>	<u>1,812,181</u>
Total amounts outstanding	<u>\$ 4,110,008</u>	<u>\$ 2,134,732</u>	<u>\$ 6,244,740</u>	<u>\$ 3,321,666</u>	<u>\$ 9,566,406</u>

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

	University	NYU Schools of Medicine	2021 Total Obligated Group	Health System	Consolidated NYU
DASNY					
Series 1998A bonds, with interest rates ranging from 5.75% to 6.00%, maturing serially through July 2020, payable thereafter in annual sinking fund installments to maturity in 2027 (including premium of \$1,560)	\$ 92,335	\$ -	\$ 92,335	\$ -	\$ 92,335
2001 Series 1 bonds, with an interest rate of 5.50%, maturing serially from July 2011, through July 2025, payable thereafter in annual sinking fund installments to maturities in July 2031 and July 2040 (including premiums of \$1,676 and \$2,007)	54,378	45,126	99,504	-	99,504
Series 2012C taxable bonds, with interest rates ranging from 1.93% to 3.62%, maturing serially through July 2027	13,590	-	13,590	-	13,590
Series 2013B taxable bonds, with interest rates ranging from 2.33% to 5.25%, maturing serially through July 2028, payable thereafter in annual sinking fund installments to maturities in July 2033 and July 2043	22,845	-	22,845	-	22,845
Series 2014 bonds, with interest rate ranging from 2.00% to 5.00%, maturing serially through July 2032 and July 2036 (including premium of \$6,626)	-	-	-	70,001	70,001
Series 2014 S2 bonds, with interest rate ranging from 3.75% to 4.95%, maturing serially through July 2034 and July 2035 (including premium of \$12,547)	-	-	-	96,107	96,107
Series 2014A taxable bonds, with an interest rate of 2.59% maturing in July 2034, payable in annual sinking fund installments through July 2034	46,365	-	46,365	-	46,365
Series 2015 bonds, with interest rates ranging from 2.00% to 5.50%, maturing serially through July 2035, payable in annual sinking fund installments from July 2036 to July 2048 (including premium of \$57,212)	627,887	-	627,887	-	627,887
Series 2016A bonds, with interest rates ranging from 2.00% to 5.00%, maturing serially through July 2036 payable thereafter in annual sinking fund installments until July 2043 (including premiums of \$58,361 and \$19,689)	465,701	141,899	607,600	-	607,600
Series 2016B taxable bonds, with interest rates ranging from 1.20% to 5.00%, maturing serially through July 2022 payable thereafter in annual sinking fund installments until July 2046	152,000	29,970	181,970	-	181,970
Series 2016A bonds, with interest rates ranging from 3.53% to 4.77%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2043 (including premium of \$18,546)	-	-	-	140,276	140,276
Series 2017A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2047 (including premium of \$32,654 and \$19,089)	305,108	165,565	470,673	-	470,673
Series 2017B taxable bonds, with interest rates ranging from 1.60% to 4.15%, maturing serially to maturity in July 2032	167,299	50,406	217,705	-	217,705
Series 2018A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$30,940 and \$8,780)	298,075	78,716	376,791	-	376,791
Series 2018B taxable bonds, with interest rates ranging from 2.27% to 4.85%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$6,301 and \$2,624)	146,440	102,053	248,493	-	248,493
Series 2019A bonds, with interest rates ranging from 4.00% to 5.00%, maturing serially through July 2049 payable thereafter in annual sinking fund installments (including premiums of \$76,182 and \$11,786)	595,287	87,591	682,878	-	682,878
Series 2019B-1 taxable bonds, with interest rates ranging from 2.76% to 4.29%, maturing serially through July 2044 payable thereafter in annual sinking fund installments	136,505	33,580	170,085	-	170,085
Series 2019B-2 taxable bonds, with an interest rate of 4.01% payable thereafter in annual sinking fund installments maturing on July 2049	77,925	5,245	83,170	-	83,170

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

	2021				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
Series 2020A bonds, with interest rates ranging from 3.00% to 4.00% maturing serially through July 2053 (including net premiums of \$54,070)	-	-	-	520,374	520,374
Series 2020B taxable bonds, with interest rates ranging from 1.29% to 2.77%, maturing serially through July 2030 and payable thereafter in annual sinking fund installments to maturity in 2043	375,060	37,830	412,890	-	412,890
Series 2021A bonds, with interest rates ranging from 0.66% to 2.23%, maturing serially through July 2041 and payable thereafter in annual sinking fund installments to maturity in 2051 (including premiums of \$41,737 and \$10,295)	214,797	49,930	264,727	-	264,727
Series 2021B taxable bonds, with interest rates ranging from 0.25% to 2.02%, maturing serially through July 2031	31,965	5,340	37,305	-	37,305
Deferred financing costs	(12,388)	(1,515)	(13,903)	(6,301)	(20,204)
Subtotal of DASNY bonds	<u>3,811,174</u>	<u>831,736</u>	<u>4,642,910</u>	<u>820,457</u>	<u>5,463,367</u>
NYU					
Series 2009 taxable bonds, with an interest rate of 5.24%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	11,842	61,778	73,620	-	73,620
Series 2010 taxable bonds, with an interest rate of 4.96%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	18,085	-	18,085	-	18,085
Series 2015 taxable bonds, with interest rates ranging from 1.32% to 4.14%, maturing serially through July 2028, payable in annual sinking fund installments from July 2029 to July 2048	227,335	-	227,335	-	227,335
Deferred financing costs	(831)	(428)	(1,259)	-	(1,259)
Subtotal of NYU bonds	<u>256,431</u>	<u>61,350</u>	<u>317,781</u>	<u>-</u>	<u>317,781</u>
NYU Langone Hospitals					
Series 2012 taxable bonds, with an interest rate of 4.40%, maturing in July 2042 (including discount of \$724)	-	-	-	249,276	249,276
Series 2013 taxable bonds, with an interest rate of 5.75%, maturing in July 2043 (including discount of \$1,051)	-	-	-	348,949	348,949
Series 2014 taxable bonds, with an interest rate of 4.78%, maturing in July 2044 (including discount of \$963)	-	-	-	299,037	299,037
Series 2017A taxable bonds, with an interest rate ranging from 4.17% to 4.37%, maturing in August 2047	-	-	-	600,000	600,000
Series 2020B taxable bonds, with a fixed interest rate of 3.38% to maturity in July 2055 (including a discount of \$2,594)	-	-	-	548,431	548,431
Deferred financing costs	-	-	-	(6,395)	(6,395)
Subtotal of NYU Langone Hospitals bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>2,039,298</u>	<u>2,039,298</u>
Nassau County Local Economic Assistance Corporation					
Series 2012 taxable bonds with varying interest rates of 3.00% to 5.00%, maturing in July 2042	-	-	-	3,260	3,260
Series 2014 taxable bonds, with an interest rate of 2.99%, maturing in July 2036	-	-	-	29,818	29,818
Subtotal of Nassau County Local Economic Assistance Corporation bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>33,078</u>	<u>33,078</u>
Other obligations					
Mortgage loans	-	40,730	40,730	11,562	52,292
Commercial loans	-	-	-	24,081	24,081
Lines of credit	-	44,400	44,400	-	44,400
Finance leases (Note 10)	169,410	1,196,860	1,366,270	300,344	1,666,614
Subtotal of other obligations	<u>169,410</u>	<u>1,281,990</u>	<u>1,451,400</u>	<u>335,987</u>	<u>1,787,387</u>
Total amounts outstanding	<u>\$ 4,237,015</u>	<u>\$ 2,175,076</u>	<u>\$ 6,412,091</u>	<u>\$ 3,228,820</u>	<u>\$ 9,640,911</u>

Interest expense on debt and other obligations totaled \$368,647 and \$368,152 for the years ended August 31, 2022 and 2021, respectively. This excludes \$18,934 and \$14,516 of interest capitalized (net of income earned on deposits with bond trustees) for the years ended August 31, 2022 and 2021, respectively, which is included in land, buildings, and equipment, net.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

NYU enters into various debt and other loan agreements that are secured by specific revenue streams, collateral and other real property or improvements, in addition to issuing debt supported by a general obligation of the University, any of which may constrain the use of certain assets. Other agreements include covenants requiring that NYU Langone Hospitals maintains certain financial ratios. At August 31, 2022 and 2021, the Obligated Group and NYU Langone Hospitals is compliant with all financial and administrative covenants.

Obligations with Financial Institutions

At August 31, 2022 and 2021, the Obligated Group has three contractually committed bank credit agreements which total \$800,000. As of August 31, 2022, these agreements expire from February 2023 to May 2025. The interest is accrued at rates based on LIBOR, the Bloomberg Short-Term Bank Yield Index, and the Secured Overnight Financing Rate. The amounts outstanding under these agreements are \$43,030 and \$44,400 as of August 31, 2022 and 2021, respectively.

At August 31, 2022, NYU Langone Hospitals has four unsecured lines of credit which total \$689,800 and expire from August 2023 to May 2024. At August 31, 2021, NYU Langone Hospitals has three unsecured lines of credit which total \$600,000 and expire from August 2023 to May 2024. The interest is accrued at rates based on LIBOR. There were no amounts outstanding as of August 31, 2022 and 2021, respectively.

Future Principal Payments

The aggregate required principal payments on all debt and other obligations, including capital leases, for each of the next five fiscal years, and thereafter to maturity, are as follows:

Year Ending August 31,	Debt and Other Obligations	Finance Leases	Total
2023	\$ 160,271	\$ 109,390	\$ 269,661
2024	168,184	99,694	267,878
2025	210,981	95,441	306,422
2026	178,449	95,335	273,784
2027	183,025	90,786	273,811
Thereafter	<u>6,536,219</u>	<u>2,406,297</u>	<u>8,942,516</u>
	7,437,129	2,896,943	10,334,072
Unamortized premiums and discounts, net	446,579	-	446,579
Unamortized deferred financing costs	(26,127)	-	(26,127)
Less: Imputed interest	-	(1,188,118)	(1,188,118)
	<u>\$ 7,857,581</u>	<u>\$ 1,708,825</u>	<u>\$ 9,566,406</u>

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

13. Professional Liabilities

NYU Langone Hospitals' professional liabilities are reported on a discounted basis and comprise estimates for known reported losses and loss expenses plus a provision for losses incurred but not reported. Losses are actuarially determined and are based on the loss experience of the insured. In management's opinion, recorded reserves for both self-insured and commercially insured exposures are adequate to cover the ultimate net cost of losses incurred to date; however, the provision is based on estimates and may ultimately be settled for a significantly greater or lesser amount.

Professional liabilities consist of the following as of August 31, 2022 and 2021:

	2022	2021
CCC550 professional liabilities	\$ 771,867	\$ 723,868
Self-insured liabilities	50,900	53,501
Commercially insured liabilities	63,062	70,541
LICH self-insured liabilities	31,400	-
Professional liabilities	<u>\$ 917,229</u>	<u>\$ 847,910</u>

NYU Langone Hospitals is self-insured for professional and general liabilities on an occurrence basis through CCC550. Beginning July 1, 2017, NYU Langone Hospital-Long Island and certain of its physicians are also self-insured through CCC550. Prior to July 1, 2017, NYU Langone Hospital-Long Island was self-insured for professional liabilities and designated funds in a revocable trust for satisfaction of claims and expenses. LICH is self-insured for professional liabilities on a claims-made basis. In addition, LICH maintains excess professional and general liability coverage through a third-party insurance company.

CCC550 provides insurance coverage to certain voluntary attending physicians and other non-employed physicians serving NYUGSoM and NYU Langone Hospitals. The cost of this insurance coverage is the responsibility of such physicians.

Assets held for professional liabilities consist of the following at August 31, 2022 and 2021:

	2022	2021
Assets held by CCC550	\$ 899,260	\$ 858,650
Self-insurance trust	51,736	55,477
Assets held for professional liabilities	<u>\$ 950,996</u>	<u>\$ 914,127</u>

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

The following tables summarize the fair value of assets held for professional liabilities at August 31, 2022 and 2021 according to the asset categories defined in Note 5:

	2022			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 51,736	\$ 726,287	\$ -	\$ 778,023
Equity	135,376	-	-	135,376
Cash and other	37,597	-	-	37,597
Total assets held for professional liabilities	<u>\$ 224,709</u>	<u>\$ 726,287</u>	<u>\$ -</u>	<u>\$ 950,996</u>

	2021			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 55,477	\$ 833,053	\$ -	\$ 888,530
Cash and other	25,597	-	-	25,597
Total assets held for professional liabilities	<u>\$ 81,074</u>	<u>\$ 833,053</u>	<u>\$ -</u>	<u>\$ 914,127</u>

Commercially insured liabilities primarily relate to policies purchased by NYU Langone Hospital-Brooklyn and NYU Langone Hospital-Long Island (for certain of its physicians) covering periods prior to October 1, 2015 and July 1, 2017, respectively. NYU Langone Hospitals recorded a corresponding insurance recovery receivable for claims covered by these policies within accounts and loans receivable, net on the consolidated balance sheets (Note 6).

14. Pension Plans and Other Postretirement Benefits

Pension Plans

Substantially all NYU employees are covered by retirement plans including various defined contribution plans, multi-employer defined benefit plans, and three NYU-sponsored benefit plans.

Defined Contribution Plans

Contributions to the defined contribution plans are based on rates required by union contracts or other contractual arrangements. Contributions of \$302,766 and \$262,571 in 2022 and 2021, respectively, are reported as expenses in the consolidated statements of activities. There is no obligation on the consolidated balance sheets for these plans.

Multi-Employer Defined Benefit Plans

Contributions to the multi-employer defined benefit plans are based on rates required by union contracts and other contractual arrangements. Contributions of \$229,544 and \$199,920 in 2022 and 2021, respectively, are reported as expenses in the consolidated statements of activities. There is no obligation on the consolidated balance sheets for these plans.

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

Defined Benefit Plans

Contributions to the three defined benefit plans are intended to provide benefits attributed to service to date, as well as for those expected to be earned in the future. Contributions are made in amounts sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974 as amended under the Pension Protection Act of 2006 (ERISA), plus such additional amounts as the sponsors may deem appropriate. Pension benefits under these defined benefit plans are based on participants' final average compensation levels and years of service and are accrued during the period the employees provide service to NYU. Contributions of \$16,699 and \$63,001 in 2022 and 2021, respectively, are reported as a reduction in the accrued benefit obligation on the consolidated balance sheets for these plans.

Postretirement Benefits

NYU has three defined benefit health and welfare plans that provide certain health care and life insurance benefits for eligible retired employees. NYU employees may become eligible for these benefits if they reach the age and service requirements of the plan while working for NYU. The costs related to these plans are accrued during the period the employees provide service to NYU. Contributions of \$28,178 and \$26,133 in 2022 and 2021, respectively, are reported as a reduction in the accrued postretirement obligation on the consolidated balance sheets for these plans.

The following tables provide information with respect to the defined benefit and other postretirement benefit plans for the years ended August 31:

Plans' Funded Status

	Defined Benefit Pension Plans		Postretirement Benefit Plans	
	2022	2021	2022	2021
Change in benefit obligation				
Benefit obligation as of beginning of year	\$ 2,892,896	\$ 2,806,713	\$ 850,054	\$ 943,159
Service cost	59,031	57,693	22,395	29,326
Interest cost	70,614	67,737	23,775	23,635
Actuarial (gain) loss	(698,354)	55,281	(169,265)	(57,811)
Benefits paid	(108,705)	(93,203)	(30,310)	(31,789)
Participant contributions	-	-	7,947	7,333
Retiree drug subsidy receipts	-	-	908	1,772
Administrative expenses	(1,448)	(1,325)	-	-
Plan amendments	-	-	-	(65,571)
Benefit obligation as of end of year	<u>2,214,034</u>	<u>2,892,896</u>	<u>705,504</u>	<u>850,054</u>
Change in fair value of plan assets				
Fair value of plan assets as of beginning of year	2,355,449	1,998,857	217,344	172,599
Actual return on plan assets	(446,679)	388,119	(29,301)	41,296
Employer contributions	16,699	63,001	28,178	26,133
Benefits paid	(108,705)	(93,203)	(30,310)	(31,789)
Participant contributions	-	-	7,947	7,333
Retiree drug subsidy receipts	-	-	908	1,772
Administrative expenses	(1,448)	(1,325)	-	-
Fair value of plan assets, end of year	<u>1,815,316</u>	<u>2,355,449</u>	<u>194,766</u>	<u>217,344</u>
Accrued benefit obligation	<u>\$ 398,718</u>	<u>\$ 537,447</u>	<u>\$ 510,738</u>	<u>\$ 632,710</u>
Benefit obligation range of assumptions as of August 31				
Discount rate	4.70% - 4.95%	2.87% - 3.15%	4.65% - 4.91%	2.80% - 2.95%
Rate of increase in compensation levels	2.91% - 5.00%	2.91% - 5.00%	N/A	N/A

The accumulated benefit obligation for the defined benefit pension plans is \$2,078,546 and \$2,681,560 at August 31, 2022 and 2021, respectively.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

Net Periodic Benefit Cost

	Defined Benefit Pension Plans		Postretirement Benefit Plans	
	2022	2021	2022	2021
Components of net periodic benefit cost				
Operating expense				
Service cost in salary and fringe	\$ 59,031	\$ 57,693	\$ 22,395	\$ 29,326
Nonoperating expense				
Interest cost	70,614	67,737	23,775	23,635
Expected return on plan assets	(147,122)	(137,365)	(13,014)	(10,329)
Amortization of prior service cost (credit)	-	2	(4,113)	92
Amortization of actuarial loss	32,723	37,422	10,966	10,768
One-time curtailment loss	-	-	-	1,761
Total non-service costs	<u>(43,785)</u>	<u>(32,204)</u>	<u>17,614</u>	<u>25,927</u>
Net periodic benefit cost	<u>\$ 15,246</u>	<u>\$ 25,489</u>	<u>\$ 40,009</u>	<u>\$ 55,253</u>
Other changes recognized in net assets without donor restrictions				
Actuarial net gain arising during period	\$ (104,554)	\$ (195,473)	\$ (126,949)	\$ (88,778)
Amortization of prior service (cost) credit	-	(2)	4,113	(2,174)
Amortization of actuarial loss	(32,723)	(37,422)	(10,966)	(10,768)
Prior service credit	-	-	-	(65,236)
Total changes in pension and postretirement obligations	<u>\$ (137,277)</u>	<u>\$ (232,897)</u>	<u>\$ (133,802)</u>	<u>\$ (166,956)</u>
Net periodic benefit cost range of assumptions				
Discount rate	2.32% - 3.15%	2.32% - 3.27%	2.80% - 2.95%	2.75% - 2.89%
Rate of increase in compensation levels	2.91% - 5.00%	2.91% - 3.00%	N/A	N/A
Expected long-term rate of return on plan assets	6.00% - 7.00%	6.00% - 7.00%	6.00% - 7.00%	6.00% - 7.00%
Initial healthcare cost trend	N/A	N/A	6.50% - 9.19%	4.75% - 7.80%
Ultimate retiree health-care cost trend	N/A	N/A	4.50%	4.50%
Year ultimate trend rate is achieved	N/A	N/A	2024-2031	2024-2031

Actuarial gains were the result of asset returns in excess of planned return as well as changes in discount rates and plan experience for the year ended August 31, 2022 and 2021.

Amounts not yet reflected in net periodic benefit cost and included in net assets without donor restrictions for the defined benefit pension plans totaled \$291,989 and \$429,266 for the years ended August 31, 2022 and 2021, respectively. Amounts not yet reflected in net periodic benefit cost and included in net assets without donor restrictions for the postretirement benefit plans totaled \$(50,274) and \$83,528 for the years ended August 31, 2022 and 2021, respectively.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

Plan Assets

The following table presents the fair value of the defined benefit plan investments at August 31, 2022 and 2021 according to the asset categories defined in Note 5:

	2022			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Public equity	\$ 821,255	\$ 260,154	\$ -	\$ 1,081,409
Fixed income	396,333	247,713	-	644,046
Real estate	17,484	-	-	17,484
Cash and other	71,853	-	-	71,853
	<u>\$ 1,306,925</u>	<u>\$ 507,867</u>	<u>\$ -</u>	<u>1,814,792</u>
Alternative investments measured at NAV as a practical expedient				<u>524</u>
				<u>\$ 1,815,316</u>

	2021			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Public equity	\$ 1,037,161	\$ 339,858	\$ -	\$ 1,377,019
Fixed income	521,732	326,417	-	848,149
Real estate	20,865	-	-	20,865
Cash and other	108,076	-	-	108,076
	<u>\$ 1,687,834</u>	<u>\$ 666,275</u>	<u>\$ -</u>	<u>2,354,109</u>
Alternative investments measured at NAV as a practical expedient				<u>1,340</u>
				<u>\$ 2,355,449</u>

The defined benefit pension assets seek to: (1) provide retirement benefits to its participants and beneficiaries; and (2) achieve full funding of the pension liability, while incurring an acceptable level of risk for the sponsor. The pension liability growth rate together with the objective to achieve and maintain a fully-funded level over a reasonable timeline implies a minimum absolute rate of return to be met through either: (1) annual budgeted contributions, (2) pension assets growth, (3) plan de-risking improvements, or (4) a combination thereof.

The strategy for achieving and maintaining a fully funded pension liability may vary with the prevailing funded level and other parameters related to the overall goal. The asset allocation process is designed to be dynamic and employ a liability-driven, glide path investment strategy, which reframes risk and performance relative to the pension liability. This approach is expected to enable pension assets to more reliably track the value of the pension liability, with less funded level

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

volatility, than a static total-return investment. Broad target allocations at the current funded level are 55-75% return-seeking assets, such as equity and real estate (REIT) funds, and 25-45% liability-hedging assets, such as fixed income funds. The expected long-term rate of return assumption is determined by adding expected inflation to expected long-term real returns of various asset classes, weighing the asset class returns by the plans' investment in each class, and taking into account expected volatility and correlation between the returns of various asset classes. Working with our actuary, NYU management believes 6% - 7% is a reasonable estimate of long-term rates of return on plan assets for 2022 and will continue to evaluate the actuarial assumptions and adjust them as necessary.

The following table presents the fair value of the postretirement benefit plan investments at August 31, 2022 and 2021 according to the asset categories defined in Note 5:

	2022			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Public equity	\$ 128,620	\$ -	\$ -	\$ 128,620
Fixed income	55,844	10,174	-	66,018
Cash and other	128	-	-	128
	<u>\$ 184,592</u>	<u>\$ 10,174</u>	<u>\$ -</u>	<u>\$ 194,766</u>

	2021			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Public equity	\$ 142,301	\$ -	\$ -	\$ 142,301
Fixed income	60,789	14,136	-	74,925
Cash and other	118	-	-	118
	<u>\$ 203,208</u>	<u>\$ 14,136</u>	<u>\$ -</u>	<u>\$ 217,344</u>

The plans' investment objectives seek a long-term total rate of return to meet NYU's current and future plan obligations.

The postretirement benefit plan target asset allocation mix is 70% equity and 30% fixed income and cash, for which each asset class has a permitted range of +/- 10%.

The expected long-term rate of return assumption is determined by adding expected inflation to expected long-term real returns of various asset classes, taking into account expected volatility and correlation between the returns of various asset classes. NYU management believes that 6%-7% is a reasonable range of long-term rates of return on plan assets for 2022 and will continue to evaluate the actuarial assumptions and adjust them as necessary.

Contributions

NYU determines the annual contributions to the plans based upon calculations prepared by the plans' actuaries. Total expected contributions for the defined benefit pension plans and other postretirement benefit plans in fiscal year 2023 are \$17,450 and \$32,753, respectively.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

Benefit Payments

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid in the following years:

	Defined Benefit Pension Plans	Postretirement Benefit Plans
Year Ending August 31,		
2023	\$ 102,424	\$ 31,659
2024	107,982	33,286
2025	113,151	34,718
2026	118,762	36,623
2027	124,044	38,730
2028-2032	692,612	222,682

Multi-Employer Benefit Plans

NYU participates in multi-employer defined benefit pension plans. NYU makes cash contributions to these plans under the terms of collective-bargaining agreements that cover its union employees based on a fixed rate and hours worked per week by the covered employees. The risks of participating in these multi-employer plans are different from other single-employer plans in the following aspects: (1) assets contributed to the multi-employer plan by one employer may be used to provide benefits to employees of other participating employers; (2) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers; and (3) if NYU chooses to stop participating in some of its multi-employer plans, NYU may be required to pay those plans an amount based on the underfunded status of the plan, referred to as a withdrawal liability.

NYU's contributions to the following multi-employer defined benefit pension and postretirement plans are reported as salary and fringe expenses in the consolidated statements of activities for the years ended August 31, 2022 and 2021:

	2022	2021
1199 SEIU Health Care Employees Health & Welfare Fund	\$ 143,426	\$ 117,710
1199 SEIU Health Care Employees Pension Fund	57,130	55,369
United Federation of Teachers Welfare Fund	19,992	18,381
Local 810 United Wire, Metal & Machine Health & Welfare Fund	5,172	4,812
Local 810 United Wire, Metal & Machine Pension Fund	3,542	3,381
Local 30 Pension Fund	228	213
Local 153 Pension Fund	54	54
	<u>\$ 229,544</u>	<u>\$ 199,920</u>

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

The Pension Protection Act zone status indicates the plan's funded status of either at least 80% funded (green) or less than 80% funded (yellow or red). A zone status of red requires the plan sponsor to implement a Funding Improvement Plan (FIP) or Rehabilitation Plan (RP). The following table includes information for related pension funds for the plan years ended December 31, 2021 and 2020.

Pension Plan Name	EIN/Pension Plan Number	Pension Protection Act Zone Status		FIP/RP Status Pending/ Implemented	Surcharge Imposed	Expiration Date of Collective-Bargaining Agreement
		2021	2020			
1199 Pension Fund	13-3604862	Green	Green	N/A	No	September 2024
Local 810 United Wire Pension Fund	13-6596940	Red	Red	Yes	Yes	June 2024
Local 30 Pension Fund	51-6045848	Green	Green	N/A	No	June 2021
Local 153 Pension Fund	13-2864289	Red	Red	Yes	N/A	December 2026

NYU's contributions to the Local 810 United Wire Pension Fund represent greater than 5% of total plan contributions, based on the most recent Form 5500 available. NYU is in withdrawal status for the Local 153 Pension Fund with quarterly withdrawal payments continuing through 2033.

15. Hospital Affiliations

NYUGSoM has three affiliation agreements with the New York City Health and Hospitals Corporation (the Corporation) to provide general care and mental health services. The three agreements are with Woodhull Medical and Mental Health Center and Cumberland Diagnostic and Treatment Center, Bellevue Hospital Center and Gouverneur Healthcare Services, and Coler Rehabilitation and Nursing Care Center and Henry J. Carter Specialty Hospital and Nursing Facility. The current affiliation agreements cover the period July 1, 2021 through June 30, 2025. NYUGSoM recognized revenues from these affiliation agreements of \$421,490 and \$388,202 for the years ended August 31, 2022 and 2021, respectively.

NYU Langone Hospitals has several clinical affiliation agreements with New York City area hospitals where physicians provide patient care and supervision of residents at affiliated organizations. NYU Langone Hospitals also maintains an affiliation agreement with Sunset Park Health Council, Inc., a New York not-for-profit corporation, d/b/a Family Health Centers at NYU Langone. NYU Langone Hospitals recognized revenue from these affiliation agreements of \$27,337 and \$27,153 for the years ended August 31, 2022 and 2021, respectively.

16. Functional Classification of Expenses

NYU's primary program services are instruction, research and patient care. NYU's additional program services are student services and libraries and auxiliary enterprises. Expenses reported as institutional services are incurred in support of one or more of NYU's program services. Natural expenses attributed to more than one functional expense category are allocated using a variety of cost allocation techniques such as square footage and time and effort. Non-clinical COVID-19 costs in non-operating activities of \$37,792 and \$110,482 are classified as institutional services for the years ended August 31, 2022 and 2021, respectively.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

Expenses by functional classification for the years ended August 31, 2022 and 2021 consist of the following:

	2022						
	Instruction and Other Academic Programs	Research and Other Sponsored Programs	Patient Care	Student Services and Libraries	Auxiliary Enterprises	Institutional Services	Total
Salary and fringe	\$ 1,477,844	\$ 613,201	\$ 5,059,729	\$ 137,527	\$ 127,921	\$ 978,441	\$ 8,394,663
Medical and pharmaceutical costs	86	1,072	1,476,271	2	-	-	1,477,431
Professional services	134,027	33,966	262,464	19,353	61,731	225,639	737,180
Facilities costs	124,777	176,427	164,444	13,450	234,268	190,877	904,243
Fees, insurance and taxes	6,139	408	257,635	1,668	13,090	181,510	460,450
Depreciation and amortization expense	91,257	39,189	479,112	17,394	99,763	219,196	945,911
Interest expense	103,082	8,713	146,801	5,875	38,509	65,667	368,647
Other	162,735	268,082	129,654	53,430	10,598	194,175	818,674
	<u>\$ 2,099,947</u>	<u>\$ 1,141,058</u>	<u>\$ 7,976,110</u>	<u>\$ 248,699</u>	<u>\$ 585,880</u>	<u>\$ 2,055,505</u>	<u>\$ 14,107,199</u>
University	\$ 2,033,905	\$ 298,461	\$ 56,698	\$ 231,274	\$ 448,184	\$ 532,961	\$ 3,601,483
NYU Langone Health	66,042	842,597	7,919,412	17,425	142,562	1,530,457	10,518,495
	<u>\$ 2,099,947</u>	<u>\$ 1,141,058</u>	<u>\$ 7,976,110</u>	<u>\$ 248,699</u>	<u>\$ 590,746</u>	<u>\$ 2,063,418</u>	<u>14,119,978</u>
						Eliminations	(12,779)
							<u>\$ 14,107,199</u>

	2021						
	Instruction and Other Academic Programs	Research and Other Sponsored Programs	Patient Care	Student Services and Libraries	Auxiliary Enterprises	Institutional Services	Total
Salary and fringe	\$ 1,388,373	\$ 569,609	\$ 4,647,114	\$ 135,396	\$ 128,267	\$ 955,673	\$ 7,824,432
Medical and pharmaceutical costs	63	1,539	1,347,896	-	-	6,738	1,356,236
Professional services	119,623	31,859	228,967	15,032	47,355	158,406	601,242
Facilities costs	106,263	133,223	139,274	12,270	178,424	260,930	830,384
Fees, insurance and taxes	5,656	456	204,370	450	14,320	185,803	411,055
Depreciation and amortization expense	91,260	32,989	471,154	17,664	93,447	195,826	902,340
Interest expense	105,432	8,251	149,958	5,581	32,922	66,008	368,152
Other	97,312	163,674	182,240	45,661	9,304	214,166	712,357
	<u>\$ 1,913,982</u>	<u>\$ 941,600</u>	<u>\$ 7,370,973</u>	<u>\$ 232,054</u>	<u>\$ 504,039</u>	<u>\$ 2,043,550</u>	<u>\$ 13,006,198</u>
University	\$ 1,848,704	\$ 261,388	\$ 51,113	\$ 214,950	\$ 397,950	\$ 460,376	\$ 3,234,481
NYU Langone Health	65,278	680,212	7,319,860	17,104	111,075	1,590,167	9,783,696
	<u>\$ 1,913,982</u>	<u>\$ 941,600</u>	<u>\$ 7,370,973</u>	<u>\$ 232,054</u>	<u>\$ 509,025</u>	<u>\$ 2,050,543</u>	<u>13,018,177</u>
						Eliminations	(11,979)
							<u>\$ 13,006,198</u>

17. Components of Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following purposes at August 31, 2022 and 2021:

	2022	2021
Scholarships and fellowships	\$ 1,516,716	\$ 1,597,392
Contributions and earnings for operating purposes	1,498,322	1,865,393
Faculty and staff salaries	865,140	838,654
Program support	634,812	578,566
FEMA award for mitigation	38,698	50,067
Annuity trust agreements	37,796	40,080
Contributions for buildings and equipment	37,955	34,463
Other	107,634	108,286
Total net assets with donor restrictions	<u>\$ 4,737,073</u>	<u>\$ 5,112,901</u>

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

NYU's investment pools include individual endowed funds established for a variety of purposes. Pooled assets include both donor restricted endowment funds and funds designated by the board to function as endowments.

NYU classifies as net assets with donor restrictions the historical value of donor-restricted endowment funds, which includes: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment required by the applicable donor gift instrument. Also included in net assets with donor restrictions is accumulated unspent earnings on donor restricted endowment funds which are available for expenditure in a manner consistent with the standard of prudence described by the New York Prudent Management of Institutional Funds Act (NYPMIFA), and deficiencies associated with funds where the value of the fund has fallen below the original value of the gift. The historical value of NYU's donor-restricted endowment funds totaled \$2,690,456 and \$2,565,794 at August 31, 2022 and 2021, respectively.

NYU defines the appropriation of endowment net assets for expenditure as the authorization of its investment spending rate as approved annually by the Board of Trustees (Note 5). However, when donors have expressly stipulated the payout percentage of earnings on endowments that differs from NYU policies, the donors' intent prevails. In making a determination to appropriate or accumulate, NYU adheres to the standard of prudence prescribed by NYPMIFA and considers the following factors: the duration and preservation of the endowment fund; NYU's mission and the purpose of the endowment fund; general economic conditions; the possible effect of inflation or deflation; the expected total return from income and the appreciation of investments; other resources of NYU; where appropriate and circumstances would otherwise warrant, alternatives to expenditures of the endowment fund giving due consideration to the effect that such alternatives may have on NYU; and the investment policy of NYU.

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor required to be retained as a fund of perpetual duration. Deficiencies of this nature are reported in net assets with donor restrictions. As of August 31, 2022 and 2021, 117 funds and 5 funds, respectively, with original gift values of \$94,432 and \$350 were underwater by \$4,114 and \$34.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

(in thousands of dollars)

All endowment funds included within net assets without donor restrictions are board-designated. The following table provides the changes in the net asset classes of NYU's endowment funds at August 31:

	2022		
	Without Donor Restrictions	With Donor Restrictions	Total
Investment pool net assets, beginning of year	\$ 1,849,753	\$ 3,928,681	\$ 5,778,434
Contributions	105,706	142,056	247,762
Investment pool return	(175,386)	(342,708)	(518,094)
Endowment distribution	(64,208)	(134,137)	(198,345)
Liquidations	(3,715)	(8,656)	(12,371)
Investment pool net assets, end of year	\$ 1,712,150	\$ 3,585,236	\$ 5,297,386

	Without Donor Restrictions	With Donor Restrictions	Total
Investment pool net assets, beginning of year	\$ 1,593,729	\$ 3,111,869	\$ 4,705,598
Contributions	30,613	151,800	182,413
Investment pool return	395,546	791,618	1,187,164
Endowment distribution	(59,335)	(126,569)	(185,904)
Liquidations	(90,145)	(20,692)	(110,837)
Reclassification of net assets	(20,655)	20,655	-
Investment pool net assets, end of year	\$ 1,849,753	\$ 3,928,681	\$ 5,778,434

18. Commitments and Contingencies

NYU has ongoing construction projects with contractual commitments totaling \$254,793 at August 31, 2022.

NYU is self-insured for workers' compensation. The University purchases an excess workers' compensation insurance policy with a retention of \$500 per claim and has maintained a surety bond in the amount of \$12,720 at August 31, 2022 and 2021. Additionally, NYU Langone Health has maintained stand-by letters of credit aggregating approximately \$79,670 and \$63,540 at August 31, 2022 and 2021, respectively.

NYU is a defendant in various legal actions arising from the normal course of its activities and amounts expended under government grants and contracts are subject to audit by governmental agencies. In addition, amounts received for patient care from Medicare and Medicaid are subject

New York University

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(in thousands of dollars)

to audit. Although the final outcome of such actions and audits cannot be determined, management believes that eventual liability, if any, will not have a material effect on NYU's consolidated balance sheets.

19. Subsequent Events

NYU performed an evaluation of subsequent events through December 14, 2022, which is the date the consolidated financial statements were issued.

In November 2022, the Obligated Group entered into multiple finance leases in the New York Metro area with lease terms exceeding 30 years and discounted future payments totaling \$193,000.

Events Subsequent to Original Issuance of Financial Statements (Unaudited)

In connection with the reissuance of the consolidated financial statements, NYU has evaluated subsequent events through March 31, 2023, the date the consolidated financial statements were available to be reissued.

NYU Langone Hospitals and NYU sued their general contractor relating to unrecovered losses suffered from Superstorm Sandy, seeking damages. In January 2023, the litigation was resolved through a Settlement Agreement pursuant to which NYU Langone Hospitals and NYU will receive, in full settlement of all claims, approximately \$510,000.

As stated in Note 1, as of August 31, 2022, LICH was not in compliance with its debt service coverage ratio covenant. In January 2023, LICH requested and received bondholder consent to permanently remove the debt service coverage ratio covenant in return for an unsecured guaranty by NYU Langone Hospitals.

In March 2023, the University purchased a Luxembourg corporation for \$143,385 whose sole asset is a building at 265 Strand Street, London.

New York University
Notes to Consolidated Financial Statements
August 31, 2022 and 2021

20. Financial Responsibility Ratios

NYU participates in federal Title IV student financial assistance programs, which require it to meet standards of financial responsibility based on criteria determined by the U.S. Department of Education (ED), as set forth in 34 CFR 668.171. The criteria for private institutions include the annual calculation by ED of a financial responsibility composite score, as further outlined in 34 CFR 668.172, using audited financial statements submitted through ED's eZ-Audit system. The composite score is based on three ratios: Primary Reserve, Equity, and Net Income.

These ratios utilize the following financial data of NYU, which are not otherwise presented in the consolidated financial statements or other notes to the financial statements, as of and for the year ended August 31, 2022:

(in thousands of dollars)

Required input per standards	Ratio(s) Uses	Input Amount	Related financial statement amount not used as input on supplementary schedule
Property, plant and equipment, net - pre-implementation	Primary reserve	\$ 9,049,021	
Property, plant and equipment, net - post-implementation with outstanding debt for original purchase	Primary reserve	1,439,462	
Property, plant and equipment, net - post-implementation without outstanding debt for original purchase	Primary reserve	828,202	
Construction in progress - post-implementation	Primary reserve	2,207,402	
Total property, plant, and equipment, net	N/A		\$ 13,524,087
Long-term debt - for long-term purposes pre-implementation	Primary reserve	\$ 6,836,457	
Long-term debt - for long-term purposes post-implementation	Primary reserve	2,686,919	
Line of Credit for Construction in progress		43,030	
Total long-term debt	Primary reserve	\$ 9,566,406	
Net assets with donor restrictions: restricted by purpose or time			
Annuities and life income funds with donor restrictions	Primary reserve	\$ 86,503	
Term endowments with donor restrictions	Primary reserve	4,449	
Net assets with donor restrictions: Other, for purpose or time	N/A		1,927,463
Net assets with donor restrictions: restricted in perpetuity	Primary reserve	2,718,658	
Total net assets with donor restrictions	N/A		\$ 4,737,073
Unsecured related party receivable	Primary reserve; Equity	\$ 94,373	
Inputs directly from the statement of activities			
Total expenses without donor restrictions (operating)	Primary reserve	\$ 14,107,199	
Plus: non-operating expenses and other losses	Primary reserve	37,792	
Total expenses and losses without donor restrictions	Primary reserve	\$ 14,144,991	
Total operating revenue and other additions	Net income	\$ 14,825,125	
Less: investment return appropriated for spending	Net income	(64,208)	
Plus: non-operating revenues and other gains	Net income	412,307	
Total revenue and gains without donor restrictions	Net income	\$ 15,173,224	

Appendix A
Supplemental Schedules to the Consolidated Financial Statements

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Balance Sheet for NYU - Summary)
August 31, 2022

<i>(in thousands of dollars)</i>	2022			Consolidated NYU
	University	NYU Langone Health	Eliminations	
Assets				
Cash and cash equivalents	\$ 1,376,923	\$ 1,637,641	\$ -	\$ 3,014,564
Short-term investments (Note 5)	175,945	-	-	175,945
Accounts and loans receivable, net (Note 6)	422,442	496,485	(71,078)	847,849
Patient accounts receivable, net (Note 4)	7,134	1,208,586	-	1,215,720
Contributions receivable, net (Note 7)	270,975	351,241	-	622,216
Other assets (Note 8)	285,011	789,059	-	1,074,070
Deposits with trustees (Note 9)	325,185	297,766	-	622,951
Long-term investments (Note 5)	4,132,485	2,347,069	-	6,479,554
Operating lease right to use asset (Note 11)	586,294	1,567,928	-	2,154,222
Assets held for professional liabilities (Note 13)	-	950,996	-	950,996
Land, buildings, and equipment, net (Note 10)	4,929,156	8,594,931	-	13,524,087
Total assets	<u>\$ 12,511,550</u>	<u>\$ 18,241,702</u>	<u>\$ (71,078)</u>	<u>\$ 30,682,174</u>
Liabilities and Net Assets				
Liabilities				
Accounts payable and accrued expenses	\$ 508,168	\$ 2,114,243	\$ (71,078)	\$ 2,551,333
Deferred revenue	1,245,891	168,034	-	1,413,925
Operating lease liability (Note 11)	619,501	1,697,485	-	2,316,986
Professional liabilities (Note 13)	-	917,229	-	917,229
Debt and other obligations (Note 12)	4,110,008	5,456,398	-	9,566,406
Funds held for others (Notes 6 and 8)	152,149	341,330	-	493,479
Accrued benefit obligation (Note 14)	9,018	389,700	-	398,718
Accrued postretirement obligation (Note 14)	341,252	169,486	-	510,738
Asset retirement obligation	204,476	82,571	-	287,047
Total liabilities	<u>7,190,463</u>	<u>11,336,476</u>	<u>(71,078)</u>	<u>18,455,861</u>
Net assets				
Without donor restrictions	2,198,755	5,290,485	-	7,489,240
With donor restrictions (Note 17)	3,122,332	1,614,741	-	4,737,073
Total net assets	<u>5,321,087</u>	<u>6,905,226</u>	<u>-</u>	<u>12,226,313</u>
Total liabilities and net assets	<u>\$ 12,511,550</u>	<u>\$ 18,241,702</u>	<u>\$ (71,078)</u>	<u>\$ 30,682,174</u>

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Balance Sheet for NYU - Summary)
August 31, 2021

<i>(in thousands of dollars)</i>	2021			Consolidated NYU
	University	NYU Langone Health	Eliminations	
Assets				
Cash and cash equivalents	\$ 1,476,606	\$ 1,863,589	\$ -	\$ 3,340,195
Short-term investments (Note 5)	193,532	-	-	193,532
Accounts and loans receivable, net (Note 6)	362,326	462,687	(66,484)	758,529
Patient accounts receivable, net (Note 4)	8,134	1,051,359	-	1,059,493
Contributions receivable, net (Note 7)	325,497	312,607	-	638,104
Other assets (Note 8)	294,423	781,008	-	1,075,431
Deposits with trustees (Note 9)	417,183	449,289	-	866,472
Long-term investments (Note 5)	4,441,775	2,652,091	-	7,093,866
Operating lease right to use asset (Note 11)	625,365	1,529,634	-	2,154,999
Assets held for professional liabilities (Note 13)	-	914,127	-	914,127
Land, buildings, and equipment, net (Note 10)	4,680,356	8,220,337	-	12,900,693
Total assets	<u>\$ 12,825,197</u>	<u>\$ 18,236,728</u>	<u>\$ (66,484)</u>	<u>\$ 30,995,441</u>
Liabilities and Net Assets				
Liabilities				
Accounts payable and accrued expenses	\$ 455,436	\$ 2,388,820	\$ (66,484)	\$ 2,777,772
Deferred revenue	1,175,206	152,383	-	1,327,589
Operating lease liability (Note 11)	655,402	1,639,684	-	2,295,086
Professional liabilities (Note 13)	-	847,910	-	847,910
Debt and other obligations (Note 12)	4,237,015	5,403,896	-	9,640,911
Funds held for others (Notes 6 and 8)	168,944	364,179	-	533,123
Accrued benefit obligation (Note 14)	21,802	515,645	-	537,447
Accrued postretirement obligation (Note 14)	419,573	213,137	-	632,710
Asset retirement obligation	198,551	155,301	-	353,852
Total liabilities	<u>7,331,929</u>	<u>11,680,955</u>	<u>(66,484)</u>	<u>18,946,400</u>
Net assets				
Without donor restrictions	2,057,276	4,878,864	-	6,936,140
With donor restrictions (Note 17)	3,435,992	1,676,909	-	5,112,901
Total net assets	<u>5,493,268</u>	<u>6,555,773</u>	<u>-</u>	<u>12,049,041</u>
Total liabilities and net assets	<u>\$ 12,825,197</u>	<u>\$ 18,236,728</u>	<u>\$ (66,484)</u>	<u>\$ 30,995,441</u>

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Balance Sheet for NYU - Detail)
August 31, 2022

	2022						Total
<i>(in thousands of dollars)</i>	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	Consolidated NYU
Assets							
Cash and cash equivalents	\$ 1,376,923	\$ 47,346	\$ -	\$ 1,424,269	\$ 1,590,295	\$ -	\$ 3,014,564
Short-term investments (Note 5)	175,945	-	-	175,945	-	-	175,945
Accounts and loans receivable, net (Note 6)	422,442	199,319	(49,739)	572,022	355,756	(79,929)	847,849
Patient accounts receivable, net (Note 4)	7,134	146,025	-	153,159	1,062,561	-	1,215,720
Contributions receivable, net (Note 7)	270,975	123,181	-	394,156	228,060	-	622,216
Other assets (Note 8)	285,011	393,939	-	678,950	395,120	-	1,074,070
Deposits with trustees (Note 9)	325,185	-	-	325,185	297,766	-	622,951
Long-term investments (Note 5)	4,132,485	1,185,739	-	5,318,224	1,161,330	-	6,479,554
Operating lease right to use asset (Note 11)	586,294	1,019,076	-	1,605,370	548,852	-	2,154,222
Assets held for professional liabilities (Note 13)	-	-	-	-	950,996	-	950,996
Land, buildings, and equipment, net (Note 10)	4,929,156	3,499,330	-	8,428,486	5,095,601	-	13,524,087
Total assets	<u>\$ 12,511,550</u>	<u>\$ 6,613,955</u>	<u>\$ (49,739)</u>	<u>\$ 19,075,766</u>	<u>\$ 11,686,337</u>	<u>\$ (79,929)</u>	<u>\$ 30,682,174</u>
Liabilities and Net Assets							
Liabilities							
Accounts payable and accrued expenses	\$ 508,168	\$ 872,494	\$ (49,739)	\$ 1,330,923	\$ 1,300,339	\$ (79,929)	\$ 2,551,333
Deferred revenue	1,245,891	42,111	-	1,288,002	125,923	-	1,413,925
Operating lease liability (Note 11)	619,501	1,097,812	-	1,717,313	599,673	-	2,316,986
Professional liabilities (Note 13)	-	-	-	-	917,229	-	917,229
Debt and other obligations (Note 12)	4,110,008	2,134,732	-	6,244,740	3,321,666	-	9,566,406
Funds held for others (Notes 6 and 8)	152,149	300,743	-	452,892	40,587	-	493,479
Accrued benefit obligation (Note 14)	9,018	-	-	9,018	389,700	-	398,718
Accrued postretirement obligation (Note 14)	341,252	95,558	-	436,810	73,928	-	510,738
Asset retirement obligation	204,476	23,043	-	227,519	59,528	-	287,047
Total liabilities	<u>7,190,463</u>	<u>4,566,493</u>	<u>(49,739)</u>	<u>11,707,217</u>	<u>6,828,573</u>	<u>(79,929)</u>	<u>18,455,861</u>
Net assets							
Without donor restrictions	2,198,755	828,790	-	3,027,545	4,461,695	-	7,489,240
With donor restrictions (Note 17)	3,122,332	1,218,672	-	4,341,004	396,069	-	4,737,073
Total net assets	<u>5,321,087</u>	<u>2,047,462</u>	<u>-</u>	<u>7,368,549</u>	<u>4,857,764</u>	<u>-</u>	<u>12,226,313</u>
Total liabilities and net assets	<u>\$ 12,511,550</u>	<u>\$ 6,613,955</u>	<u>\$ (49,739)</u>	<u>\$ 19,075,766</u>	<u>\$ 11,686,337</u>	<u>\$ (79,929)</u>	<u>\$ 30,682,174</u>

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Balance Sheet for NYU - Detail)
August 31, 2021

	2021						Total
<i>(in thousands of dollars)</i>	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	Consolidated NYU
Assets							
Cash and cash equivalents	\$ 1,476,606	\$ 58,416	\$ -	\$ 1,535,022	\$ 1,805,173	\$ -	\$ 3,340,195
Short-term investments (Note 5)	193,532	-	-	193,532	-	-	193,532
Accounts and loans receivable, net (Note 6)	362,326	216,598	(47,137)	531,787	393,790	(167,048)	758,529
Patient accounts receivable, net (Note 4)	8,134	154,934	-	163,068	896,425	-	1,059,493
Contributions receivable, net (Note 7)	325,497	117,143	-	442,640	195,464	-	638,104
Other assets (Note 8)	294,423	408,412	-	702,835	372,596	-	1,075,431
Deposits with trustees (Note 9)	417,183	-	-	417,183	449,289	-	866,472
Long-term investments (Note 5)	4,441,775	1,315,669	-	5,757,444	1,336,422	-	7,093,866
Operating lease right to use asset (Note 11)	625,365	987,477	-	1,612,842	542,157	-	2,154,999
Assets held for professional liabilities (Note 13)	-	-	-	-	914,127	-	914,127
Land, buildings, and equipment, net (Note 10)	4,680,356	3,449,620	-	8,129,976	4,770,717	-	12,900,693
Total assets	<u>\$ 12,825,197</u>	<u>\$ 6,708,269</u>	<u>\$ (47,137)</u>	<u>\$ 19,486,329</u>	<u>\$ 11,676,160</u>	<u>\$ (167,048)</u>	<u>\$ 30,995,441</u>
Liabilities and Net Assets							
Liabilities							
Accounts payable and accrued expenses	\$ 455,436	\$ 930,761	\$ (47,137)	\$ 1,339,060	\$ 1,605,760	\$ (167,048)	\$ 2,777,772
Deferred revenue	1,175,206	37,102	-	1,212,308	115,281	-	1,327,589
Operating lease liability (Note 11)	655,402	1,053,265	-	1,708,667	586,419	-	2,295,086
Professional liabilities (Note 13)	-	-	-	-	847,910	-	847,910
Debt and other obligations (Note 12)	4,237,015	2,175,076	-	6,412,091	3,228,820	-	9,640,911
Funds held for others (Notes 6 and 8)	168,944	319,626	-	488,570	44,553	-	533,123
Accrued benefit obligation (Note 14)	21,802	-	-	21,802	515,645	-	537,447
Accrued postretirement obligation (Note 14)	419,573	119,513	-	539,086	93,624	-	632,710
Asset retirement obligation	198,551	52,193	-	250,744	103,108	-	353,852
Total liabilities	<u>7,331,929</u>	<u>4,687,536</u>	<u>(47,137)</u>	<u>11,972,328</u>	<u>7,141,120</u>	<u>(167,048)</u>	<u>18,946,400</u>
Net assets							
Without donor restrictions	2,057,276	718,483	-	2,775,759	4,160,381	-	6,936,140
With donor restrictions (Note 17)	3,435,992	1,302,250	-	4,738,242	374,659	-	5,112,901
Total net assets	<u>5,493,268</u>	<u>2,020,733</u>	<u>-</u>	<u>7,514,001</u>	<u>4,535,040</u>	<u>-</u>	<u>12,049,041</u>
Total liabilities and net assets	<u>\$ 12,825,197</u>	<u>\$ 6,708,269</u>	<u>\$ (47,137)</u>	<u>\$ 19,486,329</u>	<u>\$ 11,676,160</u>	<u>\$ (167,048)</u>	<u>\$ 30,995,441</u>

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Statement of Activities for NYU - Summary)
Year Ended August 31, 2022

	2022			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
Changes in net assets without donor restrictions				
Operating revenues				
Tuition and fees (net of financial aid awards of \$827,239 University; \$25,033 NYU Langone Health)	\$ 2,408,966	\$ 43,755	\$ -	\$ 2,452,721
Grants and contracts (Note 2)	736,715	654,556	-	1,391,271
Patient care (Note 4)	49,154	8,813,683	-	8,862,837
Hospital affiliations (Note 15)	-	448,827	-	448,827
Insurance premiums earned	-	108,014	-	108,014
Contributions	36,946	37,469	-	74,415
Endowment distribution (Note 5)	153,281	45,064	-	198,345
Return on short-term investments (Note 5)	9,791	35,366	-	45,157
Auxiliary enterprises (net of financial aid awards of \$70,701)	339,752	47,219	(4,866)	382,105
Program fees and other	47,714	648,136	(7,913)	687,937
Net assets released from restrictions	110,711	62,785	-	173,496
Total operating revenues	<u>3,893,030</u>	<u>10,944,874</u>	<u>(12,779)</u>	<u>14,825,125</u>
Expenses (Note 16)				
Salaries and fringe	2,123,823	6,270,840	-	8,394,663
Medical and pharmaceutical costs	-	1,477,431	-	1,477,431
Professional services	288,469	448,711	-	737,180
Facilities costs	379,607	529,502	(4,866)	904,243
Fees, insurance and taxes	53,285	407,165	-	460,450
Depreciation and amortization	260,521	685,390	-	945,911
Interest	156,654	211,993	-	368,647
Other	339,124	487,463	(7,913)	818,674
Total expenses	<u>3,601,483</u>	<u>10,518,495</u>	<u>(12,779)</u>	<u>14,107,199</u>
Excess of operating revenues over expenses	291,547	426,379	-	717,926
Nonoperating activities				
Investment return (Note 5)	(148,564)	(326,569)	-	(475,133)
Appropriation of endowment distribution (Note 5)	(54,751)	(9,457)	-	(64,208)
Pension and postretirement nonservice costs (Note 14)	3,720	22,451	-	26,171
Changes in pension and postretirement obligations (Note 14)	80,641	190,438	-	271,079
Net assets released from restrictions for capital	8,225	11,990	-	20,215
Non-clinical COVID costs (Note 2)	(37,792)	-	-	(37,792)
Other	(1,547)	96,389	-	94,842
Increase in net assets without donor restrictions	<u>141,479</u>	<u>411,621</u>	<u>-</u>	<u>553,100</u>
Changes in net assets with donor restrictions				
Contributions	162,011	137,792	-	299,803
Investment return (Note 5)	(245,069)	(94,172)	-	(339,241)
Appropriation of endowment distribution (Note 5)	(98,530)	(35,607)	-	(134,137)
Other	(13,136)	4,594	-	(8,542)
Net assets released from restrictions	(118,936)	(74,775)	-	(193,711)
Decrease in net assets with donor restrictions	<u>(313,660)</u>	<u>(62,168)</u>	<u>-</u>	<u>(375,828)</u>
(Decrease) increase in net assets	<u>\$ (172,181)</u>	<u>\$ 349,453</u>	<u>\$ -</u>	<u>\$ 177,272</u>

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Statement of Activities for NYU - Summary)
Year Ended August 31, 2021

	2021			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
Changes in net assets without donor restrictions				
Operating revenues				
Tuition and fees (net of financial aid awards of \$800,629 University; \$25,033 NYU Langone Health)	\$ 2,063,896	\$ 43,774	\$ -	\$ 2,107,670
Grants and contracts (Note 2)	641,139	552,457	-	1,193,596
Patient care (Note 4)	43,563	8,119,353	-	8,162,916
Hospital affiliations (Note 15)	-	415,355	-	415,355
Insurance premiums earned	-	106,708	-	106,708
Contributions	21,550	45,693	-	67,243
Endowment distribution (Note 5)	144,624	41,280	-	185,904
Return on short-term investments (Note 5)	4,607	28,845	-	33,452
Auxiliary enterprises (net of financial aid awards of \$47,077)	194,653	48,961	(4,987)	238,627
Program fees and other	186,233	708,943	(6,992)	888,184
Net assets released from restrictions	62,830	72,086	-	134,916
Total operating revenues	<u>3,363,095</u>	<u>10,183,455</u>	<u>(11,979)</u>	<u>13,534,571</u>
Expenses (Note 16)				
Salaries and fringe	1,961,502	5,862,930	-	7,824,432
Medical and pharmaceutical costs	-	1,356,236	-	1,356,236
Professional services	236,746	364,496	-	601,242
Facilities costs	336,813	498,558	(4,987)	830,384
Fees, insurance and taxes	42,964	368,091	-	411,055
Depreciation and amortization	260,942	641,398	-	902,340
Interest	155,781	212,371	-	368,152
Other	239,733	479,616	(6,992)	712,357
Total expenses	<u>3,234,481</u>	<u>9,783,696</u>	<u>(11,979)</u>	<u>13,006,198</u>
Excess of operating revenues over expenses	128,614	399,759	-	528,373
Nonoperating activities				
Investment return (Note 5)	341,080	232,017	-	573,097
Appropriation of endowment distribution (Note 5)	(51,076)	(8,259)	-	(59,335)
Pension and postretirement nonservice costs (Note 14)	(10,285)	16,562	-	6,277
Changes in pension and postretirement obligations (Note 14)	162,908	236,945	-	399,853
Net assets released from restrictions for capital	10,725	8,415	-	19,140
Non-clinical COVID costs (Note 2)	(110,482)	-	-	(110,482)
Other	(65,065)	13,567	-	(51,498)
Increase in net assets without donor restrictions	<u>406,419</u>	<u>899,006</u>	<u>-</u>	<u>1,305,425</u>
Changes in net assets with donor restrictions				
Contributions	299,776	306,337	-	606,113
Investment return (Note 5)	573,231	222,148	-	795,379
Appropriation of endowment distribution (Note 5)	(93,548)	(33,021)	-	(126,569)
Other	21,657	2,829	-	24,486
Net assets released from restrictions	(73,555)	(80,501)	-	(154,056)
Increase in net assets with donor restrictions	<u>727,561</u>	<u>417,792</u>	<u>-</u>	<u>1,145,353</u>
Increase in net assets	<u>\$ 1,133,980</u>	<u>\$ 1,316,798</u>	<u>\$ -</u>	<u>\$ 2,450,778</u>

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Statement of Activities for NYU - Detail)
Year Ended August 31, 2022

	2022						Total
<i>(in thousands of dollars)</i>	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	Consolidated NYU
Changes in net assets without donor restrictions							
Operating revenues							
Tuition and fees (net of financial aid awards of \$827,239 University; and \$25,033 NYU Langone Health)	\$ 2,408,966	\$ 43,253	\$ -	\$ 2,452,219	\$ 502	\$ -	\$ 2,452,721
Grants and contracts (Note 2)	736,715	641,069	-	1,377,784	13,487	-	1,391,271
Patient care (Note 4)	49,154	2,997,408	-	3,046,562	6,651,470	(835,195)	8,862,837
Hospital affiliations (Note 15)	-	421,490	-	421,490	27,337	-	448,827
Insurance premiums earned	-	-	-	-	108,014	-	108,014
Contributions	36,946	22,548	-	59,494	14,921	-	74,415
Endowment distribution (Note 5)	153,281	43,074	-	196,355	1,990	-	198,345
Return on short-term investments (Note 5)	9,791	1	-	9,792	35,365	-	45,157
Auxiliary enterprises (net of financial aid awards of \$70,701)	339,752	25,839	(4,866)	360,725	21,380	-	382,105
Program fees and other	47,714	329,765	(7,913)	369,566	685,842	(367,471)	687,937
Net assets released from restrictions	110,711	43,646	-	154,357	19,139	-	173,496
Total operating revenues	3,893,030	4,568,093	(12,779)	8,448,344	7,579,447	(1,202,666)	14,825,125
Expenses (Note 16)							
Salaries and fringe	2,123,823	3,392,242	-	5,516,065	2,932,604	(54,006)	8,394,663
Medical and pharmaceutical costs	-	91,038	-	91,038	1,386,393	-	1,477,431
Professional services	288,469	202,780	-	491,249	1,295,512	(1,049,581)	737,180
Facilities costs	379,607	289,206	(4,866)	663,947	240,296	-	904,243
Fees, insurance and taxes	53,285	279,285	-	332,570	127,880	-	460,450
Depreciation and amortization	260,521	244,228	-	504,749	441,162	-	945,911
Interest	156,654	84,518	-	241,172	127,475	-	368,647
Other	339,124	222,997	(7,913)	554,208	363,545	(99,079)	818,674
Total expenses	3,601,483	4,806,294	(12,779)	8,394,998	6,914,867	(1,202,666)	14,107,199
Excess (deficiency) of operating revenues over expenses	291,547	(238,201)	-	53,346	664,580	-	717,926
Nonoperating activities							
Investment return (Note 5)	(148,564)	(32,541)	-	(181,105)	(294,028)	-	(475,133)
Appropriation of endowment distribution (Note 5)	(54,751)	(9,295)	-	(64,046)	(162)	-	(64,208)
Pension and postretirement nonservice costs (Note 14)	3,720	4,461	-	8,181	17,990	-	26,171
Changes in pension and postretirement obligations (Note 14)	80,641	29,177	-	109,818	161,261	-	271,079
Net assets released from restrictions for capital	8,225	2,787	-	11,012	9,203	-	20,215
Non-clinical COVID costs (Note 2)	(37,792)	-	-	(37,792)	-	-	(37,792)
Other	(1,547)	303,919	-	302,372	(207,530)	-	94,842
Mission based payment	-	50,000	-	50,000	(50,000)	-	-
Increase in net assets without donor restrictions	141,479	110,307	-	251,786	301,314	-	553,100
Changes in net assets with donor restrictions							
Contributions	162,011	82,840	-	244,851	54,952	-	299,803
Investment return (Note 5)	(245,069)	(88,164)	-	(333,233)	(6,008)	-	(339,241)
Appropriation of endowment distribution (Note 5)	(98,530)	(33,779)	-	(132,309)	(1,828)	-	(134,137)
Other	(13,136)	1,958	-	(11,178)	2,636	-	(8,542)
Net assets released from restrictions	(118,936)	(46,433)	-	(165,369)	(28,342)	-	(193,711)
(Decrease) increase in net assets with donor restrictions	(313,660)	(83,578)	-	(397,238)	21,410	-	(375,828)
(Decrease) increase in net assets	\$ (172,181)	\$ 26,729	\$ -	\$ (145,452)	\$ 322,724	\$ -	\$ 177,272

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Statement of Activities for NYU - Detail)
Year Ended August 31, 2021

	2021						Total Consolidated NYU
(in thousands of dollars)	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	
Changes in net assets without donor restrictions							
Operating revenues							
Tuition and fees (net of financial aid awards of \$800,629 University; and \$25,033 NYU Langone Health)	\$ 2,063,896	\$ 43,556	\$ -	\$ 2,107,452	\$ 218	\$ -	\$ 2,107,670
Grants and contracts (Note 2)	641,139	528,718	-	1,169,857	23,739	-	1,193,596
Patient care (Note 4)	43,563	2,771,573	-	2,815,136	6,168,438	(820,658)	8,162,916
Hospital affiliations (Note 15)	-	388,202	-	388,202	27,153	-	415,355
Insurance premiums earned	-	-	-	-	106,708	-	106,708
Contributions	21,550	37,032	-	58,582	8,661	-	67,243
Endowment distribution (Note 5)	144,624	39,865	-	184,489	1,415	-	185,904
Return on short-term investments (Note 5)	4,607	-	-	4,607	28,845	-	33,452
Auxiliary enterprises (net of financial aid awards of \$47,077)	194,653	25,683	(4,987)	215,349	23,278	-	238,627
Program fees and other	186,233	337,173	(6,992)	516,414	679,019	(307,249)	888,184
Net assets released from restrictions	62,830	54,805	-	117,635	17,281	-	134,916
Total operating revenues	3,363,095	4,226,607	(11,979)	7,577,723	7,084,755	(1,127,907)	13,534,571
Expenses (Note 16)							
Salaries and fringe	1,961,502	3,198,530	-	5,160,032	2,708,229	(43,829)	7,824,432
Medical and pharmaceutical costs	-	83,887	-	83,887	1,272,349	-	1,356,236
Professional services	236,746	142,476	-	379,222	1,217,337	(995,317)	601,242
Facilities costs	336,813	265,348	(4,987)	597,174	233,210	-	830,384
Fees, insurance and taxes	42,964	229,609	-	272,573	138,482	-	411,055
Depreciation and amortization	260,942	220,015	-	480,957	421,383	-	902,340
Interest	155,781	83,560	-	239,341	128,811	-	368,152
Other	239,733	191,845	(6,992)	424,586	376,532	(88,761)	712,357
Total expenses	3,234,481	4,415,270	(11,979)	7,637,772	6,496,333	(1,127,907)	13,006,198
Excess (deficiency) of operating revenues over expenses	128,614	(188,663)	-	(60,049)	588,422	-	528,373
Nonoperating activities							
Investment return (Note 5)	341,080	58,211	-	399,291	173,806	-	573,097
Appropriation of endowment distribution (Note 5)	(51,076)	(8,106)	-	(59,182)	(153)	-	(59,335)
Pension and postretirement nonservice costs (Note 14)	(10,285)	(7,977)	-	(18,262)	24,539	-	6,277
Changes in pension and postretirement obligations (Note 14)	162,908	44,706	-	207,614	192,239	-	399,853
Net assets released from restrictions for capital	10,725	4,574	-	15,299	3,841	-	19,140
Non-clinical COVID costs (Note 2)	(110,482)	-	-	(110,482)	-	-	(110,482)
Other	(65,065)	35,626	-	(29,439)	(22,059)	-	(51,498)
Mission based payment	-	50,000	-	50,000	(50,000)	-	-
Increase (decrease) in net assets without donor restrictions	406,419	(11,629)	-	394,790	910,635	-	1,305,425
Changes in net assets with donor restrictions							
Contributions	299,776	86,427	-	386,203	219,910	-	606,113
Investment return (Note 5)	573,231	210,854	-	784,085	11,294	-	795,379
Appropriation of endowment distribution (Note 5)	(93,548)	(31,759)	-	(125,307)	(1,262)	-	(126,569)
Other	21,657	(15,592)	-	6,065	18,421	-	24,486
Net assets released from restrictions	(73,555)	(59,379)	-	(132,934)	(21,122)	-	(154,056)
Increase in net assets with donor restrictions	727,561	190,551	-	918,112	227,241	-	1,145,353
Increase in net assets	\$ 1,133,980	\$ 178,922	\$ -	\$ 1,312,902	\$ 1,137,876	\$ -	\$ 2,450,778

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Statement of Cash Flows for NYU – Summary)
Year Ended August 31, 2022

	2022			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
Cash flows from operating activities				
Change in net assets	\$ (172,181)	\$ 349,453	\$ -	\$ 177,272
Adjustments to reconcile change in net assets to net cash provided by operating activities				
Depreciation and amortization	260,521	685,390	-	945,911
Loss (gain) on sale or disposal of land, buildings and equipment	353	(554)	-	(201)
Net loss on investments, deposits with trustees and split-interest agreements	442,371	450,648	-	893,019
Bad debt expense	16,550	1,857	-	18,407
Pension and postretirement obligation change	(80,641)	(190,438)	-	(271,079)
Contributions received for permanent investment and capital	(86,290)	(27,319)	-	(113,609)
Proceeds from insurance recovery for capital and FEMA award for future mitigation	-	(1,236)	-	(1,236)
Amortization of operating right to use assets	113,573	151,751	-	265,324
Acquisition of Long Island Community Hospital	-	(105,967)	-	(105,967)
Changes in operating assets and liabilities				
Increase in accounts and loans receivable, net	(72,060)	(22,767)	4,594	(90,233)
Decrease (increase) in patient accounts receivable	1,000	(130,017)	-	(129,017)
Decrease (increase) in nonendowment and noncapital contributions receivable	49,916	(40,491)	-	9,425
Increase in other assets	(12,908)	(18,832)	-	(31,740)
Decrease in asset retirement obligation	(4,561)	(11,704)	-	(16,265)
Increase (decrease) in accounts payable and accrued expenses	22,494	(407,696)	(4,594)	(389,796)
Decrease in operating lease liability	(110,403)	(141,911)	-	(252,314)
Increase in professional liabilities	-	45,374	-	45,374
Increase in deferred revenue	70,685	15,651	-	86,336
(Decrease) increase in accrued benefit obligation	(11,524)	10,072	-	(1,452)
Increase in accrued postretirement obligation	1,060	10,770	-	11,830
Net cash provided by operating activities	<u>427,955</u>	<u>622,034</u>	<u>-</u>	<u>1,049,989</u>
Cash flows from investing activities				
Purchases of investments	(1,345,486)	(1,926,345)	-	(3,271,831)
Sales and maturities of investments	1,127,052	1,824,770	-	2,951,822
Drawdowns of unexpended bond proceeds	87,603	-	-	87,603
Additions to land, buildings, and equipment	(490,435)	(886,591)	-	(1,377,026)
Cash from acquisition of Long Island Community Hospital	-	86,068	-	86,068
Proceeds from insurance recovery for capital	-	45	-	45
Net cash used in investing activities	<u>(621,266)</u>	<u>(902,053)</u>	<u>-</u>	<u>(1,523,319)</u>
Cash flows from financing activities				
Contributions restricted for permanent investment and capital	86,290	27,319	-	113,609
Proceeds from FEMA award for future mitigation	-	1,191	-	1,191
Proceeds from short-term borrowings	-	-	-	-
Proceeds from long-term borrowings	-	38,870	-	38,870
Principal payments on long-term borrowings	(105,275)	(126,344)	-	(231,619)
Line of credit repayments	-	-	-	-
Payments of deferred financing costs	-	-	-	-
Decrease in funds held for others	(5,590)	-	-	(5,590)
Net cash used in financing activities	<u>(24,575)</u>	<u>(58,964)</u>	<u>-</u>	<u>(83,539)</u>
Net decrease in cash	<u>(217,886)</u>	<u>(338,983)</u>	<u>-</u>	<u>(556,869)</u>
Cash, cash equivalents and restricted cash				
Beginning of year	<u>1,711,614</u>	<u>2,218,581</u>	<u>-</u>	<u>3,930,195</u>
End of year	<u>\$ 1,493,728</u>	<u>\$ 1,879,598</u>	<u>\$ -</u>	<u>\$ 3,373,326</u>
Supplemental disclosure of cash flow information				
Interest paid	\$ 162,077	\$ 223,091	\$ -	\$ 385,168
Change in noncash acquisitions of land, buildings, and equipment	30,238	29,859	-	60,097
Right-of-use assets obtained				
In exchange for new operating lease obligations	53,179	196,091	-	249,270
In exchange for new finance lease obligations	-	50,243	-	50,243

The accompanying note is an integral part of these supplemental schedules.

New York University
Supplemental Schedule to the Consolidated Financial Statements
(Consolidating Statement of Cash Flows for NYU – Summary)
Year Ended August 31, 2021

	2021			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
Cash flows from operating activities				
Change in net assets	\$ 1,133,980	\$ 1,316,798	\$ -	\$ 2,450,778
Adjustments to reconcile change in net assets to net cash provided by operating activities				
Depreciation and amortization	260,942	641,398	-	902,340
Loss on sale or disposal of land, buildings and equipment	292	69	-	361
Net gain on investments and deposits with trustees	(882,330)	(446,272)	-	(1,328,602)
Bad debt expense	19,131	2,399	-	21,530
Pension and postretirement obligation change	(162,908)	(236,945)	-	(399,853)
Contributions received for permanent investment and capital	(83,773)	(35,966)	-	(119,739)
Proceeds from insurance recovery for capital and FEMA award for future mitigation	-	(4,793)	-	(4,793)
Amortization of operating right to use assets	105,555	162,120	-	267,675
Changes in operating assets and liabilities				
Decrease (increase) in accounts and loans receivable, net	54,587	(102,823)	(45,773)	(94,009)
Increase in patient accounts receivable	(300)	(211,939)	-	(212,239)
Increase in nonendowment and noncapital contributions receivable	(80,234)	(165,266)	-	(245,500)
Increase in other assets	(5,815)	(25,176)	-	(30,991)
Decrease in asset retirement obligation	-	(980)	-	(980)
Increase in accounts payable and accrued expenses	45,102	257,976	45,773	348,851
Decrease in operating lease liability	(98,156)	(142,338)	-	(240,494)
Increase in professional liabilities	-	77,169	-	77,169
Increase (decrease) in deferred revenue	341,712	(25,348)	-	316,364
Decrease in accrued benefit obligation	(2,633)	(34,879)	-	(37,512)
Increase in accrued postretirement obligation	11,349	17,756	-	29,105
Net cash provided by operating activities	<u>656,501</u>	<u>1,042,960</u>	<u>-</u>	<u>1,699,461</u>
Cash flows from investing activities				
Purchases of investments	(1,786,404)	(2,452,455)	-	(4,238,859)
Sales and maturities of investments	1,439,265	2,227,830	-	3,667,095
Drawdowns of unexpended bond proceeds	376,744	-	-	376,744
Additions to land, buildings, and equipment	(412,692)	(630,737)	-	(1,043,429)
Proceeds from insurance recovery for capital	-	100	-	100
Net cash used in investing activities	<u>(383,087)</u>	<u>(855,262)</u>	<u>-</u>	<u>(1,238,349)</u>
Cash flows from financing activities				
Contributions restricted for permanent investment and capital	83,773	35,966	-	119,739
Proceeds from FEMA award for future mitigation	-	4,693	-	4,693
Proceeds from short-term borrowings	200,000	-	-	200,000
Proceeds from long-term borrowings	246,932	88,370	-	335,302
Principal payments on long-term borrowings	(141,024)	(135,561)	-	(276,585)
Line of credit repayments	(450,000)	-	-	(450,000)
Payments of deferred financing costs	(1,153)	-	-	(1,153)
Decrease in funds held for others	(5,983)	-	-	(5,983)
Net cash used in financing activities	<u>(67,455)</u>	<u>(6,532)</u>	<u>-</u>	<u>(73,987)</u>
Net increase in cash	205,959	181,166	-	387,125
Cash, cash equivalents and restricted cash				
Beginning of year	1,505,655	2,037,415	-	3,543,070
End of year	<u>\$ 1,711,614</u>	<u>\$ 2,218,581</u>	<u>\$ -</u>	<u>\$ 3,930,195</u>
Supplemental disclosure of cash flow information				
Interest paid	\$ 160,531	\$ 226,535	\$ -	\$ 387,066
Change in noncash acquisitions of land, buildings, and equipment	1,989	(119,918)	-	(117,929)
Right-of-use assets obtained				
In exchange for new operating lease obligations	34,846	113,668	-	148,514
In exchange for new finance lease obligations	843	808,975	-	809,818

The accompanying note is an integral part of these supplemental schedules.

New York University
Note to Consolidating Supplemental Schedules
August 31, 2022 and 2021

1. Basis of Presentation – Consolidating Supplemental Schedules

The consolidating supplemental schedules (consolidating information) presented on pages 48-57 was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, changes in net assets and cash flows of the individual companies within NYU and is not a required part of the consolidated financial statements. The individual reporting entities within NYU as presented within the consolidating information are disclosed within Note 1 to the consolidated financial statements.

The consolidating financial statements were prepared on an accrual basis of accounting, consistent with the consolidated financial statements (Note 2). All transactions between and amounts due to (from) the reporting entities within NYU have been eliminated within the consolidating supplemental schedules.

Part II
Supplemental Schedule of Expenditures of Federal Awards

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Research & Development Cluster:								
	U.S. Department of Agriculture (USDA)							
	Agricultural Research, Basic and Applied Research	10.001	\$ 82,330	\$ -			\$ 82,330	\$ -
	Organic Agriculture Research and Extension Initiative	10.307	77,431	-			77,431	9,350
	Agriculture and Food Research Initiative (AFRI)	10.310	840,010	-			840,010	197,158
	Agriculture and Food Research Initiative (AFRI)	10.310	96,145	-			96,145	26,135
	Agriculture and Food Research Initiative (AFRI)	10.310	-	92,280	Iowa State University	024408G Amd 01	92,280	-
	Cooperative Extension Service	10.500	1,428,610	-			1,428,610	-
	Cooperative Extension Service	10.500	-	156,963	Pennsylvania State University	S001734-USDA	156,963	-
	State Agency, Farm to School Program Training and Curricula	10.531	-	85,704	National Center for Appropriate Technology	Amendment 1	85,704	-
	Total U.S. Department of Agriculture (USDA)		2,524,526	334,947			2,859,473	232,643
	U.S. Department of Commerce							
	Climate and Atmospheric Research	11.431	189,157	-			189,157	-
	Center for Sponsored Coastal Ocean Research Coastal Ocean Program	11.478	-	120,491	Mote Marine Laboratory and Aquarium	193-549-4	120,491	-
	Multi Modal Robot-Assisted Visual Localization System for first responders	11.RD	-	4,780	Indiana University	Phase II	4,780	-
	Total U.S. Department of Commerce		189,157	125,271			314,428	-
	U.S. Department of Defense (DOD)							
	Type A: Multi-level randomized algorithms for high-frequency wave propagation	12.RD	164,561	-			164,561	-
	Basic and Applied Scientific Research	12.300	3,215,853	-			3,215,853	1,026,520
	Basic and Applied Scientific Research	12.300	-	33,465	City University of New York	CM00005538-00	33,465	-
	Basic and Applied Scientific Research	12.300	-	6,338	Columbia University	1(G9012619) Amd 05	6,338	-
	Basic and Applied Scientific Research	12.300	-	(3,038)	Purdue University	13000477-011 Amd 9	(3,038)	-
	Basic and Applied Scientific Research	12.300	-	247,445	Texas A&M Engineering Experiment Station	M1801652 Amd 006	247,445	-
	Basic and Applied Scientific Research	12.300	-	33,096	University of California Davis	A17-0260-S003	33,096	-
	Basic and Applied Scientific Research	12.300	-	228,700	University of Nebraska Lincoln	25-0509-0202-004 A04	228,700	-
	Military Medical Research and Development	12.420	4,950,205	-			4,950,205	359,716
	Military Medical Research and Development	12.420	1,445,300	-			1,445,300	6,181
	Military Medical Research and Development	12.420	-	43,824	Montefiore Medical Center	321168	43,824	-
	Military Medical Research and Development	12.420	-	32,988	Oregon Health & Science University	1019348_NYU	32,988	-
	Military Medical Research and Development	12.420	-	98,390	Thomas Jefferson University	080-27000-X17501	98,390	-
	Military Medical Research and Development	12.420	-	45,062	University of Alabama at Birmingham	000516840-009-T001	45,062	-
	Military Medical Research and Development	12.420	-	(79)	University of Alabama at Birmingham	000516840-SC009-T002	(79)	-
	Military Medical Research and Development	12.420	-	6,456	University of Pittsburgh	CNVA00056666 (413614-21)	6,456	-
	Military Medical Research and Development	12.420	-	10,987	University of Connecticut Health Center	436326	10,987	-
	Military Medical Research and Development	12.420	-	277,978	Wright State University	670766-1 / W81XWH1820027	277,978	-
	Basic Scientific Research	12.431	1,132,910	-			1,132,910	-
	Basic Scientific Research	12.431	-	(27)	Luna, Inc.	333202NYU	(27)	-
	Basic Scientific Research	12.431	-	(487)	Research Foundation of CUNY on behalf of City University of New York	CM00002270 NCE	(487)	-
	Basic Scientific Research	12.431	-	81,177	University of Chicago	AWD101110 (SUB00000271) A02	81,177	-
	Basic Scientific Research	12.431	-	42,637	University of Maryland	110193-Z8470203	42,637	-
	Basic Scientific Research	12.431	-	14,047	University of Maryland	60590-Z8078201 Amd C	14,047	-
	Basic Scientific Research	12.431	-	185,058	University of Southern California	79573913 A09	185,058	-
	Basic, Applied, and Advanced Research in Science and Engineering	12.630	-	6,000	Rochester Institute of Technology	Agreement dated 2021-04-01	6,000	-
	Basic, Applied, and Advanced Research in Science and Engineering	12.630	-	(940)	University of Pennsylvania	572622	(940)	-
	Basic, Applied, and Advanced Research in Science and Engineering	12.630	-	134,837	University of Pennsylvania	579327 Amd 2	134,837	-
	Air Force Defense Research Sciences Program	12.800	940,828	-			940,828	-
	Air Force Defense Research Sciences Program	12.800	-	8,210	Massachusetts Institute of Technology	S5204 PO#534323	8,210	-
	Air Force Defense Research Sciences Program	12.800	-	163,763	Research Foundation of CUNY on behalf of City University of New York	CM00005540-03 Amd 3	163,763	-
	Air Force Defense Research Sciences Program	12.800	-	151,429	University of Central Florida	24086226-GR102560 A04	151,429	-
	Air Force Defense Research Sciences Program	12.800	-	73,489	University of Michigan	SUBK00010366 Amendment 4	73,489	-
	Research and Technology Development	12.910	1,108,577	-			1,108,577	77,996
	Research and Technology Development	12.910	4,165,069	-			4,165,069	767,849
	Research and Technology Development	12.910	-	495	Baylor College of Medicine	PO 7000000604 A04	495	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Research and Technology Development	12.910	\$ -	\$ 34,738	Columbia University	3(GG017183-01)	34,738	\$ -
	Research and Technology Development	12.910	-	61,755	Evocative Design	HR001117C0068	61,755	-
	Research and Technology Development	12.910	-	241,775	Oregon State University	X-0220A-B Amd 05	241,775	-
	Air Force Medical Readiness Agency Mental Health Resilience Program Evaluation and Enhancement	12.RD	-	168,908	Cherokee Insights LLC.	29700-0005	168,908	-
	Applications Driving Architectures (ADA) Center	12.RD	-	242,764	University of Michigan	SUBK00013583 Amd 03	242,764	-
	DARPA AISS	12.RD	-	19,170	Texas A&M Engineering Experiment Station	M2002172	19,170	-
	Department of Defense Cyber Scholarship Program Academic Year 2021-2022	12.RD	51,474	-			51,474	-
	Magnetic optical and acoustic neural access device for high-bandwidth non-surgical brain computer interfaces (MOANA)	12.RD	-	100,010	Rice University	R1A26I (N66001-19-C-4020) Amd 2	100,010	-
	Rapid Assured Microelectronics Prototypes using Advanced Commercial Capabilities	12.RD	-	121,481	International Business Machines Inc.	CW3085862 Amd 1	121,481	-
	ROBUST PREDICTION OF ORDNANCE DEPTH OF BURIAL IN SOILS USING FIELD CALIBRATED PHENOMENOLOGICAL MODEL& PROBABILISTIC SIMULATIONS	12.RD	409,299	-			409,299	185,706
	STTR: Phase 2: Multi-Input Strength Loss Sensing for Webbing Structures	12.RD	-	93,303	Luna Innovations	374802NYU	93,303	-
	TREBUCHET	12.RD	-	122,293	Duality Technologies Inc.	Duality-DPRIVE Phase 2	122,293	-
	Total U.S. Department of Defense (DOD)		<u>17,584,076</u>	<u>3,127,497</u>			<u>20,711,573</u>	<u>2,423,968</u>
	U.S. Department of Housing and Urban Development							
	General Research and Technology Activity	14.506	105,466	-			105,466	14,515
	Total U.S. Department of Housing and Urban Development		<u>105,466</u>	<u>-</u>			<u>105,466</u>	<u>14,515</u>
	Department of the Interior							
	American Battlefield Protection	15.926	-	9,695	The Fort Ticonderoga Association	2022-01	9,695	-
	Total Department of the Interior		<u>-</u>	<u>9,695</u>			<u>9,695</u>	<u>-</u>
	U.S. Department of Justice (DOJ)							
	National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	16,253	-			16,253	16,253
	National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	-	76,172	Northeastern University	504629-78052	76,172	-
	National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	-	58,345	RTI International	Subaward Number 2-312-0217807-66610L	58,345	-
	Public Safety Partnership and Community Policing Grants	16.710	-	4,209	Seattle Police Department	Agreement dated 2022-05-31	4,209	-
	Edward Byrne Memorial Justice Assistance Grant Program	16.738	155,789	-			155,789	-
	Harold Rogers Prescription Drug Monitoring Program	16.754	-	5,524	Pennsylvania Department of Corrections	PO 4300635966	5,524	-
	Smart Prosecution Initiative	16.825	-	36,925	Winnebago County (WI)	Agreement dated 2022-10-11	36,925	-
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.828	544,996	-			544,996	-
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	-	28,189	Bronx Co. New York	2018-AR-BX-K025	28,189	13,914
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	-	29,000	Davidson Co. Tennessee	Agreement dated 2022-10-12	29,000	-
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	-	80,809	Harris Co. Texas	2018-AR-BX-K030 (19/0313 NCE)	80,809	-
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	-	84,417	Ohio Department of Rehabilitation and Correction	2019-BJA-ODRC-VRAT-0001 (Year 3)	84,417	35,200
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	-	47,415	Seattle Police Department	19-02974	47,415	-
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	-	15,195	Winnebago County (WI)	Agmt signed 9-14-20	15,195	-
	Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	-	33,662	Winnebago County (WI)	Agreement dated 2022-10-11 (years 2-3)	33,662	-
	Court-led Opioid Interventions--DCIL	16.RD	-	75,208	Dekalb County Court Services	2018-NYUCOAP1	75,208	-
	Total U.S. Department of Justice (DOJ)		<u>717,038</u>	<u>575,070</u>			<u>1,292,108</u>	<u>65,367</u>

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	U.S. Department of Labor							
	Reentry Employment Opportunities	17.270	\$ 842,588	\$ -			\$ 842,588	\$ 295,760
	Occupational Safety and Health Susan Harwood Training Grants	17.502	26,187	-			26,187	-
	Total U.S. Department of Labor		<u>868,775</u>	<u>-</u>			<u>868,775</u>	<u>295,760</u>
	U.S. Department of State							
	International Programs to Combat Human Trafficking	19.019	76,534	-			76,534	61,026
	International Programs to Combat Human Trafficking	19.019	-	10,733	Innovations for Poverty Action	USDOS-20-10001-X5	10,733	4,148
	International Programs to Combat Human Trafficking	19.019	-	182,931	University of Georgia	Sub No.: SUB00002736	182,931	126,693
	International Programs to Combat Human Trafficking	19.019	-	46,831	University of Georgia	Sub No.: SUB00002737 Mod 02	46,831	-
	International Programs to Combat Human Trafficking	19.019	-	25,283	University of Massachusetts Lowell	S51000000046677	25,283	-
	Investing in People in The Middle East and North Africa	19.021	28,168	-			28,168	-
	International Programs to Support Democracy, Human Rights and Labor	19.345	303,203	-			303,203	75,152
	Academic Exchange Programs - Scholars	19.401	-	369,555	University of Montana	PG22-26974-02	369,555	-
	Total U.S. Department of State		<u>407,905</u>	<u>635,333</u>			<u>1,043,238</u>	<u>267,019</u>
	U.S. Department of Transportation							
	Highway Training and Education	20.215	7,282	-			7,282	-
	University Transportation Centers Program	20.701	1,338,154	-			1,338,154	350,363
	Federal Support for Local Decision-Making	20.RD	-	5,330	Veris Inc.	BTS TO-1 (693JK422D800007)	5,330	-
	Intelligent Transportation Systems (ITS) Deployment Evaluation ProgramData Collection and Information Synthesis Support	20.RD	-	165,421	NOBLIS	20S1DEPNVU Mod 02	165,421	-
	Total U.S. Department of Transportation		<u>1,345,436</u>	<u>170,751</u>			<u>1,516,187</u>	<u>350,363</u>
	National Aeronautics and Space Administration							
	Science	43.001	830,128	-			830,128	8,229
	Science	43.001	-	159,487	American Museum of Natural History	627-2016-1 Amd 7	159,487	-
	Science	43.001	-	47,967	Emory University	A136841 Amendment 4	47,967	-
	Science	43.001	-	91,606	Jet Propulsion Laboratory (NASA)	1658891	91,606	-
	Science	43.001	-	25,155	Jet Propulsion Laboratory (NASA)	1671475	25,155	-
	Science	43.001	-	25,720	Jet Propulsion Laboratory (NASA)	1679798	25,720	-
	Science	43.001	-	6,260	Smithsonian Astrophysical Observatory	GO0-21102X A02	6,260	-
	Science	43.001	-	46,802	University of Chicago	FF070308-01 A03	46,802	-
	Exploration	43.003	-	9,640	City University of New York	CM00004989-00	9,640	-
	Space Operations	43.007	23,412	-			23,412	-
	Office of Stem Engagement (OSTEM)	43.008	-	30,602	Cornell University	76156-10488 Amd 7	30,602	-
	Decoding Extragalactic Stellar Streams: What will they teach us about dark matter?	43.RD	-	34,195	Space Telescope Science Institute	HST-HF2-51466.001-A	34,195	-
	Decoding Extragalactic Stellar Streams: What will they teach us about dark matter?	43.RD	-	101,200	Space Telescope Science Institute	HST-HF2-51466.001-A A01 REVISED	101,200	-
	Early-Time UV Spectroscopy of Stripped-Envelope Supernovae: A New Window	43.RD	-	14,999	Space Telescope Science Institute	HST-GO-16178.007-A	14,999	-
	Oceans Melting Greenland-OMG	43.RD	-	(4,710)	Jet Propulsion Laboratory (NASA)	1541570 Mod 005	(4,710)	-
	Total National Aeronautics and Space Administration		<u>853,540</u>	<u>588,923</u>			<u>1,442,463</u>	<u>8,229</u>
	Federal Council on the Arts and The Humanities							
	Promotion of the Humanities Teaching and Learning Resources and Curriculum Development	45.162	49,436	-			49,436	-
	Total Federal Council on the Arts and The Humanities		<u>49,436</u>	<u>-</u>			<u>49,436</u>	<u>-</u>
	Institute of Museum and Library Services							
	National Leadership Grants	45.312	-	41,723	Intrepid Museum Foundation	2019-10-1 Amd 1	41,723	-
	Total Institute of Museum and Library Services		<u>-</u>	<u>41,723</u>			<u>41,723</u>	<u>-</u>
	National Endowment for the Humanities							
	Promotion of the Humanities Research	45.161	207,353	-			207,353	-
	Promotion of the Humanities Office of Digital Humanities	45.169	9,041	-			9,041	-
	Total National Endowment for the Humanities		<u>216,394</u>	<u>-</u>			<u>216,394</u>	<u>-</u>

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	National Science Foundation	47.RD	\$ 34,510	\$ -			\$ 34,510	\$ -
	Education and Human Resources	47.041	31,286	-			31,286	3,351
	COVID-19 Engineering Grants	47.041	-	-			-	-
	Engineering	47.041	4,268,873	-			4,268,873	225,729
	Engineering	47.041	-	11	George Washington University	15-S30-Mod #4	11	-
	Engineering	47.041	-	42,577	John Jay College of Criminal Justice (CUNY)	CM00007109-00	42,577	-
	Engineering	47.041	-	33,624	New York Institute of Technology	CBET-1856032-NYU-4	33,624	-
	Engineering	47.041	-	15,833	Pi Radio	Amendment executed 2021-02-25	15,833	-
	Engineering	47.041	-	52,172	Research Foundation of CUNY on behalf of City College of New York	CM00001891-03	52,172	-
	Engineering	47.041	-	153,178	Research Foundation of CUNY on behalf of City University of New York	CM00001895-00 Amd 2	153,178	-
	Engineering	47.041	-	220,168	Research Foundation of CUNY on behalf of City University of New York	CM00007240	220,168	-
	Engineering	47.041	-	22,894	University of Wisconsin Madison	893K432 Amendment 2	22,894	-
	Engineering	47.041	-	48,778	Worcester Polytechnic Institute	11118-GR	48,778	-
	Engineering Grants	47.041	147,530	-			147,530	-
	Mathematical and Physical Sciences	47.049	(1,967)	-			(1,967)	-
	Mathematical and Physical Sciences	47.049	8,651,466	-			8,651,466	50,789
	Mathematical and Physical Sciences	47.049	-	79,895	Clemson University	2340-206-2014878 A01	79,895	-
	Mathematical and Physical Sciences	47.049	-	20,042	Columbia University	1(GG017158-01)	20,042	-
	Mathematical and Physical Sciences	47.049	-	51,035	Columbia University	37(GG018228)	51,035	-
	Mathematical and Physical Sciences	47.049	-	20,515	Queens College (CUNY)	CM00001826-01 (PI Change)	20,515	-
	Mathematical and Physical Sciences	47.049	-	19,899	University of Notre Dame	204303NYU	19,899	-
	Geosciences	47.050	1,362,173	-			1,362,173	297,637
	Geosciences	47.050	-	91,613	University Corporation of Atmospheric Research	SUBAWD002258 Mod 1	91,613	-
	Computer and Information Science and Engineering	47.070	58,090	-			58,090	-
	Computer and Information Science and Engineering	47.070	10,409,083	-			10,409,083	269,803
	Computer and Information Science and Engineering	47.070	-	17,505	Columbia University	23(GG014586-02) SAPO G16339	17,505	-
	Computer and Information Science and Engineering	47.070	-	87,203	Computing Research Association	2021CIF-NewYork-43	87,203	-
	Computer and Information Science and Engineering	47.070	-	27,423	Computing Research Association	CIF2020-NYU-08 Amd 01	27,423	-
	Computer and Information Science and Engineering	47.070	-	131,628	Computing Research Association	CIF2020-NYU-51	131,628	-
	Computer and Information Science and Engineering	47.070	-	74,107	Cornell University	138698-21082	74,107	-
	Computer and Information Science and Engineering	47.070	-	138,349	Cornell University	90026-11333 Amendment 2	138,349	-
	Computer and Information Science and Engineering	47.070	-	20,090	Iowa State University	019136A Amd 1	20,090	-
	Computer and Information Science and Engineering	47.070	-	156,527	Princeton University	SUB0000278 A04	156,527	-
	Computer and Information Science and Engineering	47.070	-	6,078	University of Arizona	576988	6,078	-
	Computer and Information Science and Engineering	47.070	-	85,864	University of Southern California	SCON-00002553	85,864	-
	Computer and Information Science and Engineering	47.070	-	29,511	University of Southern California	SCON-00003372	29,511	-
	Biological Sciences	47.074	1,989,602	-			1,989,602	-
	Biological Sciences	47.074	2,546,915	-			2,546,915	891,255
	Biological Sciences	47.074	-	58,076	Cold Spring Harbor Laboratory	52670414 A04	58,076	-
	Biological Sciences	47.074	-	3,351	Columbia University	3(GG016611-01) A01	3,351	-
	Biological Sciences	47.074	-	104,724	Rutgers University	1103 MOD 3	104,724	-
	Biological Sciences	47.074	-	208,906	University Of Colorado Boulder	1559641	208,906	-
	Biological Sciences	47.074	-	29,973	University of Illinois at Urbana-Champaign	101519-18743	29,973	-
	Biological Sciences	47.074	-	72,521	University of Michigan	3004704725	72,521	-
	Biological Sciences	47.074	-	94,339	Yale University	GR110626 (CON-80002608) A02	94,339	-
	Social, Behavioral, and Economic Sciences	47.075	184,727	-			184,727	-
	Social, Behavioral, and Economic Sciences	47.075	3,936,127	-			3,936,127	73,884
	Social, Behavioral, and Economic Sciences	47.075	-	9,615	University of Texas at Dallas	2008625_001	9,615	-
	Social, Behavioral, and Economic Sciences	47.075	-	916	University of Maryland	89226-24766001 Mod A	916	-
	Social, Behavioral, and Economic Sciences	47.075	-	47,406	University of Montana	PG19-66897-01	47,406	-
	Social, Behavioral, and Economic Sciences	47.075	-	71,416	University of Pennsylvania	574835 NCE	71,416	-
	Social, Behavioral, and Economic Sciences	47.075	-	11,440	Villanova University	525919NYU A02	11,440	-
	Education and Human Resources	47.076	221,975	-			221,975	-
	Education and Human Resources	47.076	7,061,408	-			7,061,408	433,586
	Education and Human Resources	47.076	-	152,080	Education Development Center	12389 Amd 3	152,080	-
	Education and Human Resources	47.076	-	8,099	ETR	PO-1935	8,099	-
	Education and Human Resources	47.076	-	12,627	Rensselaer Polytechnic Institute	RPI-A20-0005-S005 Amd 1	12,627	-
	Education and Human Resources	47.076	-	2,597	University of California Irvine	2019-3714 Amd 02	2,597	-
	Education and Human Resources	47.076	-	24,821	University of Florida	SUB00002869	24,821	-
	Education and Human Resources	47.076	-	55,201	University of Illinois at Urbana-Champaign	083755-16481 Amd 03	55,201	-
	COVID-19 Office of International and Integrative Activities	47.079	-	8,474	University of Wisconsin	000000756	8,474	-
	Office of International Science and Engineering	47.079	109,527	-			109,527	-
	Office of International Science and Engineering	47.079	-	135,714	University of Nevada Las Vegas	GR06611 AMD 5	135,714	-
	Integrative Activities	47.083	29,695	-			29,695	-
	Office of Integrative Activities	47.083	-	85,702	University of Michigan	3003847460	85,702	-
	NSF Technology, Innovation, and Partnerships	47.084	30,984	-			30,984	-
	Data governance for the Blue Economy	47.RD	-	138,500	Multiplier	Multiplier-Intertidal 2021 Agreement	138,500	-
	Dispersal, connectivity and local adaption al ong an extreme environmental gradient	47.RD	-	3,001	University of North Carolina at Charlotte	20190599-01-NYU	3,001	-
	Total National Science Foundation		41,072,004	2,986,018			44,058,022	2,259,819

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Department of Veterans Affairs							
	Veteran Affairs Medical Center	64.RD	\$ 1,864,669	\$ -			\$ 1,864,669	\$ -
	Total Department of Veterans Affairs		<u>1,864,669</u>	<u>-</u>			<u>1,864,669</u>	<u>-</u>
	U.S. Environmental Protection Agency (EPA)							
	Science To Achieve Results (STAR) Research Program	66.509	261,538	-			261,538	80,397
	Science To Achieve Results (STAR) Research Program	66.509	-	(19)	American Heart Association	FX-ATRAC-NYU-05	(19)	-
	Science To Achieve Results (STAR) Research Program	66.509	-	12,112	University of California Davis	A21-2341-S001	12,112	-
	P3 Award: National Student Design Competition for Sustainability	66.516	3,631	-			3,631	-
	Total U.S. Environmental Protection Agency (EPA)		<u>265,169</u>	<u>12,093</u>			<u>277,262</u>	<u>80,397</u>
	U.S. Department of Energy							
	State Energy Program	81.041	200,002	-			200,002	-
	Office of Science Financial Assistance Program	81.049	3,495,077	-			3,495,077	389,361
	Office of Science Financial Assistance Program	81.049	-	85,592	Case Western Reserve University	RES513719	85,592	-
	Office of Science Financial Assistance Program	81.049	-	131,574	College of William and Mary	744402 A001	131,574	-
	Office of Science Financial Assistance Program	81.049	-	223,710	Georgia Institute of Technology	AWD-100234-G2 Amd 16	223,710	-
	Office of Science Financial Assistance Program	81.049	-	107,089	Northwestern University	SP0027267-PROJ0007140 A09	107,089	-
	Office of Science Financial Assistance Program	81.049	-	17,282	Parallel Works Inc.	DE-SC0019695-SA1	17,282	-
	Office of Science Financial Assistance Program	81.049	-	117,489	University of California San Diego	111163617 (S9002150) A004	117,489	-
	Conservation Research and Development	81.086	-	64,462	Iowa State University	022853A	64,462	-
	Renewable Energy Research and Development	81.087	105,015	-			105,015	-
	Renewable Energy Research and Development	81.087	-	42,710	Yale University	CON-80003263 (GR114316)	42,710	-
	Nuclear Energy Research, Development and Demonstration	81.121	-	(174)	Ohio State University	60054137 Mod 2	(174)	-
	Advanced Research Projects Agency - Energy	81.135	-	139,998	Columbia University	1(GG017021) Amd 01	139,998	-
	Advanced Research Projects Agency - Energy	81.135	-	112,049	Iowa State University	022218A Amd 01	112,049	-
	Advanced Dissolution-based Monolayer Exfoliation/Transfer Methods	81.RD	-	101,625	Brookhaven National Laboratory	PR No. 390681 Mod 01	101,625	-
	AI-based modeling and control for traffic flow systems	81.RD	-	119,819	UT-Battelle LLC, c/o Oak Ridge National Laboratory	4000189094 Mod 2	119,819	-
	COINFLIPS: CO-designed Improved Neural Foundations Leveraging Inherent Physics Stochasticity	81.RD	-	138,755	Sandia National Laboratories	2329277 Revision 2	138,755	-
	CyberSim: A Flexible Simulation Environment for the Evaluation of Cyber Risk in Nuclear Power Plants in Support of the Design of Cyber Protection Architectures; NE-1: Nuclear Energy-Cyber Security Research Topics and	81.RD	-	60,003	Ohio State University	GR121298-SPC-100004799 Amd 1	60,003	-
	Ice Sheet Model Optimization and Uncertainty Quantification	81.RD	-	153,278	TRIAD National Security LLC.	458494 Mod 5	153,278	-
	SBIR Phase II: A Platform for Scientific Data Management Modeling and Analysis with Machine Learning	81.RD	-	54,793	Parallel Works Inc.	DE-SC0020464-SA1 A01	54,793	-
	SiGe-AI Josephson Junction Field-Effect Transistors	81.RD	-	(11,496)	Sandia National Laboratories	1915665 Rev. 1	(11,496)	-
	Total U.S. Department of Energy		<u>3,800,094</u>	<u>1,658,558</u>			<u>5,458,652</u>	<u>389,361</u>
	U.S. Department of Education (ED)							
	National Resource Centers Program for Foreign Language and Area Studies or Foreign Language and International Studies Program and Foreign Language and Area Studies Fellowship Program	84.015	500,514	-			500,514	95,997
	National Resource Centers Program for Foreign Language and Area Studies or Foreign Language and International Studies Program and Foreign Language and Area Studies Fellowship Program	84.015	-	122,674	Columbia University	1(GG013993) Amendment 3	122,674	-
	Overseas Programs - Doctoral Dissertation Research Abroad	84.022	235,414	-			235,414	-
	Rehabilitation Services_Vocational Rehabilitation Grants to States	84.126	361,668	-			361,668	-
	Graduate Assistance in Areas of National Need	84.200	41,819	-			41,819	-
	Education Research, Development and Dissemination	84.305	3,722,906	-			3,722,906	595,059
	Education Research, Development and Dissemination	84.305	-	61,657	American Institutes for Research	0467100005 Mod 2	61,657	-
	Education Research, Development and Dissemination	84.305	-	125,722	Boston College	5108121-01 Amd 03	125,722	-
	Education Research, Development and Dissemination	84.305	-	67,701	Boston University	4500002734-003	67,701	-
	Education Research, Development and Dissemination	84.305	-	41,727	MDRC	1413-NYU-01 Mod # 1	41,727	-
	Education Research, Development and Dissemination	84.305	-	53,716	Ohio University	UT21878	53,716	-
	Education Research, Development and Dissemination	84.305	-	11,669	The Children's Hospital Of Philadelphia	20259641	11,669	-
	Education Research, Development and Dissemination	84.305	-	20,616	University of North Carolina Greensboro	20210415.2 Amd 1	20,616	-
	Teacher Quality Partnership Grants	84.336	-	36,740	American Museum of Natural History	802-2020-01 Amd 4	36,740	-
	Teacher and School Leader Incentive Grants (formerly the Teacher Incentive Fund)	84.374	-	4,703	Eskolta School Research and Design Inc.	Agreement effective 2020-06-01	4,703	-
	Education Innovation and Research (formerly Investing in Innovation (i3) Fund)	84.411	-	7,636	ExpandedED Schools	Amendment executed 2020-10-02	7,636	-
	Education Innovation and Research (formerly Investing in Innovation (i3) Fund)	84.411	-	132,242	ExpandedED Schools	U411C180023	132,242	-
	Total U.S. Department of Education (ED)		<u>4,862,321</u>	<u>686,803</u>			<u>5,549,124</u>	<u>691,056</u>

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	U.S. Department of Health and Human Services (HHS)							
	Training in General, Pediatric, and Public Health Dentistry	93.059	\$ 558,642	\$ -			\$ 558,642	\$ 173,973
	Training in General, Pediatric, and Public Health Dentistry	93.059	355,206	-			355,206	1,000
	Chronic Diseases: Research, Control, and Prevention	93.068	993,302	-			993,302	35,195
	Chronic Diseases: Research, Control, and Prevention	93.068	-	230,464	Cicatelli Associates, Inc.	21-A0-00-1006723	230,464	-
	COVID-19 Chronic Diseases: Research, Control, and Prevention	93.068	78,009	-			78,009	26,035
	Environmental Public Health and Emergency Response	93.070	-	3,192	Health Research, Inc.	6750-01	3,192	-
	Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	421,951	-			421,951	-
	Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	-	2,473	University of Michigan	SUBK00014314 Carryover Approval	2,473	-
	Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	-	23,170	University of California San Francisco	12400sc	23,170	-
	Food and Drug Administration Research	93.103	132,865	-			132,865	-
	Food and Drug Administration Research	93.103	-	3,412	Pharment, International	19164	3,412	-
	Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED)	93.104	-	21,885	New York State Office of Mental Health	156246	21,885	-
	COVID-19 Environmental Health	93.113	78,430	-			78,430	-
	Environmental Health	93.113	5,813,327	-			5,813,327	475,861
	Environmental Health	93.113	641,899	-			641,899	-
	Environmental Health	93.113	-	1,491	Alaska Community Action on Toxics	R01-10-NYU	1,491	-
	Environmental Health	93.113	-	67,467	Boston University	4500003653	67,467	-
	Environmental Health	93.113	-	121,276	George Mason University	E2050591	121,276	-
	Environmental Health	93.113	-	2,888,993	Health Research, Inc.	6508-02	2,888,993	-
	Environmental Health	93.113	-	223,019	Michigan State University	RC111324A	223,019	-
	Environmental Health	93.113	-	41,238	Mount Sinai School of Medicine	0255-B391-4609	41,238	-
	Environmental Health	93.113	-	69,599	Northwestern University	60052569 NYU A03	69,599	-
	Environmental Health	93.113	-	18,876	Seattle Children's Hospital	20-A0-00-1005558	18,876	-
	Oral Diseases and Disorders Research	93.121	861,685	-			861,685	45,533
	Oral Diseases and Disorders Research	93.121	4,784,199	-			4,784,199	696,717
	Oral Diseases and Disorders Research	93.121	-	132,163	Carolinas Healthcare System	13100310228 (A21-0106-S005)	132,163	-
	Oral Diseases and Disorders Research	93.121	-	108,963	Indiana University	8150 - P00227689	108,963	-
	Oral Diseases and Disorders Research	93.121	-	1,907	Loma Linda University	Advanced S1837	1,907	-
	Oral Diseases and Disorders Research	93.121	-	7,396	Rutgers University	0280 Mod 2	7,396	-
	Oral Diseases and Disorders Research	93.121	-	3,952	The Regents of The University of California	13471sc	3,952	-
	Oral Diseases and Disorders Research	93.121	-	133,963	University Of Pennsylvania	583210	133,963	-
	Oral Diseases and Disorders Research	93.121	-	1,087,421	University of Michigan	3004717497	1,087,421	-
	Oral Diseases and Disorders Research	93.121	-	(724)	University of Michigan	3004717497 Amendment 4	(724)	-
	Oral Diseases and Disorders Research	93.121	-	8,548	University of Pennsylvania	580833	8,548	-
	Oral Diseases and Disorders Research	93.121	-	5,112	University of Pennsylvania	580832 Amend 1	5,112	-
	Oral Diseases and Disorders Research	93.121	-	78,084	Virtually Better, Inc.	VBI Subcontracting Agreement 2	78,084	-
	Grants to Increase Organ Donations	93.134	-	116,501	Hennepin Healthcare Research Institute	22-A0-00-1008729	116,501	-
	Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	1,951,301	-			1,951,301	298,178
	Injury Prevention and Control Research and State and Community Based Programs	93.136	780,872	-			780,872	60,266
	Injury Prevention and Control Research and State and Community Based Programs	93.136	240,813	-			240,813	111,691
	Injury Prevention and Control Research and State and Community Based Programs	93.136	-	24,244	Columbia University	4(GG014278-18)	24,244	-
	Community Programs to Improve Minority Health Grant Program	93.137	-	44,203	Columbia University	1(GG017882-01)	44,203	-
	NIEHS Hazardous Waste Worker Health and Safety Training	93.142	-	85,706	Rutgers University	1922 Amd 1	85,706	-
	Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	465,236	-			465,236	188,034
	COVID-19 Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	16,228	-			16,228	-
	Human Genome Research	93.172	2,936,606	-			2,936,606	336,169
	Human Genome Research	93.172	95,320	-			95,320	31,814
	Human Genome Research	93.172	-	18,569	Columbia University	1(GG013080-01) AMD 2	18,569	-
	Human Genome Research	93.172	-	47,253	Mount Sinai School of Medicine	0255-C621-4609	47,253	-
	Human Genome Research	93.172	-	119,903	New York Genome Center	2019-0014-NYU-01 A03	119,903	-
	Human Genome Research	93.172	-	124,737	The Ontario Institute for Cancer Research	P2017-0001	124,737	-
	Research Related to Deafness and Communication Disorders	93.173	3,983,156	-			3,983,156	553,983
	Research Related to Deafness and Communication Disorders	93.173	4,479,479	-			4,479,479	794,864
	Research Related to Deafness and Communication Disorders	93.173	-	234,283	Brandeis University	403626	234,283	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Research Related to Deafness and Communication Disorders	93.173	-	36,978	Montclair State University	1R15DCU19775-NYU Amd 1	\$ 36,978	\$ -
	Research Related to Deafness and Communication Disorders	93.173	-	178,241	North Carolina State University	2018-2600-01	178,241	-
	Research Related to Deafness and Communication Disorders	93.173	-	200,896	North Carolina State University	2018-3244-01	200,896	-
	Research Related to Deafness and Communication Disorders	93.173	-	38,286	University Of Iowa	1001622176	38,286	-
	Research Related to Deafness and Communication Disorders	93.173	-	27,498	University of Cincinnati	012336-00007 Amd 04	27,498	-
	Research Related to Deafness and Communication Disorders	93.173	-	14,532	University of Pittsburgh	CNVA00059569 (130900-1) Amd 4	14,532	-
	Research Related to Deafness and Communication Disorders	93.173	-	239,349	University of Texas at Dallas	1806253	239,349	-
	Research Related to Deafness and Communication Disorders	93.173	-	184,475	York Sound Inc.	19-A0-00-1003898	184,475	-
	Disabilities Prevention	93.184	-	6,858	University of Alabama at Birmingham	000512145-SC018	6,858	-
	Immunization Research, Demonstration, Public Information and Education_Training and Clinical Skills Improvement Projects	93.185	-	207,327	Asian/Pacific Islander American Health Forum	NYU-EVAC-2022	207,327	-
	National Research Service Award in Primary Care Medicine	93.186	431,039	-			431,039	-
	Research and Training in Complementary and Alternative Medicine	93.213	3,348,755	-			3,348,755	618,145
	Research and Training in Complementary and Alternative Medicine	93.213	-	44,783	Columbia University	1(GG017691-01)	44,783	-
	Research and Training in Complementary and Integrative Health	93.213	908,953	-			908,953	-
	National Research Service Awards_Health Services Research Training	93.225	688,811	-			688,811	72,967
	Research on Healthcare Costs, Quality and Outcomes	93.226	1,030,836	-			1,030,836	83,609
	Research on Healthcare Costs, Quality and Outcomes	93.226	-	14,732	Children's Hospital/Boston	GENFD0002176432	14,732	-
	Research on Healthcare Costs, Quality and Outcomes	93.226	-	56,177	University of Michigan	Agreement dated 2022-01-06	56,177	-
	National Center on Sleep Disorders Research	93.233	419,914	-			419,914	-
	National Center on Sleep Disorders Research	93.233	-	73,898	Columbia University	\$26,048.301 (GG015006-04)	73,898	-
	Mental Health Research Grants	93.242	14,855,888	-			14,855,888	4,170,314
	Mental Health Research Grants	93.242	6,367,899	-			6,367,899	972,768
	Mental Health Research Grants	93.242	-	9,368	Brown University	00001444	9,368	-
	Mental Health Research Grants	93.242	-	18,305	Child Mind Institute Inc.	5R01MH115363-03 SubN 1	18,305	-
	Mental Health Research Grants	93.242	-	20,769	Child Mind Institute Inc.	5R01MH115363 Sub N4_AMD5	20,769	-
	Mental Health Research Grants	93.242	-	316,816	Cold Spring Harbor Laboratory	65500112	316,816	-
	Mental Health Research Grants	93.242	-	312,273	Downstate Medical Center (SUNY)	100-1147125-81588 A04	312,273	-
	Mental Health Research Grants	93.242	-	184,320	Hunter College	CM00003379	184,320	-
	Mental Health Research Grants	93.242	-	162	Johns Hopkins University	2004361458 A01	162	-
	Mental Health Research Grants	93.242	-	8,802	Johns Hopkins University	2004660765 Amend 2	8,802	-
	Mental Health Research Grants	93.242	-	17,430	Johns Hopkins University	2004845715 Amendment 2	17,430	-
	Mental Health Research Grants	93.242	-	12,660	Massachusetts Institute of Technology	S4714	12,660	-
	Mental Health Research Grants	93.242	-	(6,746)	Max Planck Florida Institute For Neuroscience	NYU19842RY10	(6,746)	-
	Mental Health Research Grants	93.242	-	60,452	Mount Sinai Medical Center	0255-4091-4609	60,452	-
	Mental Health Research Grants	93.242	-	84,487	Northern Illinois University	G1A62768-1	84,487	-
	Mental Health Research Grants	93.242	-	200,237	Pennsylvania State University	NYUMH124605	200,237	-
	Mental Health Research Grants	93.242	-	19,217	Ponce Medical School Foundation Inc.	8571 Anns 1	19,217	-
	Mental Health Research Grants	93.242	-	65,865	Princeton University	SUB0000199	65,865	-
	Mental Health Research Grants	93.242	-	158,617	Princeton University	SUB0000484_002	158,617	-
	Mental Health Research Grants	93.242	-	27,660	Research Foundation for Mental Hygiene Inc.	PO 148855 (R01MH123639-01)_AMD2	27,660	-
	Mental Health Research Grants	93.242	-	550	Research Foundation For Mental Hygiene Inc.	154740	550	-
	Mental Health Research Grants	93.242	-	18,240	Research Foundation For Mental Hygiene Inc.	19-A0-00-1002259	18,240	-
	Mental Health Research Grants	93.242	-	81,194	The Mclean Hospital Corporation	401568	81,194	-
	Mental Health Research Grants	93.242	-	24,338	Washington University	WU-19-191 MOD 2	24,338	-
	Mental Health Research Grants	93.242	-	29,414	Washington University	WU-19-202- MOD 2	29,414	-
	Mental Health Research Grants	93.242	-	14,793	Washington University	WU-19-413 MOD 3	14,793	-
	Mental Health Research Grants	93.242	-	39,626	Washington University	WU-22-0246	39,626	-
	Mental Health Research Grants	93.242	-	12,437	Trustees of Boston University	4500004172	12,437	-
	Mental Health Research Grants	93.242	-	9,722	University of Illinois at Chicago	17716	9,722	-
	Mental Health Research Grants	93.242	-	303,647	University of Minnesota	N006784001	303,647	-
	Mental Health Research Grants	93.242	-	118,106	University Of Pennsylvania	583303	118,106	-
	Mental Health Research Grants	93.242	-	30,686	Universidad de O'Higgins	Subcontract Year 4	30,686	-
	Mental Health Research Grants	93.242	-	31,690	University Medical Center Utrecht	R01MH111417	31,690	-
	Mental Health Research Grants	93.242	-	222,616	University of California Berkeley	00010481 A03	222,616	-
	Mental Health Research Grants	93.242	-	18,902	University of California San Francisco	12239sc-02 NCE	18,902	-
	Mental Health Research Grants	93.242	-	49,199	University of Pittsburgh Medical Center	AWD00003551 (135683-1)	49,199	-
	Mental Health Research Grants	93.242	-	66,520	Utrecht University	1R01MH11417-01-1_AMD 6	66,520	-
	Mental Health Research Grants	93.242	-	30,614	Washington University	WU-20-233-MOD-3	30,614	-
	Mental Health Research Grants	93.242	-	195,466	Washington University/St. Louis School of Medicine	WU-21-103	195,466	-
	Mental Health Research Grants	93.242	-	2,035	Weill Cornell Medical College	221922-2	2,035	-
	Mental Health Research Grants	93.242	-	77,745	Yale University	GR107130 (CON-80001851)	77,745	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Mental Health Research Grants	93.242	-	3,334	Yale University	GR104369 (CON-80001429) A01	3,334	-
	Mental Health Research Grants	93.242	-	70,977	Yale University, School of Medicine	GR 108340 (CON-80002129)	70,977	-
	Substance Abuse and Mental Health Services, Projects of Regional and National Significance	93.243	839,632	-			839,632	17,680
	Substance Abuse and Mental Health Services, Projects of Regional and National Significance	93.243	-	36,189	American Academy of Addiction Psychiatry	MFG-18-1	36,189	-
	Substance Abuse and Mental Health Services, Projects of Regional and National Significance	93.243	-	4,010	Frontline Service	001	4,010	-
	Substance Abuse and Mental Health Services, Projects of Regional and National Significance	93.243	-	159,631	Richmond University Medical Center	20-A0-00-1005530	159,631	-
	Substance Abuse and Mental Health Services, Projects of Regional and National Significance	93.243	-	17,322	Research Foundation For Mental Hygiene Inc.	150458	17,322	-
	Substance Abuse and Mental Health Services, Projects of Regional and National Significance	93.243	-	17,266	University of Connecticut	UCHC7-137475441-A6	17,266	-
	Substance Abuse and Mental Health Services, Projects of Regional and National Significance	93.243	-	1,511	University of Connecticut	UCHC7-137481591-A5	1,511	-
	COVID-19 Occupational Safety and Health Program	93.262	-	1,142,872	University of Washington	UWSC12630	1,142,872	-
	Occupational Safety and Health Program	93.262	5,355,434	-			5,355,434	86,973
	Occupational Safety and Health Program	93.262	-	49,954	Children's Hospital/Boston	75D30120C10297	49,954	-
	Occupational Safety and Health Program	93.262	-	3,627	Icahn School of Medicine at Mount Sinai	0253-7122-4609 Amendment No 1 (NCE)	3,627	-
	Occupational Safety and Health Program	93.262	-	197,577	Icahn School of Medicine at Mount Sinai	0253-7131-4609	197,577	-
	Occupational Safety and Health Program	93.262	-	8,445	Icahn School of Medicine at Mount Sinai	0253-7132-4609 YEAR 2 FUNDING	8,445	-
	Occupational Safety and Health Program	93.262	-	(662)	Mount Sinai School of Medicine	0253-6530-4609	(662)	-
	Occupational Safety and Health Program	93.262	-	5,382	Mount Sinai School of Medicine	0253-7121-4609	5,382	-
	Occupational Safety and Health Program	93.262	-	73,331	Mount Sinai School of Medicine	0253-7131-4609	73,331	-
	Occupational Safety and Health Program	93.262	-	11,878	Mount Sinai School of Medicine	0254-8033-4609	11,878	-
	Occupational Safety and Health Program	93.262	-	31,444	Mount Sinai School of Medicine	0254-8182-4609	31,444	-
	Occupational Safety and Health Program	93.262	-	73,564	Ohio State University	SPC-1000005812 / GR125645	73,564	-
	Occupational Safety and Health Program	93.262	-	19,121	University of Pittsburgh	CNVA00053367 (131632-1)	19,121	-
	Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief	93.266	10,828	-			10,828	-
	Viral Hepatitis Prevention and Control	93.270	-	35,545	University of Rochester	417702G/URFAO:GR511033 YEAR 4	35,545	-
	Alcohol Research Programs	93.273	2,467,970	-			2,467,970	368,016
	Alcohol Research Programs	93.273	43,531	-			43,531	7,642
	Alcohol Research Programs	93.273	-	(107,917)	Columbia University	1 (GG013596-01)	(107,917)	-
	Alcohol Research Programs	93.273	-	32,041	Pacific Institute For Research And Evaluation	1031	32,041	-
	Alcohol Research Programs	93.273	-	26,152	Research Foundation For Mental Hygiene Inc.	149979	26,152	-
	Alcohol Research Programs	93.273	-	10,558	State University of New York Downstate Medical Center	100-1171618-92873	10,558	-
	Alcohol Research Programs	93.273	-	25,366	University of California San Francisco	13142sc	25,366	-
	Alcohol Research Programs	93.273	-	12,816	University of Massachusetts, Worcester	OSP31181-NYU	12,816	-
	Alcohol Research Programs	93.273	-	15,937	University of Sheffield	5R01AA024443-04 SUB03 NYU	15,937	-
	COVID-19 Drug Abuse and Addiction Research Programs	93.279	577,941	-			577,941	60,912
	Drug Abuse and Addiction Research Programs	93.279	28,980,752	-			28,980,752	15,678,433
	Drug Abuse and Addiction Research Programs	93.279	8,916,552	-			8,916,552	1,170,658
	Drug Abuse and Addiction Research Programs	93.279	-	71,462	Boston Medical Center	02_NYU_05701 (4300913001)	71,462	-
	Drug Abuse and Addiction Research Programs	93.279	-	216,366	Brown University	1568; 1630; 2039	216,366	-
	Drug Abuse and Addiction Research Programs	93.279	-	25,013	Columbia University	06(GG015428-07)	25,013	-
	Drug Abuse and Addiction Research Programs	93.279	-	15,556	Columbia University	1(GG015428-05)	15,556	-
	Drug Abuse and Addiction Research Programs	93.279	-	8,381	Columbia University	1(GG015428-07)	8,381	-
	Drug Abuse and Addiction Research Programs	93.279	-	37,508	Columbia University	2(GG017257-01)	37,508	-
	Drug Abuse and Addiction Research Programs	93.279	-	29,127	Columbia University	8(GG010654-01) G15940	29,127	-
	Drug Abuse and Addiction Research Programs	93.279	-	43,738	Columbia University	G16101_1(GG014271-01)	43,738	-
	Drug Abuse and Addiction Research Programs	93.279	-	(1,410)	Genecentrix, Inc.	19-A0-00-1003202	(1,410)	-
	Drug Abuse and Addiction Research Programs	93.279	-	3,374	Genecentrix, Inc.	21-A0-00-1007576	3,374	-
	Drug Abuse and Addiction Research Programs	93.279	-	49,958	George Mason University	E2056603	49,958	-
	Drug Abuse and Addiction Research Programs	93.279	-	23,646	Georgia State University	SP00014333-02 Year 3	23,646	-
	Drug Abuse and Addiction Research Programs	93.279	-	340,611	Hennepin Healthcare Research Institute	15390-06	340,611	-
	Drug Abuse and Addiction Research Programs	93.279	-	40,810	Johns Hopkins University	20-A1-00-1004519	40,810	-
	Drug Abuse and Addiction Research Programs	93.279	-	65,313	Nathan S. Kline Institute For Psychiatric Research	26746	65,313	-
	Drug Abuse and Addiction Research Programs	93.279	-	2,999	National Development and Research Institutes	Project 662B00 (R21DA046739)	2,999	-
	Drug Abuse and Addiction Research Programs	93.279	-	39,776	Research Foundation For Mental Hygiene Inc.	903-9014A_TICR 19950	39,776	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Drug Abuse and Addiction Research Programs	93.279	\$ -	\$ 31,483	RTI International	2-312-0217653-66169L Modification Number 2	\$ 31,483	\$ -
	Drug Abuse and Addiction Research Programs	93.279	-	125,386	RTI International	3-312-0216573-65366L Mod 6	125,386	-
	Drug Abuse and Addiction Research Programs	93.279	-	96,274	Sensodx II, LLC.	25-67180-S0821	96,274	-
	Drug Abuse and Addiction Research Programs	93.279	-	62,897	Sensodx II, LLC.	20-A0-00-1003932	62,897	-
	Drug Abuse and Addiction Research Programs	93.279	-	4,550	The Miriam Hospital	7147185AMB	4,550	-
	Drug Abuse and Addiction Research Programs	93.279	-	17,677	The Miriam Hospital	7147185SC	17,677	-
	Drug Abuse and Addiction Research Programs	93.279	-	211,518	University of California Los Angeles	1557 G WC495	211,518	-
	Drug Abuse and Addiction Research Programs	93.279	-	49,591	University of Florida	SUB00003086	49,591	-
	Drug Abuse and Addiction Research Programs	93.279	-	85,540	University of Florida	SUB00003238	85,540	-
	Drug Abuse and Addiction Research Programs	93.279	-	94,427	University of Minnesota	D009105901	94,427	-
	Drug Abuse and Addiction Research Programs	93.279	-	15,666	University of Rhode Island	0066817/111219	15,666	-
	Drug Abuse and Addiction Research Programs	93.279	-	76,218	University of Washington	UWSC12904	76,218	-
	Drug Abuse and Addiction Research Programs	93.279	-	54,709	University of California San Francisco	12627sc Amend 01	54,709	-
	Drug Abuse and Addiction Research Programs	93.279	-	(535)	University of California Davis	A18-0560-S002	(535)	-
	Drug Abuse and Addiction Research Programs	93.279	-	18,556	University of Chicago	AWD0662288 (SUB00000091)	18,556	-
	Drug Abuse and Addiction Research Programs	93.279	-	54,727	University of Chicago	AWD100228 (SUB00000245)	54,727	-
	Drug Abuse and Addiction Research Programs	93.279	-	28,614	University of Kentucky	3210001561-21-297	28,614	-
	Drug Abuse and Addiction Research Programs	93.279	-	131,895	University of Michigan	SUBK00013921 Amd 1	131,895	-
	Drug Abuse and Addiction Research Programs	93.279	-	63,346	University of Washington	UWSC11152 Yr 3 (Amd 2)	63,346	-
	Drug Abuse and Addiction Research Programs	93.279	-	34,088	University of Washington	UWSC11152 Yr 4 (Amd 3)	34,088	-
	Drug Abuse and Addiction Research Programs	93.279	-	266,799	Weill Medical College of Cornell University	220398-2	266,799	-
	Drug Abuse and Addiction Research Programs	93.279	-	136,708	Weill Medical College of Cornell University	222480-1 A02	136,708	-
	Drug Abuse and Addiction Research Programs	93.279	-	31,974	Westat Inc.	6410-S-03 MOD 12	31,974	-
	Drug Abuse and Addiction Research Programs	93.279	-	117,741	Yale University	GR104440 (CON-80001625) A04	117,741	-
	Drug Abuse and Addiction Research Programs	93.279	-	52,968	Yale University	GR104754	52,968	-
	Drug Abuse and Addiction Research Programs	93.279	-	53,410	Yale University	GR110961 (CON-80002662)	53,410	-
	Centers for Disease Control and Prevention_ Investigations and Technical Assistance	93.283	-	1,144	Emory University	A385972	1,144	-
	Centers for Disease Control and Prevention_ Investigations and Technical Assistance	93.283	-	14,542	Stony Brook University	20-A0-00-1005718	14,542	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	5,498,683	-	-	-	5,498,683	233,127
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	127,272	-	-	-	127,272	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	19,706	Children'S Research Institute	30004680-04	19,706	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	53,170	Cincinnati Children's Hospital	314370	53,170	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	80,503	Emory University	A571715	80,503	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	24,300	KiWare Inc.	K003169-00-S02 Mod 01	24,300	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	31,436	Regents of The University of Minnesota	N006269303	31,436	18,547
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	(1,156)	Riverside Research Institute	NYO.1187.00057.16	(1,156)	-
	COVID-19 Minority Health and Health Disparities Research	93.307	787,586	-	-	-	787,586	96,569
	Minority Health and Health Disparities Research	93.307	4,899,804	-	-	-	4,899,804	825,784
	Minority Health and Health Disparities Research	93.307	-	35,857	Columbia University	8(GG017227-02)	35,857	-
	Minority Health and Health Disparities Research	93.307	-	43,890	George Washington University	21-M44	43,890	-
	Minority Health and Health Disparities Research	93.307	-	1,705	Rand Corporation	SCON-00000078	1,705	-
	Minority Health and Health Disparities Research	93.307	-	1,279	Rand Corporation	SCON-00000366	1,279	-
	Minority Health and Health Disparities Research	93.307	-	53,489	Rutgers University	2139	53,489	-
	Minority Health and Health Disparities Research	93.307	-	97,759	University of California Los Angeles	1557 G UB690	97,759	-
	Minority Health and Health Disparities Research	93.307	-	389,569	University of California San Francisco	13035sc	389,569	-
	Minority Health and Health Disparities Research	93.307	715,835	-	-	-	715,835	28,861
	Minority Health and Health Disparities Research	93.307	-	38,870	Boston Medical Center	04-02_NYU_05386	38,870	-
	Minority Health and Health Disparities Research	93.307	-	13,485	Columbia University	1(GG012238-01) Amd 04	13,485	-
	Minority Health and Health Disparities Research	93.307	-	340,156	Rutgers University	2138	340,156	-
	Minority Health and Health Disparities Research	93.307	-	21,128	University of Georgia	SUB00002058 Yr 3	21,128	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Minority Health and Health Disparities Research		93.307	\$ -	\$ 3	Yale University	GR107368(CON-80001890) Amendment 3	\$ 3	\$ -
COVID-19 Trans-NIH Research Support		93.310	(234,949)	-			(234,949)	(343,905)
Trans-NIH Research Support		93.310	13,117,372	-			13,117,372	3,752,462
Trans-NIH Research Support		93.310	948,223	-			948,223	73,918
Trans-NIH Research Support		93.310	-	53,472	Brown University	00001862	53,472	-
Trans-NIH Research Support		93.310	-	8,639	Columbia University	2(GG017680-01)	8,639	-
Trans-NIH Research Support		93.310	-	60,322	Columbia University	3(GG017590-05)	60,322	-
Trans-NIH Research Support		93.310	-	6,355	Connecticut Children's	22-181075-03	6,355	-
Trans-NIH Research Support		93.310	-	28,496	Duke University	2037934	28,496	-
Trans-NIH Research Support		93.310	-	2,730	Duke University	A03-3801	2,730	-
Trans-NIH Research Support		93.310	-	96,470	Narrows Institute for Biomedical Research	19-A0-00-1002521	96,470	-
Trans-NIH Research Support		93.310	-	56,852	Oregon Health & Science University	1014493 NYU	56,852	-
Trans-NIH Research Support		93.310	-	68,071	Yale University	CON-80003429 (GR115119)	68,071	-
Emerging Infections Programs		93.317	-	230	Eastern Virginia Medical School	S270141-25	230	-
The Healthy Brain Initiative: Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels		93.334	559,025	-			559,025	-
COVID-19 National Center for Advancing Translational Sciences		93.350	9,655,027	-			9,655,027	1,602,951
COVID-19 National Center for Advancing Translational Sciences		93.350	-	1,117	Albert Einstein College of Medicine	311784	1,117	-
National Center for Advancing Translational Sciences		93.350	12,885,782	-			12,885,782	1,360,481
National Center for Advancing Translational Sciences		93.350	-	(452)	Boston University	4500003370	(452)	-
National Center for Advancing Translational Sciences		93.350	-	101,824	Spherix Inc.	1 A02	101,824	-
National Center for Advancing Translational Sciences		93.350	-	26,164	University of Illinois at Chicago	18565	26,164	-
21st Century Cures Act - Beau Biden Cancer Moonshot		93.353	-	402,157	Dana-Farber Cancer Center	1205904	402,157	-
21st Century Cures Act - Beau Biden Cancer Moonshot		93.353	-	238,125	Dana-Farber Cancer Center	1244010	238,125	-
21st Century Cures Act - Beau Biden Cancer Moonshot		93.353	-	353,173	University of Utah	10048536-01	353,173	-
COVID-19 21st Century Cures Act - Beau Biden Cancer Moonshot		93.353	-	5,352	University of Utah	10048536-01	5,352	-
Public Health Emergency Response: Cooperative Agreement for Emergency Response: Public Health Crisis Response		93.354	-	4,284	JSI Research and Training Institute Inc.	DrN-NYU1-10172022-0001	4,284	-
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development		93.360	-	68,352	Mapp Biopharmaceutical, Inc.	20-A0-00-1004376	68,352	-
Nursing Research		93.361	1,121,590	-			1,121,590	127,453
Nursing Research		93.361	2,572,522	-			2,572,522	161,274
Nursing Research		93.361	-	19,792	Icahn School of Medicine at Mount Sinai	0255-C121-4609 - Amend2	19,792	-
Nursing Research		93.361	-	102,042	Icahn School of Medicine at Mount Sinai	0255-F241-4609	102,042	-
Nursing Research		93.361	-	82,773	Icahn School of Medicine at Mount Sinai	0255-F241-4609; 5R01NR019792-02; AMENDMENT 2	82,773	-
Nursing Research		93.361	-	26,946	Stanford University	62080080-125082	26,946	-
Cancer Cause and Prevention Research		93.393	10,631,398	-			10,631,398	1,469,774
Cancer Cause and Prevention Research		93.393	598,499	-			598,499	274,388
Cancer Cause and Prevention Research		93.393	-	14,657	Case Western Reserve University	RESS13827	14,657	-
Cancer Cause and Prevention Research		93.393	-	61,137	George Washington University	20-M119 Yr 3	61,137	-
Cancer Cause and Prevention Research		93.393	-	25,138	Georgetown University	425076_GR424531-NYUGSM	25,138	-
Cancer Cause and Prevention Research		93.393	-	22,411	Harvard University	117202-5104484	22,411	-
Cancer Cause and Prevention Research		93.393	-	29,211	Iowa State University	023864A Mod 2	29,211	-
Cancer Cause and Prevention Research		93.393	-	1,067	Johns Hopkins University	21-A0-00-1006802	1,067	-
Cancer Cause and Prevention Research		93.393	-	8,471	Johns Hopkins University	2005330186	8,471	-
Cancer Cause and Prevention Research		93.393	-	7,622	Memorial Sloan Kettering Cancer Center	5 R01 CA207442-05	7,622	-
Cancer Cause and Prevention Research		93.393	-	23,321	Memorial Sloan Kettering Cancer Center	5 R01 CA207442-06	23,321	-
Cancer Cause and Prevention Research		93.393	-	111,772	New York-Presbyterian/Weill Cornell Medicine	221105	111,772	-
Cancer Cause and Prevention Research		93.393	-	78,157	Pennsylvania State University	NYUCA173465 A02	78,157	-
Cancer Cause and Prevention Research		93.393	-	7,824	Rutgers University	1367	7,824	-
Cancer Cause and Prevention Research		93.393	-	10,278	Surgivance Inc.	19-A0-00-1002706	10,278	-
Cancer Cause and Prevention Research		93.393	-	17,488	The Rockefeller University	SUB00000142_AMD1	17,488	-
Cancer Cause and Prevention Research		93.393	-	173,341	University of New Mexico	3RCQ4	173,341	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Cancer Cause and Prevention Research	93.393	\$ -	\$ 14,988	University of California San Diego	86288856 S9001612) Amendment 004	\$ 14,988	\$ -
	Cancer Cause and Prevention Research	93.393	-	315,673	University Of North Carolina - Chapel Hi	5118235	315,673	-
	Cancer Cause and Prevention Research	93.393	-	53,130	University of Wisconsin Madison	000000901 Mod 2	53,130	-
	COVID-19 Cancer Cause and Prevention Research	93.393	1,096,274	-			1,096,274	-
	Cancer Detection and Diagnosis Research	93.394	5,340,227	-			5,340,227	1,298,749
	Cancer Detection and Diagnosis Research	93.394	-	(3,420)	Boston University	4500004241, 4500004242	(3,420)	-
	Cancer Detection and Diagnosis Research	93.394	-	41,686	Case Western Reserve University	RES516211	41,686	-
	Cancer Detection and Diagnosis Research	93.394	-	11,300	City University of New York	CM000004951-00	11,300	-
	Cancer Detection and Diagnosis Research	93.394	-	51,177	Johns Hopkins University	2004249337	51,177	-
	Cancer Detection and Diagnosis Research	93.394	-	139,409	Northwestern University	60058989 NYUSOM	139,409	-
	Cancer Detection and Diagnosis Research	93.394	-	43,832	University of Michigan	SUBK00014247	43,832	-
	Cancer Detection and Diagnosis Research	93.394	-	53,126	University Of Texas Southwestern Medical	GMO: 210504	53,126	-
	COVID-19 Cancer Detection and Diagnosis Research	93.394	120,002	-			120,002	45,033
	Cancer Treatment Research	93.395	8,216,300	-			8,216,300	692,101
	Cancer Treatment Research	93.395	936,543	-			936,543	135,425
	Cancer Treatment Research	93.395	-	749	Case Western Reserve University	27469-123	749	-
	Cancer Treatment Research	93.395	-	297,547	Children's Hospital/Boston	GENFD0002027145	297,547	-
	Cancer Treatment Research	93.395	-	411,849	Cynvec LLC.	19-A0-00-1003874	411,849	-
	Cancer Treatment Research	93.395	-	225,958	Dana-Farber Cancer Center	1288103	225,958	-
	Cancer Treatment Research	93.395	-	4,621	Eastern Cooperative Oncology Group	U10CA180820-01-NYU1	4,621	-
	Cancer Treatment Research	93.395	-	127,387	Eastern Cooperative Oncology Group	U10CA180820-06-NYU1A	127,387	-
	Cancer Treatment Research	93.395	-	257,330	Massachusetts General Hospital	#227583	257,330	-
	Cancer Treatment Research	93.395	-	264,312	Massachusetts General Hospital	233272	264,312	-
	Cancer Treatment Research	93.395	-	277,974	Md Anderson Cancer Center	3001544835	277,974	-
	Cancer Treatment Research	93.395	-	265,630	Medical University of South Carolina	A00-3465-S001	265,630	-
	Cancer Treatment Research	93.395	-	200,773	Memorial Sloan Kettering Cancer Center	C21957411	200,773	-
	Cancer Treatment Research	93.395	-	121,930	New York-Presbyterian/Weill Cornell Medicine	213821	121,930	-
	Cancer Treatment Research	93.395	-	307,000	Nrg Oncology	2021-001	307,000	-
	Cancer Treatment Research	93.395	-	155	Nrg Oncology	BIQSFP NRG-BN011	155	-
	Cancer Treatment Research	93.395	-	64,416	Perionics Care LLC.	1R41CA250892-01	64,416	-
	Cancer Treatment Research	93.395	-	31,330	Public Health Institute	AR03275	31,330	-
	Cancer Treatment Research	93.395	-	90,615	Tezcat Laboratories	21-A0-00-1006992	90,615	-
	Cancer Treatment Research	93.395	-	57,661	Tezcat Laboratories	22-A0-00-1007484	57,661	-
	Cancer Treatment Research	93.395	-	10	The Children's Hospital Of Philadelphia	15221_SUB868_01	10	-
	Cancer Treatment Research	93.395	-	4,000	The Children's Hospital Of Philadelphia	FP00013087_SUB209_01	4,000	-
	Cancer Treatment Research	93.395	-	28,402	The Children's Hospital Of Philadelphia	FP00026529_SUB97_01	28,402	-
	Cancer Treatment Research	93.395	-	14,706	University of Pennsylvania	576794 Amd 2	14,706	-
	COVID-19 Cancer Treatment Research	93.395	837,924	-			837,924	36,883
	COVID-19 Cancer Treatment Research	93.395	-	276,679	Duke University	116	276,679	-
	Cancer Biology Research	93.396	12,248,517	-			12,248,517	645,322
	Cancer Biology Research	93.396	673,079	-			673,079	-
	Cancer Biology Research	93.396	-	64,298	Columbia University	C1(GG013650-08)-PROJECT 3	64,298	-
	Cancer Biology Research	93.396	-	180,537	Dana-Farber Cancer Center	1198610	180,537	-
	Cancer Biology Research	93.396	-	229,424	Georgia Tech Research Corporation	AWD-101351-G1	229,424	-
	Cancer Biology Research	93.396	-	378,898	Md Anderson Cancer Center	3001751142	378,898	-
	Cancer Biology Research	93.396	-	329,821	Memorial Sloan Kettering Cancer Center	BD523773D	329,821	-
	Cancer Biology Research	93.396	-	184,799	Memorial Sloan Kettering Cancer Center	SUB00000365AM2	184,799	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Cancer Biology Research	93.396		12,531	Northwestern University	60061067 NYU	12,531	-
	Cancer Biology Research	93.396	\$ -	3,410	Rutgers University	1724	3,410	-
	Cancer Biology Research	93.396	-	(16,921)	Sloan Kettering Institute for Cancer Research	BD520651D	(16,921)	-
	Cancer Biology Research	93.396	-	5,719	The Children's Hospital Of Philadelphia	GRT-00001899	5,719	-
	Cancer Biology Research	93.396	-	8,954	University of California Los Angeles	0865 G Y896	8,954	-
	Cancer Biology Research	93.396	-	29,217	University of California San Francisco	12695sc	29,217	-
	Cancer Biology Research	93.396	-	34,137	Yale University	CON-80003463(GR115260)	34,137	-
	Cancer Centers Support Grants	93.397	5,711,524	-			5,711,524	41,149
	Cancer Centers Support Grants	93.397	-	18,472	Albert Einstein College of Medicine	312138	18,472	-
	Cancer Centers Support Grants	93.397	-	90,379	Albert Einstein College of Medicine	311958 Amend 1 supplemental funds	90,379	-
	Cancer Centers Support Grants	93.397	-	84,969	Indiana University	9214	84,969	-
	Cancer Research Manpower	93.398	1,501,570	-			1,501,570	-
	Cancer Research Manpower	93.398	-	34,429	H Lee Moffitt Cancer Center and Research Institute	10-18711-05-01-G3	34,429	-
	Cancer Control	93.399	-	10,858	Case Western Reserve University	20-A0-00-070834	10,858	-
	Cancer Control	93.399	-	113,404	Leidos Biomedical Research, Inc.	TO#: 18X100F2	113,404	-
	Cancer Control	93.399	-	108,226	Luna, Inc.	3483.02NYU	108,226	-
	Cancer Control	93.399	-	5,144	Public Health Institute	UG1CA169955	5,144	-
	Cancer Control	93.399	-	380	The Children's Hospital Of Philadelphia	20-A0-00-1004639	380	-
	Cancer Control	93.399	-	203,214	University of Georgia	SUB00002152-3U	203,214	-
	Cancer Control	93.399	-	22,186	Westat Inc.	6410-S-04-TO1	22,186	-
	COVID-19 Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	-	306,657	Asian/Pacific Islander American Health Forum	20-A0-00-1005825	306,657	-
	COVID-19 Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	-	223,554	Asian/Pacific Islander American Health Forum	NYU-FPRR-2021	223,554	-
	COVID-19 Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	-	83,585	The Task Force For Global Health, Inc	PO 3837	83,585	-
	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	-	60,168	Asian/Pacific Islander American Health Forum	NYU-IPC-2021	60,168	-
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	589,535	-			589,535	-
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	3,215	Craig Hospital	2694-RuskBY3	3,215	-
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	7,185	Indiana University	8694	7,185	-
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	12,535	Public Health Institute	00622 (90DP0081-01-01) Amd 3	12,535	-
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	51,197	Public Health Institute	03349-AR14422	51,197	-
	National Harm Reduction Technical Assistance and Syringe Services Program (SSP) Monitoring and Evaluation Funding Opportunity	93.488	-	13,772	University of Washington	UWSC11453 Amd 1	13,772	-
	National Harm Reduction Technical Assistance and Syringe Services Program (SSP) Monitoring and Evaluation Funding Opportunity	93.488	-	152,248	University of Washington	UWSC11453 Amd 3	152,248	-
	ACA-Transforming Clinical Practice Initiative: Practice Transformation Networks (PTNs)	93.638	(197)	-			(197)	-
	Mental and Behavioral Health Education and Training Grants	93.732	502,723	-			502,723	-
	Centers for Medicare and Medicaid Services (CMS) Research, Demonstrations and Evaluations	93.779	-	54,258	Yale New Haven Health System	21-A0-00-1007631	54,258	-
	Cardiovascular Diseases Research	93.837	32,138,149	-			32,138,149	5,811,465
	Cardiovascular Diseases Research	93.837	1,570,798	-			1,570,798	369,011
	Cardiovascular Diseases Research	93.837	-	1,976	Brigham & Women's Hospital	17-WH-CN-100027	1,976	-
	Cardiovascular Diseases Research	93.837	-	1,376	Case Western Reserve University	RES511883	1,376	-
	Cardiovascular Diseases Research	93.837	-	(1,102)	Columbia University	1(GG012712-01)	(1,102)	-
	Cardiovascular Diseases Research	93.837	-	988	Columbia University	7(GG015243-01)	988	-
	Cardiovascular Diseases Research	93.837	-	64,100	Columbia University	8(GG015243-01) Amd 1	64,100	-
	Cardiovascular Diseases Research	93.837	-	2,362	Downstate Medical Center (SUNY)	100-1091654-90560	2,362	-
	Cardiovascular Diseases Research	93.837	-	16,347	Icahn School of Medicine at Mount Sinai	0255-E231-4609 A01	16,347	-
	Cardiovascular Diseases Research	93.837	-	385,282	Louisiana State University Health New Orleans	20-92-005	385,282	-
	Cardiovascular Diseases Research	93.837	-	46,338	Mayo Clinic	NEW-271673/PO #67491353	46,338	-
	Cardiovascular Diseases Research	93.837	-	52	Medstar Health Research Institute	5001921634	52	-
	Cardiovascular Diseases Research	93.837	-	212	Mount Sinai School of Medicine	0249-4004-4605	212	-
	Cardiovascular Diseases Research	93.837	-	155,185	Mount Sinai School of Medicine	0254-3895-4609	155,185	-
	Cardiovascular Diseases Research	93.837	-	281,334	Mount Sinai School of Medicine	0255-E231-4609	281,334	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Cardiovascular Diseases Research		93.837		66,930	Nationwide Children's Hospital	700190-1122-00	\$ 66,930	\$ -
Cardiovascular Diseases Research		93.837	\$ -	32,928	New York-Presbyterian/Weill Cornell Medicine	212515	\$ 32,928	-
Cardiovascular Diseases Research		93.837	-	18,295	Northwestern University	60058632 NYU	18,295	-
Cardiovascular Diseases Research		93.837	-	(264,040)	New York Academy Of Medicine	GT002661_NYU_SOM	(264,040)	-
Cardiovascular Diseases Research		93.837	-	209	Ohio State University	GR119800	209	-
Cardiovascular Diseases Research		93.837	-	16,179	Ohio State University	GR126030 SPC-1000006049	16,179	-
Cardiovascular Diseases Research		93.837	-	136,111	Rutgers University	1733	136,111	-
Cardiovascular Diseases Research		93.837	-	17,898	Tamkeen NYU Abu Dhabi	OS00000881	17,898	-
Cardiovascular Diseases Research		93.837	-	7,469	Washington University	WU-22-0333-MOD-2	7,469	-
Cardiovascular Diseases Research		93.837	-	64,187	Tufts University	NH0001 Y12	64,187	-
Cardiovascular Diseases Research		93.837	-	181,641	University of Alabama at Birmingham	000528903-SC002	181,641	-
Cardiovascular Diseases Research		93.837	-	94,873	University of Massachusetts, Worcester	OSP27238-NYU	94,873	-
Cardiovascular Diseases Research		93.837	-	4,826	University of Miami	OS00000855	4,826	-
Cardiovascular Diseases Research		93.837	-	21,910	University of Miami Miller School of Medicine	OS00000775AM2	21,910	-
Cardiovascular Diseases Research		93.837	-	290	University of Rochester	417522G/UR FAO GR510851	290	-
Cardiovascular Diseases Research		93.837	-	426,848	University of Washington	UWSC12145	426,848	-
Cardiovascular Diseases Research		93.837	-	67,871	University of Washington	UWSC12146	67,871	-
Cardiovascular Diseases Research		93.837	-	220,639	University of California San Francisco	112948c	220,639	-
Cardiovascular Diseases Research		93.837	-	33,239	University of Michigan	SUBK00015230	33,239	-
Cardiovascular Diseases Research		93.837	-	8,440	University of North Carolina at Chapel Hill	5118768	8,440	-
Cardiovascular Diseases Research		93.837	-	24,258	University of North Carolina at Chapel Hill	5120350	24,258	-
Cardiovascular Diseases Research		93.837	-	98,201	Vanderbilt University Medical Center	VUMC75904	98,201	-
Cardiovascular Diseases Research		93.837	-	4,267	Vanderbilt University	VUMC99716	4,267	-
Cardiovascular Diseases Research		93.837	-	8,663	Washington University/St. Louis School of Medicine	WU-21-431	8,663	-
Cardiovascular Diseases Research		93.837	-	181,835	Westat Inc.	6793-00-RC004	181,835	6,916
COVID-19 Cardiovascular Diseases Research		93.837	63,587	-			63,587	-
COVID-19 Cardiovascular Diseases Research		93.837	-	811,939	Westat Inc.	6793-02-S013	811,939	291,700
COVID-19 Lung Diseases Research		93.838	89,864,249	-			89,864,249	75,749,344
Lung Diseases Research		93.838	441,770	-			441,770	-
Lung Diseases Research		93.838	-	33,469	Cvpath Institute, Inc.	21-A0-00-1007507	33,469	-
Lung Diseases Research		93.838	-	58,629	New York-Presbyterian/Weill Cornell Medicine	220367-4	58,629	-
Lung Diseases Research		93.838	-	62,153	Northshore University Health Systems	EH17-325-S2	62,153	-
Lung Diseases Research		93.838	-	6,053	Northwestern University	160053487 NYU	6,053	-
Lung Diseases Research		93.838	-	359,404	Rhode Island Hospital	7137715	359,404	-
Lung Diseases Research		93.838	-	356,491	RH Health Solutions	31-312-0217571-66402L	356,491	272,300
Lung Diseases Research		93.838	-	43,471	Stanford University	62346242-131009	43,471	-
Lung Diseases Research		93.838	-	23,726	University of Cincinnati	013615-00003/00004	23,726	-
Lung Diseases Research		93.838	-	6,102	University of Illinois at Chicago	18843	6,102	-
Lung Diseases Research		93.838	-	11,760,395	University of Pittsburgh Medical Center	AWD00002796-1A0	11,760,395	8,346,795
Lung Diseases Research		93.838	-	32,035	Yale University, School of Medicine	GR110769(CON-80002544)	32,035	-
Blood Diseases and Resources Research		93.839	994,600	-			994,600	199,991
Blood Diseases and Resources Research		93.839	-	22,511	Cleveland Clinic Foundation	CCF21110593	22,511	-
Blood Diseases and Resources Research		93.839	-	9,721	Rutgers University	SS01501	9,721	-
Blood Diseases and Resources Research		93.839	-	439,616	University Of Pennsylvania	585262	439,616	-
Blood Diseases and Resources Research		93.839	-	43,258	Washington University	WU-18-220-MOD-3	43,258	-
Blood Diseases and Resources Research		93.839	-	7,276	Washington University	WU-18-273-MOD-3	7,276	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders		93.840	1,646,389	-			1,646,389	283,063
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders		93.840	225,500	-			225,500	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders		93.840	-	29,759	Case Western Reserve University	RESS15477	29,759	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	\$ -	\$ (1,178)	Case Western Reserve University	RESS16378	(1,178)	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	11,088	Covance Inc.	caProtocol # 20203331	11,088	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	197,084	Kintampo Health Research Centre	Hy-Trec 001	197,084	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	(9,475)	Moi University School of Medicine	19-A0-00-1002675	(9,475)	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	23,377	Northwestern University	60057974 NYU	23,377	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	10,412	University of Washington	UWSC13652	10,412	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	154,756	University of Washington	UWSC13675	154,756	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	341,152	University of Abuja	NYU 001	341,152	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	11,542,807	-	-	-	11,542,807	1,093,478
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	16,058	Brigham & Women's Hospital	119899	16,058	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	9,526	Cincinnati Children's Hospital	306894	9,526	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	11,231	Hospital for Special Surgery	5R01AR077145-02 A01	11,231	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	147	Mount Sinai School of Medicine	0255-G021-4609	147	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	121,968	University Of Pennsylvania	577986	121,968	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	40,706	University of Rochester	SUB00000298/URFAO:GR53226	40,706	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	9,510,019	-	-	-	9,510,019	862,441
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1,108,488	-	-	-	1,108,488	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	49,483	Albert Einstein College of Medicine	31126D	49,483	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	74,498	Albert Einstein College of Medicine	311303	74,498	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	65,573	Augusta University Research Institute	32307-79	65,573	59,763
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	36,448	Columbia University	1(GG015926-02)	36,448	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(18,391)	George Washington University	19-B04	(18,391)	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	83,687	George Washington University	20-B04	83,687	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	113,329	Johns Hopkins University	2005476879	113,329	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	167	Md Anderson Cancer Center	3001657188	167	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(8,031)	Montana State University	G197-19-W7522	(8,031)	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	55,252	Mount Sinai School of Medicine	0255-4476-4609	55,252	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	176,467	The Rockefeller University	21-A0-00-1005207	176,467	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	24,555	Rush University Medical Center	16091506-Sub01	24,555	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	6,041	Rutgers University	0113 (Mod 5)	6,041	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	61,954	Stanford University	62713287-213702	61,954	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	5,717	Tulane University	TUL-HSC-560068-22/23	5,717	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	8,031	University of California San Francisco	12644sc	8,031	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	6,847	University of Ghana	5U54DK116913-10	6,847	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	21,231	University Of Pennsylvania	572700	21,231	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	14,979	University Of Pennsylvania	579594	14,979	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	33,608	University Of Pennsylvania	582481	33,608	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	76,854	University Of Pennsylvania	582534	76,854	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	6,080	University of South Florida	#3732	6,080	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	112,624	University Of Colorado Denver	FY22.269.003	112,624	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	\$ -	\$ 8,795	University of Michigan	SUBK00012123	\$ 8,795	\$ -
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	3,828	University of Utah	10053701-01	3,828	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	5,536	Wake Forest University	249-55811085045103-100005	5,536	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	16,836	Wake Forest University	96-101750-110154	16,836	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	87,273	-			87,273	-
	COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	895,322	-			895,322	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	35,620,304	-			35,620,304	4,550,704
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	4,361,403	-			4,361,403	438,368
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	131,999	Allen Institute	2022-0140	131,999	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	158,112	Baylor College of Medicine	PO 7000001288 A01	158,112	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	21,768	Boston University	4500004159	21,768	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,765	CND Life Sciences	1R44NS117214	9,765	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,250	Columbia University	1 (GG014507)	9,250	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	23,852	Columbia University	1(GG013374-01) AMD 4	23,852	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	49,130	Columbia University	1(GG017644-02)	49,130	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	145,656	Columbia University	1(GG017705-02)	145,656	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	45,035	Columbia University	4(GG015295-01)	45,035	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,398	Columbia University	9(GG017143-08) A01	3,398	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	15,400	Columbia University Irving Medical Center	1 GG015368-01	15,400	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	117,751	Duke University	303-000278	117,751	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	916	Duke University	A03-0339 A02	916	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	5,517	Emory University	T662050 (Yr4 T472196)	5,517	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	160,482	Epitel, Inc.	20-A0-00-1005233	160,482	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	30,668	Indiana University	9316-NYU	30,668	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	211,306	Johns Hopkins University	2004835505	211,306	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	2,537	Massachusetts General Hospital	22-A0-00-1007957	2,537	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	12,134	Massachusetts General Hospital	233102	12,134	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	15,975	Massachusetts General Hospital	238069	15,975	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,212	Massachusetts General Hospital	238257	9,212	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	489,046	Massachusetts General Hospital	239654	489,046	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	844,978	Massachusetts General Hospital	239655	844,978	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	203,622	Massachusetts Institute of Technology	S5071 - PO#476438 Year 2	203,622	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,993	Medical University of South Carolina	A20-0051-S002	9,993	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	189,407	Mount Sinai School of Medicine	0255-E771-4609	189,407	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	12,375	Mount Sinai School of Medicine	0255-F851-4609	12,375	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	46,224	New Jersey Institute of Technology	997809GSM	46,224	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	66,270	New York Genome Center	2019-0018-NYU-01 A03	66,270	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	82,863	New York Genome Center	2019-0035-NYU-01 A01	82,863	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	15,739	Northwestern University	60054977-NYU	15,739	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,060	Northwestern University	60054977-NYU-FR	1,060	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	178,176	Ohio State University	GR128737 SPC-1000006867	178,176	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	107,518	Purdue University	11000790-010	107,518	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	107,909	Research Foundation of CUNY on behalf of City University of New York	CM00001407-04 A04	107,909	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	611,697	Stanford University	61752758-128562	611,697	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	11,413	Stanford University	61869960-125439	11,413	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	12,601	Temple University	264814-NYU	12,601	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	328	The Regents of The University of California	9835sc	328	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	279,350	University of California At Berkeley	00010180	279,350	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	35,554	University of Cincinnati	010785-138466	35,554	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	\$ -	\$ 10,799	University of Cincinnati	012043-138466	10,799	\$ -
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,300	University of Cincinnati	012044-138466	1,300	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	148	University of Cincinnati	012340-138466	148	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	26,810	University of Southern California	132589641	26,810	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	472	University of Tennessee	18-A0-00-1001518	472	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	218,278	University of California Los Angeles	2000 G WM035 A01	218,278	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	20,719	University of Chicago	AWD101996 (SUB00000504)	20,719	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	851,359	University of Chicago	FP066214-02-PR-C	851,359	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	460,367	University of Chicago	FP066214-02-PR-F	460,367	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	6,062	University of Cincinnati College of Medicine	011337-138466	6,062	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	12,753	University Of Colorado Denver	FY21.237.005_AMD2	12,753	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	23,680	University Of Colorado Denver	FY21.620.002	23,680	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	21,413	University of Georgia	SUB00002740	21,413	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	82,372	University of Michigan	SUBK00010533	82,372	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	838,586	University of Rochester	417852-G / UR FAO GR511130 A02	838,586	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(36,364)	University of Rochester	417852GUR FAO GR511130	(36,364)	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	2,519	University of Rochester	417852GUR FAO GR511130 A03	2,519	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,329	University of Washington	UWSC10761 A02	1,329	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	122,491	University of Washington	UWSC10761 A04	122,491	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	53,140	Weill Cornell Medical College	212518	53,140	-
	Allergy and Infectious Diseases Research	93.855	23,245,755	-			23,245,755	2,151,762
	Allergy and Infectious Diseases Research	93.855	3,353,801	-			3,353,801	882,556
	Allergy and Infectious Diseases Research	93.855	-	(3,864)	Aaron Diamond Aids Research Center	A09-200-NYU-Kong	(3,864)	-
	Allergy and Infectious Diseases Research	93.855	-	27,549	Benaroya Research Institute at Virginia	FY21TN421	27,549	-
	Allergy and Infectious Diseases Research	93.855	-	180,014	Benaroya Research Institute at Virginia	FY22TN552	180,014	-
	Allergy and Infectious Diseases Research	93.855	-	55,371	Caldara Medical, LLC.	22-A0-00-1007906	55,371	-
	Allergy and Infectious Diseases Research	93.855	-	83,602	Columbia University	1(GG017900-01)	83,602	-
	Allergy and Infectious Diseases Research	93.855	-	102,649	Columbia University	3(GG012754-25)	102,649	-
	Allergy and Infectious Diseases Research	93.855	-	933	Feinstein Institute for Medical Research	AWD00001202 - NYU	933	-
	Allergy and Infectious Diseases Research	93.855	-	78,238	Fred Hutchinson Cancer Research Center	0001064988	78,238	-
	Allergy and Infectious Diseases Research	93.855	-	200,646	Fred Hutchinson Cancer Research Center	0001081382	200,646	-
	Allergy and Infectious Diseases Research	93.855	-	2,017	Johns Hopkins University	18-A0-00-1001680	2,017	-
	Allergy and Infectious Diseases Research	93.855	-	2,149	Johns Hopkins University	19-A0-00-1003004	2,149	-
	Allergy and Infectious Diseases Research	93.855	-	6,437	Johns Hopkins University	LDR 03	6,437	-
	Allergy and Infectious Diseases Research	93.855	-	77,616	Johns Hopkins University	TOH: LDR 04 MOD 01	77,616	-
	Allergy and Infectious Diseases Research	93.855	-	40,188	Leidos Biomedical Research, Inc.	22CTA-DM0016	40,188	-
	Allergy and Infectious Diseases Research	93.855	-	296,461	Lyndra Therapeutics Inc.	084	296,461	-
	Allergy and Infectious Diseases Research	93.855	-	26,076	Massachusetts General Hospital	234439	26,076	-
	Allergy and Infectious Diseases Research	93.855	-	33,623	Mount Sinai School of Medicine	0255-8891-4609	33,623	-
	Allergy and Infectious Diseases Research	93.855	-	71,255	Mount Sinai School of Medicine	0255-D001-4609	71,255	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Allergy and Infectious Diseases Research	93.855	\$ -	\$ 20,994	Mount Sinai School of Medicine	0255-D231-4609	20,994	\$ -
	Allergy and Infectious Diseases Research	93.855	-	98,065	Mount Sinai School of Medicine	0255-D341-4609	98,065	-
	Allergy and Infectious Diseases Research	93.855	-	78,343	Mount Sinai School of Medicine	0255-E321-4609	78,343	-
	Allergy and Infectious Diseases Research	93.855	-	328,452	Mount Sinai School of Medicine	0258-A504-4609	328,452	-
	Allergy and Infectious Diseases Research	93.855	-	99,996	Neochromosome Inc.	Neo-NYU-HLA	99,996	-
	Allergy and Infectious Diseases Research	93.855	-	13,788	Northeastern University	500828-78052	13,788	-
	Allergy and Infectious Diseases Research	93.855	-	37,935	Princeton University	SUB0000173	37,935	-
	Allergy and Infectious Diseases Research	93.855	-	1,452	Quality Biological, Inc.	TonyuSAMP001-PO#43317	1,452	-
	Allergy and Infectious Diseases Research	93.855	-	(456)	Quality Biological, Inc.	TOV1v2ppts001	(456)	-
	Allergy and Infectious Diseases Research	93.855	-	93,774	The Rockefeller University	SUB00000211	93,774	-
	Allergy and Infectious Diseases Research	93.855	-	42,880	Rutgers University	1565	42,880	-
	Allergy and Infectious Diseases Research	93.855	-	213,434	St. Jude Children's Research Hospital	11246704A-8099685 A03	213,434	-
	Allergy and Infectious Diseases Research	93.855	-	127,901	Stanford University	62561929-194071	127,901	-
	Allergy and Infectious Diseases Research	93.855	-	23,625	Stanford University Medical Center	62500013-128779	23,625	-
	Allergy and Infectious Diseases Research	93.855	-	42,330	Stellenbosch University, South Africa	S006234	42,330	-
	Allergy and Infectious Diseases Research	93.855	-	62,950	University of Florida	SUB00001704	62,950	-
	Allergy and Infectious Diseases Research	93.855	-	143,322	University Of Pennsylvania	583556	143,322	-
	Allergy and Infectious Diseases Research	93.855	-	166,006	University of Georgia	SUB00002152	166,006	-
	Allergy and Infectious Diseases Research	93.855	-	(9,878)	University of Georgia	SUB00002153 A01	(9,878)	-
	Allergy and Infectious Diseases Research	93.855	-	7,061	University of Georgia	SUB00002153 A04	7,061	-
	Allergy and Infectious Diseases Research	93.855	-	700,496	University of Georgia	SUB00002153-SU A06	700,496	-
	Allergy and Infectious Diseases Research	93.855	-	140,715	University of Maryland	1701066C/UMB Ref.4468	140,715	-
	Allergy and Infectious Diseases Research	93.855	-	25,013	University of Maryland	20338-0761	25,013	-
	Allergy and Infectious Diseases Research	93.855	-	12,639	University of North Carolina at Chapel Hill	5120657	12,639	-
	Allergy and Infectious Diseases Research	93.855	-	50,681	University of Texas at Arlington	2021GCO742	50,681	-
	Allergy and Infectious Diseases Research	93.855	-	75,100	Yale University	GR107761 (CON-80001959) Amd 02	75,100	-
	Allergy and Infectious Diseases Research	93.855	-	(6,835)	Zymeron Corporation	FUTURE	(6,835)	-
	Allergy and Infectious Diseases Research	93.855	-	10,676	Zymeron Corporation	NIAD050-1NYU	10,676	-
	Allergy and Infectious Diseases Research	93.855	-	59,380	Zymeron Corporation	Z121/NYU	59,380	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	5,727,113	-			5,727,113	62,488
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	218,297	Humanetics Corporation	272201800011C	218,297	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	113,459	Ingenious Targeting Laboratory	20-00-00-1005256	113,459	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	32,517	Johns Hopkins University	U01AI138897	32,517	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	77,261	Leidos Biomedical Research, Inc.	20CTA-DM0007	77,261	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	197,899	Leidos Biomedical Research, Inc.	22CTA-DM0013	197,899	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	50,025	Leidos Biomedical Research, Inc.	22CTA-DM0016	50,025	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	32,837	University of Rochester	417758/URFAO: GR511063	32,837	-
	Biomedical Research and Research Training	93.859	13,870,131	-			13,870,131	348,479
	Biomedical Research and Research Training	93.859	11,484,323	-			11,484,323	212,716
	Biomedical Research and Research Training	93.859	-	74,484	Cornell University	213071	74,484	-
	Biomedical Research and Research Training	93.859	-	42,370	Drexel University	900003	42,370	-
	Biomedical Research and Research Training	93.859	-	33,635	Drexel University	900173	33,635	-
	Biomedical Research and Research Training	93.859	-	27,516	The Rockefeller University	SUB00000161	27,516	-
	Biomedical Research and Research Training	93.859	-	45,816	University of California San Diego	122991430-001 (S9002428)	45,816	-
	Biomedical Research and Research Training	93.859	-	34,220	University of Chicago	AWD101048 Amendment 1	34,220	-
	Biomedical Research and Research Training	93.859	-	129,390	University of Connecticut	150946017	129,390	-
	Biomedical Research and Research Training	93.859	-	72,375	University Of Mississippi	19-07-006	72,375	-
	Child Health and Human Development Extramural Research	93.865	7,059,264	-			7,059,264	1,482,982

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Child Health and Human Development Extramural Research	93.865	\$ 5,928,047	\$ -			\$ 5,928,047	\$ 816,380
	Child Health and Human Development Extramural Research	93.865	-	558	Digital Health Empowerment	R42HD088325	558	-
	Child Health and Human Development Extramural Research	93.865	-	7,712	Emory University	A43864	7,712	-
	Child Health and Human Development Extramural Research	93.865	-	193,112	Emory University	A513975 A01	193,112	-
	Child Health and Human Development Extramural Research	93.865	-	(12)	Harvard School Of Public Health	114205-1514-5096794	(12)	-
	Child Health and Human Development Extramural Research	93.865	-	255,730	Harvard School Of Public Health	117267-0114-5119096	255,730	-
	Child Health and Human Development Extramural Research	93.865	-	187,636	Harvard School Of Public Health	117267-0180-5119094	187,636	-
	Child Health and Human Development Extramural Research	93.865	-	4,486	Kessler Foundation	40568-01 Amd 2	4,486	-
	Child Health and Human Development Extramural Research	93.865	-	116,597	Nathan S. Kline Institute For Psychiatric Research	148691	116,597	-
	Child Health and Human Development Extramural Research	93.865	-	69,154	Princeton University	SUB0000200	69,154	-
	Child Health and Human Development Extramural Research	93.865	-	31,677	Rehabilitation Institute of Chicago	82327.NYU.Y2	31,677	-
	Child Health and Human Development Extramural Research	93.865	-	19,723	Rutgers University	1471	19,723	-
	Child Health and Human Development Extramural Research	93.865	-	262,369	Rutgers University	PID#825656/ SUB 0924	262,369	-
	Child Health and Human Development Extramural Research	93.865	-	5,587	Saint Louis University	21612-43391	5,587	-
	Child Health and Human Development Extramural Research	93.865	-	30,179	The Trustees Of Columbia Univ	1(GG017649-01)	30,179	-
	Child Health and Human Development Extramural Research	93.865	-	222,602	Washington University	WU-19-419-MOD-2	222,602	-
	Child Health and Human Development Extramural Research	93.865	-	845	Tulane University	TUL-HSC-557473-19/20 (CoreB) Amd 1	845	-
	Child Health and Human Development Extramural Research	93.865	-	(1,101)	Tulane University	TUL-HSC-557474-19/20 Amd 1	(1,101)	-
	Child Health and Human Development Extramural Research	93.865	-	(3,545)	University of California Los Angeles	2000 G XA415	(3,545)	-
	Child Health and Human Development Extramural Research	93.865	-	30,493	University of California San Francisco	12343cc	30,493	-
	Child Health and Human Development Extramural Research	93.865	-	79,383	University of Minnesota	A008487501	79,383	-
	Child Health and Human Development Extramural Research	93.865	-	18,557	University of North Carolina at Chapel Hill	5109090 Amd 3	18,557	-
	Child Health and Human Development Extramural Research	93.865	-	(174)	Weill Cornell Medical College	161040536-01	(174)	-
	Aging Research	93.866	25,562,474	-			25,562,474	4,326,662
	Aging Research	93.866	5,281,814	-			5,281,814	868,982
	Aging Research	93.866	-	503,099	Arizona Board of Regents for and on behalf of Arizona State University	ASUB00000533 A03	503,099	-
	Aging Research	93.866	-	8,724	Brown University	2054	8,724	-
	Aging Research	93.866	-	68,452	Brown University	00000974	68,452	-
	Aging Research	93.866	-	40,723	Brown University	00001363	40,723	-
	Aging Research	93.866	-	41,867	Brown University	00001370 Amendment 6	41,867	-
	Aging Research	93.866	-	223,118	Brown University	00001370; AMD 4	223,118	-
	Aging Research	93.866	-	48,654	Brown University	00001371	48,654	-
	Aging Research	93.866	-	373,948	Brown University	00001642	373,948	-
	Aging Research	93.866	-	153,223	Brown University	00002031	153,223	-
	Aging Research	93.866	-	16,310	Charles River Analytics Inc	SC1821601	16,310	-
	Aging Research	93.866	-	34,594	Columbia University	1(GG016423-01)	34,594	-
	Aging Research	93.866	-	2,443	Columbia University	11(GG015822-05)	2,443	-
	Aging Research	93.866	-	13,466	Columbia University	2(GG015245-04)	13,466	-
	Aging Research	93.866	-	53,859	Columbia University	3(GG012042-06)	53,859	-
	Aging Research	93.866	-	8,837	Columbia University	3(GG01242-03)	8,837	-
	Aging Research	93.866	-	25,140	Columbia University	GG015245 Yr 3	25,140	-
	Aging Research	93.866	-	71,816	Dartmouth College	R1624	71,816	-
	Aging Research	93.866	-	42,051	Diarrir, LLC.	17-A0-00-006660	42,051	-
	Aging Research	93.866	-	43,845	Duke University Medical Center	A035570	43,845	-
	Aging Research	93.866	-	256,819	Johns Hopkins University	2004459373	256,819	73,650
	Aging Research	93.866	-	19,880	Massachusetts General Hospital	236564	19,880	-
	Aging Research	93.866	-	24,052	Massachusetts General Hospital	236484	24,052	-
	Aging Research	93.866	-	20,076	Md Anderson Cancer Center	3001841638	20,076	-
	Aging Research	93.866	-	199,044	Memorial Sloan Kettering Cancer Center	BD523817	199,044	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Aging Research		93.866		155,271	Memorial Sloan Kettering Cancer Center	C21919392	155,271	
Aging Research		93.866	\$ -	14,082	Mount Sinai School of Medicine	0255-3651-4609	14,082	\$ -
Aging Research		93.866		77,677	Mount Sinai School of Medicine	0255-D521-4609	77,677	
Aging Research		93.866		33,052	New York-Presbyterian/Weill Cornell Medicine	201931	33,052	
Aging Research		93.866		170,975	New York-Presbyterian/Weill Cornell Medicine	202565-1	170,975	
Aging Research		93.866		10,127	New York-Presbyterian/Weill Cornell Medicine	214331	10,127	
Aging Research		93.866		19,424	New York-Presbyterian/Weill Cornell Medicine	220555	19,424	
Aging Research		93.866		26,369	Northern California Institute for Research and Education	79634841	26,369	
Aging Research		93.866		36,121	Rutgers University	2204	36,121	
Aging Research		93.866		8,944	Rutgers University	1888	8,944	
Aging Research		93.866		3,336	Rutgers University	0874 ANTICIPATED FUNDING	3,336	
Aging Research		93.866		17,722	Rutgers University	5P30AG059304-04: 2165	17,722	
Aging Research		93.866		9,153	Rutgers University	Subaward No 9002 NCE	9,153	
Aging Research		93.866		(2,478)	St. Joseph's Hospital & Medical Center	1032146-NYUMC	(2,478)	
Aging Research		93.866		182,480	St. Joseph's Hospital & Medical Center	32114-NYUSOM	182,480	
Aging Research		93.866		35,612	Washington University	WU-19-57-AMD 4	35,612	
Aging Research		93.866		92,426	Translational Genomics Research Institute	SCHORR-19-01 Mod. 02	92,426	
Aging Research		93.866		202,191	University of California Irvine	2018-3569	202,191	
Aging Research		93.866		325	University of California San Diego	110038908	325	
Aging Research		93.866		(92)	University of Massachusetts, Worcester	OSP2018113	(92)	
Aging Research		93.866		29,999	University Of Pennsylvania	582905	29,999	
Aging Research		93.866		336	University of Southern California	19-A0-00-1003733	336	
Aging Research		93.866		3,530	University of Southern California	81622917	3,530	
Aging Research		93.866		32,570	University of Washington	UWSC12989	32,570	
Aging Research		93.866		15,524	University of California San Francisco	13186sc	15,524	
Aging Research		93.866		23,606	University of Pennsylvania	580208	23,606	
Aging Research		93.866		198,517	University of Wisconsin	0000001234	198,517	
Aging Research		93.866		37,794	Yale University	CON-80003339(GR114070) Amendment No 1	37,794	
Aging Research		93.866		37,452	Yale University	CON-80003446 (GR115071)	37,452	
COVID-19 Aging Research		93.866	(29,637)	-			(29,637)	
Vision Research		93.867	6,377,371	-			6,377,371	733,117
Vision Research		93.867	5,056,078	-			5,056,078	52,652
Vision Research		93.867	-	86,708	Arizona Board of Regents for and on behalf of Arizona State University	ASUB00000931	86,708	
Vision Research		93.867	-	82,320	Baylor College of Medicine	7000000348 A05	82,320	
Vision Research		93.867	-	317	Columbia University	1(GSO11726) Amendment # 6	317	
Vision Research		93.867	-	29,322	Harvard Medical School	533387	29,322	
Vision Research		93.867	-	159,639	Northwestern University	60060095 NYU	159,639	
Vision Research		93.867	-	7,834	Oregon Health & Science University	22-A0-00-1008110	7,834	
Vision Research		93.867	-	65,000	Physical Sciences, Inc.	86433-1998-46	65,000	
Vision Research		93.867	-	56,581	University of California San Francisco	12057sc	56,581	
Vision Research		93.867	-	1,570	University of Alabama at Birmingham	000513702-SCO03	1,570	
Vision Research		93.867	-	165,558	University of California Irvine	2020-1255 A03	165,558	
Vision Research		93.867	-	2,605	University of Michigan	3004206297	2,605	
Medical Library Assistance		93.879	684,636	-			684,636	81,358
Medical Library Assistance		93.879	285,220	-			285,220	-
Medical Library Assistance		93.879	-	10,020	Medical University of South Carolina	A00-3641-S0003	10,020	-
Medical Library Assistance		93.879	-	8,008	Medical University of South Carolina	A00-3641-S0002	8,008	-

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Medical Library Assistance	93.879	-	108,669	Stevens Institute of Technology	2102971-01 Amd 03	108,669	-
	Medical Library Assistance	93.879	-	531,347	University of Massachusetts School of Medicine	SUB00000030	531,347	-
	Medical Library Assistance	93.879	-	8,827	University of Washington	20-A0-00-1005170	8,827	-
	Grants for Primary Care Training and Enhancement	93.884	-	15,024	Mayo Clinic	NYU-268163-01	15,024	-
	Primary Care Training and Enhancement	93.884	61,404	-			61,404	-
	Hospital Preparedness Program (HPP) and Public Health Emergency Preparedness (PHEP) Aligned Cooperative Agreements	93.889	-	234,585	Public Health Solutions	19-NYULH-01/Account:76608	234,585	-
	National Bioterrorism Hospital Preparedness Program	93.889	-	12,650	Public Health Solutions	19-NYULH-02	12,650	-
	National Bioterrorism Hospital Preparedness Program	93.889	-	32,299	Yale University	GR107609 (CON-80001923) Amd 04	32,299	-
	COVID-19 Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	34,719	-			34,719	-
	Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	625,858	-			625,858	251,956
	Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Grants	93.924	250,360	-			250,360	249,332
	HIV Demonstration, Research, Public and Professional Education Projects	93.941	55,231	-			55,231	-
	Assistance Programs for Chronic Disease Prevention and Control	93.945	566,636	-			566,636	-
	CDC's Collaboration with Academia to Strengthen Public Health	93.967	-	80,906	Association of American Medical Colleges	GT-32016-21-19	80,906	-
	Primary Care Medicine and Dentistry Clinician Educator Career Development Awards	93.976	145,122	-			145,122	1,916
	Medicare Access and CHIP Reauthorization Act (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program	93.986	-	52,259	Yale New Haven Health System	20-A0-00-1005685	52,259	-
	International Research and Research Training	93.989	624,479	-			624,479	293,245
	International Research and Research Training	93.989	132,069	-			132,069	10,338
	International Research and Research Training	93.989	-	7,383	Africa Health Research Institute	LoA R99	7,383	-
	Maternal and Child Health Services Block Grant to the States	93.994	41,761	-			41,761	-
	(NBT Task 3) Pilot Testing Refinement and Validating of the NBT and Preparation for Norming Study	93.994	-	129,713	Northwestern University	SP0070625 60061130 TO 3 NYU	129,713	-
	Pilot Testing, Refinement, and Validating of the NBT, and Preparation for Norming Study	93.RD	-	30,110	Northwestern University	SP0064431 60057520 TO2 NYU Amd 1	30,110	-
	Total U.S. Department of Health and Human Services (HHS)		<u>513,065,638</u>	<u>64,085,840</u>			<u>577,151,478</u>	<u>150,969,686</u>
	U.S. Department Of Homeland Security							
	Assistance to Firefighters Grant	97.044	303,340	-			303,340	-
	Centers for Homeland Security	97.061	-	48,613	University of Michigan	SUBK00015680	48,613	-
	Total U.S. Department Of Homeland Security		<u>303,340</u>	<u>48,613</u>			<u>351,953</u>	<u>-</u>
	U.S. Agency for International Development (USAID)							
	USAID Foreign Assistance for Programs Overseas	98.001	-	38,894	National Academy of Sciences	2000010558 Mod 01	38,894	-
	USAID Foreign Assistance for Programs Overseas	98.001	-	29,344	Purdue University	F9002550402096	29,344	-
	Total U.S. Agency for International Development (USAID)		<u>-</u>	<u>68,238</u>			<u>68,238</u>	<u>-</u>
	Total Research and Development Cluster		<u>590,094,984</u>	<u>75,155,373</u>			<u>665,250,357</u>	<u>158,048,183</u>

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Health Center Program Cluster:								
	U.S. Department of Health and Human Services (HHS) Consolidated Health Centers (Community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care)	93.224	\$ -	\$ 975,455	The Division of Public Health Services / Health Resources and Services Administration	H8F41242	\$ 975,455	\$ -
	Total U.S. Department of Health and Human Services (HHS)		<u>-</u>	<u>975,455</u>			<u>975,455</u>	<u>-</u>
	Total Health Center Program Cluster		<u>-</u>	<u>975,455</u>			<u>975,455</u>	<u>-</u>
Highway Planning and Construction Cluster:								
	U.S. Agency for International Development (USAID) Highway Planning and Construction	20.205	-	505,369	New York State Department of Transportation	TA SR-20-05 Letter of Agreement #1	505,369	146,223
	Highway Planning and Construction	20.205	-	34,000	Research Foundation of CUNY on behalf of City College of New York	Subaward #: CM00006804-00 Account #: 55606-10-29 (Time Ext letter of 10-26-2022)	34,000	-
	Highway Planning and Construction	20.205	-	153,349	Research Foundation of CUNY on behalf of City University of New York	57315-01-29 NCE	153,349	-
	Highway Planning and Construction	20.205	-	68,299	Research Foundation of CUNY on behalf of City University of New York	57315-03-29 NCE	68,299	-
	Highway Planning and Construction	20.205	-	361	Research Foundation of CUNY on behalf of City University of New York	Subaward # CM00005104	361	-
	Total U.S. Agency for International Development (USAID)		<u>-</u>	<u>761,378</u>			<u>761,378</u>	<u>146,223</u>
	Total Highway Planning and Construction Cluster		<u>-</u>	<u>761,378</u>			<u>761,378</u>	<u>146,223</u>
Trio Cluster:								
	U.S. Department of Education (ED) TRIO Student Support Services	84.042	434,183	-			434,183	-
	Total U.S. Department of Education (ED)		<u>434,183</u>	<u>-</u>			<u>434,183</u>	<u>-</u>
	Total Trio Cluster		<u>434,183</u>	<u>-</u>			<u>434,183</u>	<u>-</u>
Student Financial Assistance Cluster:								
	U.S. Department of Education (ED) Federal Supplemental Educational Opportunity Grants	84.007	11,861,211	-			11,861,211	-
	Federal Work-Study Program	84.033	6,158,715	-			6,158,715	-
	Teacher Education Assistance for College and Higher Education Grants (TEACH Grants)	84.379	206,841	-			206,841	-
	Teacher Education Assistance for College and Higher Education Grants (TEACH Grants)	84.379	-	6,000	Higher Education Services Corporation	APTS 2021-2022	6,000	-
	Federal Direct Student Loans	84.268	685,245,997	-			685,245,997	-
	Federal Pell Grant Program	84.063	31,702,833	-			31,702,833	-
	Federal Perkins Loan Program							
	• Outstanding loans at September 1, 2021	84.038	35,225,238	-			35,225,238	-
			<u>35,225,238</u>	<u>-</u>			<u>35,225,238</u>	<u>-</u>
	Total U.S. Department of Education (ED)		<u>770,408,835</u>	<u>6,000</u>			<u>770,408,835</u>	<u>-</u>
	U.S. Department of Health and Human Services Health Professions Student Loan Program							
	Health Professions Student Loan Program/Loans to Disadvantaged Students	93.342						
	• Outstanding loans at September 1, 2021		23,468,714	-			23,468,714	-
	• New loans issued during fiscal year 2022		<u>3,852,835</u>	<u>-</u>			<u>3,852,835</u>	<u>-</u>
			<u>27,321,549</u>	<u>-</u>			<u>27,321,549</u>	<u>-</u>
	Nursing Student Loans							
	Undergraduate Nursing Student Loans	93.364						
	• Outstanding loans at September 1, 2021		1,387,806	-			1,387,806	-
	• New loans issued during fiscal year 2022		<u>273,080</u>	<u>-</u>			<u>273,080</u>	<u>-</u>
			<u>1,660,886</u>	<u>-</u>			<u>1,660,886</u>	<u>-</u>
	Graduate Nursing Loans							
	Graduate Nursing Student Loans	93.364						
	• Outstanding loans at September 1, 2021		134,503	-			134,503	-
			<u>134,503</u>	<u>-</u>			<u>134,503</u>	<u>-</u>
	Nursing Faculty Loans							
	Faculty Nursing Student Loans	93.264						
	• Outstanding loans at September 1, 2021		741,924	-			741,924	-
			<u>741,924</u>	<u>-</u>			<u>741,924</u>	<u>-</u>
	Total U.S. Department of Health and Human Services		<u>29,858,862</u>	<u>-</u>			<u>29,858,862</u>	<u>-</u>
	Total Student Financial Assistance Cluster		<u>800,259,697</u>	<u>6,000</u>			<u>800,259,697</u>	<u>-</u>

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Other Programs:								
	U.S. Department of Defense (DOD)							
	Language Grant Program	12.900	\$ 36,865	\$ -			\$ 36,865	\$ 28,465
	Total U.S. Department of Defense (DOD)		<u>36,865</u>	<u>-</u>			<u>36,865</u>	<u>28,465</u>
	U.S. Department of Justice (DOJ)							
	Edward Byrne Memorial Justice Assistance Grant Program	16.738	-	6,300	National Policing Institute	S059	6,300	-
	Girls in the Juvenile Justice System	16.830	-	10,911	New York State Unified Court System	C250563 Amd #1	10,911	-
	Total U.S. Department of Justice (DOJ)		<u>-</u>	<u>17,211</u>			<u>17,211</u>	<u>-</u>
	U.S. Department of State							
	International Programs to Combat Human Trafficking	19.019	4,507	-			4,507	-
	Investing in People in The Middle East and North Africa	19.021	160,373	-			160,373	-
	Educational and Cultural Exchange Programs Appropriation Overseas Grants	19.022	73,999	-			73,999	-
	Educational and Cultural Exchange Programs Appropriation Overseas Grants	19.022	-	112,898	International Research and Exchange Board	FY21-ILUF-NYU-01 mod 5	112,898	17,499
	Public Diplomacy Programs	19.040	73,999	112,898			186,897	17,499
	Total U.S. Department of State		<u>265,810</u>	<u>112,898</u>			<u>378,708</u>	<u>23,099</u>
	U.S. Department of Transportation							
	Highway Training and Education	20.215	22,790	-			22,790	-
	Total U.S. Department of Transportation		<u>22,790</u>	<u>-</u>			<u>22,790</u>	<u>-</u>
	Federal Council on the Arts and The Humanities							
	Promotion of the Arts Grants to Organizations and Individuals	45.024	62,137	-			62,137	-
	Native American and Native Hawaiian Library Services	45.311	-	5,598	Penobscot Nation	NG-03-18-0183-18	5,598	-
	Total Federal Council on the Arts and The Humanities		<u>62,137</u>	<u>5,598</u>			<u>67,735</u>	<u>-</u>
	Institute of Museum and Library Services							
	National Leadership Grants	45.312	269,618	-			269,618	-
	Laura Bush 21st Century Librarian Program	45.313	197,057	-			197,057	177,665
	Total Institute of Museum and Library Services		<u>466,675</u>	<u>-</u>			<u>466,675</u>	<u>177,665</u>
	National Endowment for the Humanities							
	Promotion of the Humanities Division of Preservation and Access	45.149	304,024	-			304,024	-
	Promotion of the Humanities Research	45.161	70,433	-			70,433	661
	Promotion of the Humanities Office of Digital Humanities	45.169	20,414	-			20,414	-
	Total National Endowment for the Humanities		<u>394,871</u>	<u>-</u>			<u>394,871</u>	<u>661</u>
	Department of Veterans Affairs							
	Vocational Rehabilitation for Disabled Veterans	64.116	23,287	-			23,287	-
	Total Department of Veterans Affairs		<u>23,287</u>	<u>-</u>			<u>23,287</u>	<u>-</u>

The accompanying notes are an integral part of this schedule

New York University

Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
U.S. Department of Education (ED)								
	Education Research, Development and Dissemination	84.305	\$ -	\$ 17,191	MDRC	1168-NYU-01 Mod 04	\$ 17,191	\$ -
	Education Research, Development and Dissemination	84.305	-	150,785	University of Houston	R-20-0084 Amd 1	150,785	-
	Teacher and School Leader Incentive Grants (formerly the Teacher Incentive Fund)	84.374	-	167,976			167,976	-
	Education Innovation and Research (formerly Investing in Innovation (i3) Fund)	84.411	-	119,601	Eskolta School Research and Design Inc.	Agreement dated 20210201	119,601	-
			-	35,569	ExpandedED Schools	Agreement Dated 2020-12-10	35,569	-
	COVID-19 Education Stabilization Fund: Higher Education Emergency Relief Fund - Student Portion	84.425E	1,230,474	-			1,230,474	-
	COVID-19 Education Stabilization Fund: Higher Education Emergency Relief Fund - Institutional Portion	84.425F	1,230,324	-			1,230,324	-
			2,460,798	-			2,460,798	-
	Total U.S. Department of Education (ED)		2,460,798	323,146			2,783,944	-
U.S. Department of Health and Human Services (HHS)								
	U.S. Department of Health and Human Services (HHS)							
	Training in General, Pediatric, and Public Health Dentistry	93.059	243,059	-			243,059	-
	Hospital Preparedness Program (HPP) and Public Health Emergency Preparedness (PHEP) Aligned Cooperative Agreements	93.074	-	(8,898)	Public Health Solutions	17-NYULH-01	(8,898)	-
	Maternal and Child Health Federal Consolidated Programs	93.110	-	459	Children's Hospital of Philadelphia	3208960821 / PO# 20260738 Amd 2	459	-
	Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	443,401	-			443,401	-
	Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	-	5,755	The Danya Institute Inc.	Agreement SM08785-03	5,755	-
			443,401	5,755			449,156	-
	Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief	93.266	-	211,635	Brigham and Women's Hospital	116337 Amendmet 12	211,635	49,914
	COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution	93.498	23,815,345	-			23,815,345	-
	COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund	93.461	1,882,009	-			1,882,009	-
	Preventive Health and Health Services Block Grant	93.991	-	1,318	New York State Department of Health	C-028946	1,318	-
	Maternal and Child Health Services Block Grant to the States	93.994	-	(59,828)	New York State Department of Health	DOH01-C32428GG-3450000	(59,828)	-
	The Rest of Us	93.U01	-	5,504	The Danya Institute Inc.	MHTTC-03	5,504	-
	Total U.S. Department of Health and Human Services (HHS)		26,383,814	155,945			26,539,759	49,914
U.S. Department Of Homeland Security								
	Capped Grant	97.036	-	11,267,824	NYS Division of Homeland Security and Emergency Management	PW4005	11,267,824	-
	COVID-19 Expedited Project Worksheets	97.036	-	10,185,173	NYS Division of Homeland Security and Emergency Management	PW 00006, PW 00180	10,185,173	-
	COVID-19 Expedited Project Worksheets	97.036	-	4,128,227	NYS Division of Homeland Security and Emergency Management	PW582 PW591 PW614 PW835 PW871 PW891 PW784	4,128,227	-
	Project Worksheets	97.036	-	745,508	NYS Division of Homeland Security and Emergency Management	PW 00006, PW 00007	745,508	-
	Total U.S. Department Of Homeland Security		-	26,326,732			26,326,732	-
	Total Other Programs		30,117,047	26,941,530			57,058,577	279,804
	Total Expenditures of Federal Awards		\$ 1,420,905,911	\$ 103,839,736			\$ 1,524,745,647	\$ 158,474,210

The accompanying notes are an integral part of this schedule

New York University

Notes to Schedule of Expenditures of Federal Awards

Year Ended August 31, 2022

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (“the Schedule”) presents the federal grant activity of NYU and is presented on the accrual basis of accounting.

The information in this Schedule is presented in accordance with the requirements of the Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and therefore, some amounts may differ from amounts presented in, or used in the preparation of NYU’s consolidated financial statements. Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years arising out of the normal course of business. Assistance Listing Numbers (“ALN”) and pass-through numbers are provided when available.

The research expenditures for direct costs are recognized using the cost accounting principles contained in OMB Circular A-21, *Cost Principles for Educational Institutions*, and OMB Uniform Guidance, where applicable. Under those cost principles, certain types of expenditures are not allowed for reimbursement. In addition, expenditures include a portion of costs associated with general NYU activities (facilities and administrative) which are allocated to federal awards under negotiated formulas commonly referred to as facilities and administrative rates (also under the provisions of OMB Circular A-21 and OMB Uniform Guidance, where applicable).

As described in Note 2, NYU, with the exception of NYU Langone Hospitals, does not use the 10% de-minimis indirect cost rate for sponsored programs.

2. Facilities and Administrative Cost Rates

The University had predetermined facilities and administrative cost rates for the fiscal year ended 2022, under a rate agreement with the Department of Health and Human Services (“DHHS”), the University’s federal cognizant agency. The base rate for on-campus research was 60% for fiscal 2022. The base rate for off-campus research was 26% for fiscal 2022.

NYUGSoM and NYU Long Island School of Medicine had predetermined facilities and administrative cost rates for the fiscal year ended 2022, under separate rate agreements with the DHHS, their federal cognizant agency. The NYUGSoM base rates for on-campus and off-campus research, respectively, were 69.5% and 26% for fiscal 2022. The NYU Long Island School of Medicine base rates for on-campus and off-campus research, respectively, were 54% and 17% for fiscal 2022.

New York University
Notes to Schedule of Expenditures of Federal Awards
Year Ended August 31, 2022

3. Federal Student Loan Programs

NYU administers and accounts for all aspects of the campus-based student loan programs. Accordingly, NYU's consolidated financial statements include all activity related to these programs. The amount of loans outstanding under each of these programs at August 31, 2022 are presented below.

Program	Assistance Listing	Amount Outstanding at August 31, 2022
Federal Perkins Loan	84.038	\$ 28,795,934
Health Professions Student Loans - Loans to Disadvantaged Students	93.342	4,401,955
Health Professions Student Loans	93.342	21,017,108
Nursing Student Loans	93.364	1,478,396
Graduate Nursing Loans	93.364	120,284
Nursing Faculty Loans	93.264	518,923
Nursing Faculty Loans - ARRA	93.264	125,711
		\$ 56,458,311

With respect to the Federal Direct Loan Program, NYU is only responsible for the performance of certain administrative duties. Therefore, the transactions and the balances of loans outstanding related to this program are not included in NYU's consolidated financial statements. The Schedule includes the loans issued to NYU students during the year ended August 31, 2022.

The administrative cost allowance for the Federal Pell Grant Program of \$29,245 and for the College Work Study Program of \$661,970 have been included in the schedule of expenditures of federal awards.

NYU did not receive an administrative cost allowance from the Federal Perkins Loan Program (ALN 84.038) for the year ended August 31, 2022.

4. HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

NYU Langone Health conducted COVID-19 testing and/or provided treatment for uninsured individuals with a COVID-19 primary diagnosis on or after February 4, 2020 and as such has requested claims reimbursement under ALN 93.461.

NYU has recorded \$1,882,009 on the Schedule consisting of \$2,007,071 reimbursed to date from HRSA on claims with service dates during fiscal year 2022 and an adjustment of (\$125,062) related to claims with service dates prior to fiscal year 2022.

New York University
Notes to Schedule of Expenditures of Federal Awards
Year Ended August 31, 2022

5. Department of Health and Human Services PRF and ARP Rural Distribution administered by the Health Resources and Services Administration (HRSA)

The Schedule includes grant activity related to the ALN 93.498. As required based on guidance in the 2022 OMB Compliance Supplement, the Schedule includes all Period 2 funds received between July 1, 2020 and December 31, 2020 and expended by December 31, 2021 as reported to HRSA via the PRF Reporting Portal. NYU Langone Health did not receive Period 3 funding.

6. Superstorm Sandy

As described in Note 2 to the accompanying consolidated financial statements, as a result of Superstorm Sandy, NYU Langone Health sustained widespread damage to the main campus facilities including NYU Langone Hospital's inpatient and outpatient facilities and the NYUGSoM research, faculty group clinical practice and education facilities, all of which were temporarily closed. Under Federal Emergency Management Agency ("FEMA") regulations, NYU Langone Health qualified for funding as a private non-profit facility that supplies critical services to the community. For Superstorm Sandy, FEMA (through the U.S. Department of Homeland Security) reimburses eligible entities at 90% of all eligible costs awarded.

In 2014, FEMA awarded NYU Langone Health a fixed, capped Public Assistance Grant ("Capped Grant") totaling \$1,088,252,436, which includes a reduction of \$3,383,139 due to a commercial insurance claim recovery. The award is to be spent over a 9 year performance period for activities covered in the agreed upon scopes of work. The \$1,088,252,436 will be subject to offset for future commercial insurance recoveries related to property damage. All reimbursement under the Capped Grant is passed through from New York State to the University, to NYU Langone Health. Included in the Schedule are \$11,267,824 of NYU Langone Health expenditures under the Capped Grant.

In 2013, NYU Langone Health received \$179,394,000 of expedited funding under their initial FEMA Project Worksheet applications, which is separate funding from the FEMA Capped Grant. These Project Worksheets are subject to review and finalization by FEMA. The expenses associated with these Project Worksheets are included in the Schedule in the year the Project Worksheets are approved. Included in the Schedule are \$745,508 of NYU Langone Health expenditures related to these Project Worksheets.

New York University

Schedule of Financial Responsibility Data

Year Ended August 31, 2022

(in thousands of dollars)

NYU participates in federal Title IV student financial assistance programs, which require it to meet standards of financial responsibility based on criteria determined by the U.S. Department of Education (ED), as set forth in 34 CFR 668.171. The criteria for private institutions include the annual calculation by ED of a financial responsibility composite score, as further specified in 34 CFR 668.172, using the institution's audited financial statements submitted with the annual Uniform Guidance (UG) report through ED's eZ-Audit system. The composite score is based on three ratios: Primary Reserve, Equity, and Net Income. These ratios utilize the following financial data of NYU, as of and for the year ended August 31, 2022:

Location in financial statements or related notes	Financial element	GAAP financial statement line item or disclosure	Amount used as ratio input
Primary Reserve Ratio: Expendable Net Assets			
Balance sheet	Net assets without donor restrictions	\$ 7,489,240	\$ 7,489,240
Balance sheet	Net assets with donor restrictions	4,737,073	4,737,073
Note 20, Financial Responsibility Standards	Unsecured related party receivable	94,373	94,373
Note 20, Financial Responsibility Standards	Total property, plant, and equipment, net	13,524,087	
Note 20, Financial Responsibility Standards	Property, plant and equipment, net - pre-implementation		9,049,021
Note 20, Financial Responsibility Standards	Property, plant and equipment, net - post-implementation with outstanding debt for original purchase		1,439,462
Note 20, Financial Responsibility Standards	Property, plant and equipment, net - post-implementation without outstanding debt for original purchase		828,202
Note 20, Financial Responsibility Standards	Construction in progress		2,207,402
Balance sheet	Total lease right-of-use assets	2,154,222	
N/A	Lease right-of-use assets, pre-implementation		-
Balance sheet	Lease right-of-use assets, post-implementation		2,154,222
Note 8, Other Assets	Intangible assets	51,199	51,199
Balance sheet	Accrued benefit obligation	398,718	398,718
	Accrued postretirement obligation (Accrued employee benefit liabilities)	510,738	510,738
Note 20, Financial Responsibility Standards	Total long-term debt	9,566,406	
Note 20, Financial Responsibility Standards	Long-term debt - for long-term purposes pre-implementation		6,836,457
Note 20, Financial Responsibility Standards	Long-term debt - for long-term purposes post-implementation		2,686,919
Note 20, Financial Responsibility Standards	Line of Credit for Construction in progress		43,030
Balance sheet	Total liability related to lease right-of-use assets	2,316,986	
Balance sheet	Liability related to lease right-of-use assets - pre-implementation		-
Balance sheet	Liability related to lease right-of-use assets - post-implementation		2,316,986
Note 20, Financial Responsibility Standards	Annuities and life income funds with donor restrictions		86,503
Note 20, Financial Responsibility Standards	Term endowments with donor restrictions		4,449
Note 20, Financial Responsibility Standards	Net assets with donor restrictions: restricted in perpetuity		2,718,658
Primary Reserve Ratio: Expenses and Losses			
Statement of activities	Total expenses and losses without donor restrictions	\$ 14,144,991	\$ 14,144,991
Equity Ratio: Modified Net Assets			
Balance sheet	Net assets without donor restrictions	\$ 7,489,240	\$ 7,489,240
Balance sheet	Net assets with donor restrictions	4,737,073	4,737,073
Note 8, Other Assets	Intangible assets	51,199	51,199
Note 20, Financial Responsibility Standards	Unsecured related party receivable		94,373
Equity Ratio: Modified Assets			
Balance sheet	Total assets	\$ 30,682,174	\$ 30,682,174
Balance sheet	Lease right-of-use assets, pre-implementation		-
Note 8, Other Assets	Intangible assets	51,199	51,199
Note 20, Financial Responsibility Standards	Unsecured related party receivable		94,373
Net Income Ratio			
Statement of activities	Change in net assets without donor restrictions	\$ 553,100	\$ 553,100
Note 20, Financial Responsibility Standards	Total revenues and gains without donor restrictions	\$ 15,173,224	\$ 15,173,224

Part III
Reports on Internal Control and Compliance



**Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance
and Other Matters Based on an Audit of Financial Statements Performed in Accordance with
*Government Auditing Standards***

To the Board of Trustees of
New York University

We have audited in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of New York University and its subsidiaries (the "Company"), which comprise the consolidated balance sheet as of August 31, 2022, and the related consolidated statements of activities and of cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements") and have issued our report thereon dated December 14, 2022, except for Note 20 to the consolidated financial statements and with respect to the opinion on the schedule of financial responsibility data, as to which the date is March 31, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Company's internal control over financial reporting (internal control) as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that have not been identified.



Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

New York, New York

December 14, 2022, except for Note 20 to the consolidated financial statements and with respect to the opinion on the schedule of financial responsibility data, as to which the date is March 31, 2023



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To the Board of Trustees of
New York University

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited New York University and its subsidiaries' (the "Company") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company's major federal programs for the year ended August 31, 2022. The Company's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company's federal programs.



Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Company's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the OMB *Compliance Supplement*, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 13 "Gramm-Leach-Bliley Act-Student Information Security." This section includes three suggested audit procedures with respect to verification that the institution (1) designated an employee or employees to coordinate the information security program, (2) performed a risk assessment that addresses the three required areas in 16 CFR 314.4(b), and (3) documented a safeguard for each risk identified. Our procedures in relation to these three items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these three items. Our procedures did not include an analysis of the adequacy



or completeness of the risk assessment performed or the safeguards for each risk identified by management.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

New York, New York
March 31, 2023

Part IV
Findings

New York University
Schedule of Findings and Questioned Costs
Year Ended August 31, 2022

Section I – Summary of Auditor’s Results

Financial Statements

Type of auditor’s report issued:

Unmodified Opinion

Internal control over financial reporting:

- Material weakness(es) identified?
- Significant deficiency(ies) identified that are not considered to be material weaknesses?
- Noncompliance material to financial statements noted?

_____ Yes X No
 _____ Yes X None reported
 _____ Yes X No

Federal Awards

Internal control over major programs:

- Material weakness(es) identified?
- Significant deficiency(ies) identified that are not considered to be material weaknesses?

_____ Yes X No
 _____ Yes X None reported

Type of auditor’s report issued on compliance for major programs:

Unmodified Opinion

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

_____ Yes X No

Identification of major programs:

Assistance Listing Number(s)

Various
 Various

93.498

93.461

Name of Federal Program or Cluster

Student Financial Assistance Cluster
 Research and Development Cluster
 COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
 COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Dollar threshold used to distinguish between type A and type B programs:

\$4,574,237

Auditee qualified as low-risk auditee?

 X Yes _____ No

New York University
Schedule of Findings and Questioned Costs
Year Ended August 31, 2022

Section II- Financial Statement Findings

As a result of our audit, no instances of noncompliance related to the financial statements that are required to be reported in accordance with *Government Auditing Standards* were identified.

Section III - Federal Award Findings and Questioned Costs

No federal award findings and questioned costs were reported as a result of our audit.

New York University
Summary Schedule of Status of Prior Audit Findings
Year Ended August 31, 2022

Section II - Financial Statement Findings – 2021

There are no findings from prior year that require an update in this report.

Section III - Federal Award Findings and Questioned Costs – 2021

2021-001: Advertising Expense Duplication

Federal Agency: Department of Health and Human Services

Program: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

Assistance Listing #: 93.498

Award Year: 2020-2021

Pass-through entity: Not applicable

Condition

In accordance with the Health Resources and Services Administration (HRSA) Provider Relief Fund Terms and Conditions, eligible providers may use Provider Relief Funds to prevent, prepare for, and respond to coronavirus, and for related expenses or lost revenues attributable to coronavirus. The PRF – Reporting Period 1 submission to HRSA included \$2,087,585 of duplicate expenditures related to advertising expenses. The amount included both the original invoice amounts and the related amortization expense in NYU Langone Hospitals' total expenses reported to HRSA.

Status

The duplicated expenses were removed in the Period 2 submission. NYU Langone Health management successfully completed a review to ensure prepaid amortization duplication did not occur in other transactions reported in subsequent submissions.